Document:

EX-10.9

 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN EXCLUDED
PURSUANT TO REGULATION S-K, ITEM 601(b)(10). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. 

EXECUTION COPY 
  

 Exhibit 10.9 
  

EXCLUSIVE LICENSE AGREEMENT 
 This
EXCLUSIVE LICENSE AGREEMENT (“Agreement”) is made on the 15th day of AUGUST 2016 (“Effective Date”) by and between 

NATIONAL UNIVERSITY OF SINGAPORE, (Company Registration Number: 200604346E), a company limited by guarantee incorporated in Singapore, having its
registered address at 21 Lower Kent Ridge Road, Singapore 119077 (“NUS”), 
 And 

ST. JUDE CHILDREN’S RESEARCH HOSPITAL, INC., a Tennessee
not-for-profit corporation located at 262 Danny Thomas Place, Memphis, Tennessee 38105, U.S.A. (“St. Jude”), 

(Collectively, NUS and St. Jude shall be referred to as “Licensors”) 

And 
 NKARTA, INC., a Delaware corporation, having its
registered address at 5425 Wisconsin Avenue, Suite 800, Chevy Chase, Maryland 20815, U.S.A. (“Licensee”). 
 (NUS, St. Jude and
Licensee shall hereinafter be referred to individually as a “Party” and collectively as “Parties”) 
 WHEREAS:

  

	A.	 Licensors are, individually or jointly, the owners of certain Patent Rights (as later defined
herein) relating to a method for expanding natural killer cells; a chimeric receptor with NKG2D specificity; and a method for supporting autonomous natural killer cell function as described in Schedule 1; and have the right to grant licenses
under said Patent Rights. 

  

	B.	 Licensee is interested in licensing and further developing the Patent Rights for commercial
applications. 

  

	C.	 Licensee is desirous of obtaining an exclusive license under Licensors’ Patent Rights.

  

	D.	 Licensors are desirous of granting such a license to Licensee in accordance with the terms of
this Agreement. 

 NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, the Parties
hereto agree as follows: 
  

	1.	 DEFINITIONS 

In this Agreement, unless the context otherwise requires, the following expressions have the following respective meanings: 

 

					
	Academic Purposes	 	-	  	Academic research, scholarly publications and educational purposes. Sponsored research shall be included provided that such sponsorship arrangements do not require NUS and/or St Jude to grant to any third party any rights that are
inconsistent with the rights and licenses granted under this Agreement.

  

			
	

	  	Page 1 of 39

 EXECUTION COPY 

 

					
	Common Stock	 	-	  	Duly authorized common stock of the Licensee having a par value of $0.0001.
			
	Confidential Information	 	-	  	Any information disclosed by one Party to the other Party in any form, which, if disclosed in tangible form, is marked at the time of disclosure as being confidential or proprietary or with words of similar import, and
if disclosed orally or visually or in other intangible form, is described as confidential at the time of such disclosure and confirmed in writing as confidential to the receiving Party [***].
			
	Consolidated Screening List	 	-	  	 the United States Government’s Consolidated Screening List of parties for which the United States Government maintains restrictions on
certain exports, re-exports or transfers of items, which list can be found as of the Effective Date at the following hyperlink:

http://20l6.export.gov/ecr/eg_main_023148.asp

			
	Field of Use	 	-	  	All therapeutic uses and applications.
			
	Invention	 	-	  	The invention as described in Schedule 1.
			
	Investigational New Drug Application	 	-	  	A request for authorization from the Food and Drug Administration (FDA), or its equivalent in countries other than the United States, to administer an investigational drug or biological product to humans.
			
	Joint Improvements	 	-	  	Any modifications, additions, alterations, enhancements, upgrades or new versions of compositions, methods, processes and/or any other subject matter claimed in the Patent Rights, but which are not claimed under any of
the Patent Rights and are made jointly by Licensee with NUS.
			
	Licensee Improvements	 	-	  	Any modifications, additions, alterations, enhancements, upgrades or new versions of the compositions, methods, processes and/or any other subject matter claimed in the Patent Rights, but which are not claimed under
any of the Patent Rights and are made by or on behalf or for the benefit of Licensee other than Joint Improvements or NUS Improvements.
			
	Licensed Product(s)	 	-	  	Any product, the manufacture, use, sale, offer for sale or import of which, but for the rights granted hereunder, would constitute an infringement of any Valid Claim in the Patent
Rights.

  

			
	

	  	Page 2 of 39

 EXECUTION COPY 

 

					
	NUS Improvements	 	-	  	 Any modifications, addition, alterations, enhancements, upgrades or new versions of compositions, methods, processes and/or any other subject
matter claimed in the Patent Rights but that are not claimed under any of the Patent Rights, and are made by NUS without assistance from or in collaboration with Licensee which meet all of the following
criteria:
  
 (i) arise from research
performed solely in the laboratory of Dario Campana;
  

(ii)  are available for licensing after satisfaction of any obligations to any governmental granting
agencies.

			
	Net Sales	 	-	  	 The gross amount of monies that is paid to Licensee, and/or its Related Company(ies) and/or Sub- Licensee(s)
for the Licensed Products by sale or any other mode of transfer, less:
  

(i) customary and reasonable trade, quantity or cash discounts and
non-affiliated brokers’ or agents’ commissions actually allowed;
  

(ii)  credits, discounts, chargebacks and allowances granted by reason of rejection or return;

 
 (iii)  taxes, tariffs, import/export
duties, and/or other governmental levies imposed on the sale or transfer, to the extent the same is separately stated on invoices, or other documents of sale or transfer; and
  

(iv) transportation, freight and insurance charges, to the extent the same is separately stated on invoices, or
other documents of sale or transfer.

			
		 		  	 Net Sales also includes the fair market value of any non-cash consideration received by
Licensee its Related Company(ies) and/or Sub-Licensee(s) for the sale, or other modes of transfer of Licensed Products. On sale or any other mode of transfer of Licensed
Products made in other than arm’s-length transactions, the value of the Net Sales attributed to such a transaction shall be that which would have been received in an arm’s-length transaction, based on a like transaction at that time.
  

In no event shall any particular amount of deduction identified above be deducted more than once in calculating Net Sales (i.e., no “double
counting” of reductions).

  

			
	

	  	Page 3 of 39

 EXECUTION COPY 

 

					
		 		  	For purposes of calculating Net Sales, (a) sales between Licensee, its Related Company(ies) and/or Sub-Licensee(s) for end use by the purchasing entity (but
not sales for further resale, or for production of finished Licensed Products for sale, by such purchasing entity) will be treated as Net Sales, and (b) Licensed Products provided at or below cost as promotional samples,
for indigent care or patient assistance programs, or to be administered in clinical trials of Licensed Products (except to the extent the recipient is charged for such Licensed Products in any post-approval clinical trial) shall be
excluded in the calculation of Net Sales; provided that, for purposes of this Agreement, royalties payable by Licensee to Licensors pursuant to Section 7.2 below shall not be included in the calculation of the cost of a Licensed
Product.
			
		 		  	If a Licensed Product is sold in a combination with other active components (“Combination Sale”), Net Sales on the Combination Sale shall be calculated by multiplying the Net Sales
of that Combination Sale by the fraction A/B, where A is the average sale price in the relevant country of the Licensed Product included in the Combination Sale (or
similar Licensed Product with the same dosage and route of administration) when sold separately and B is the average sale price in that country of the combination. If no such separate sales are made by Licensee, its Related
Companies or Sub-Licensees, the Parties shall, in good faith, determine an equitable method of determining Net Sales of such combination prior to the end of the accounting period in question,
provided the fraction A/B shall under no circumstances fall below [***].
			
	Other Patent Rights	 		  	Any patent application or issued patent that discloses or claims (a) an NUS Improvement that is exclusively licensed to Licensee pursuant to Section 3.6(a) or
Section 3.6(b) below; (b) any Additional NUS Composition (as defined in Section 3.6) that is exclusively licensed to Licensee pursuant to Section 3.6(c) or
Section 3.6(d) below; (c) a Joint Improvement with respect to which NUS has granted to Licensee an exclusive license under NUS’ interest in such Joint Improvement pursuant to
Section 3.8; and/or (d) solely for the purposes of Section 9, a NUS Improvement or Joint Improvement with respect to which Licensee’s Improvement Option has not expired or been terminated
in accordance with Section 3.7.

  

			
	

	  	Page 4 of 39

 EXECUTION COPY 

 

					
	Patent Rights	 	-	  	 (a) Rights to NK cell expansion technology under patent [***], and [***], and any patent application from which the foregoing patents issued
to the extent such patent application or patent, as applicable, is directed to expansion of NK cells; and (b) applications [***], and [***]; and any patent issued based on any such patent applications. Patent Rights shall further include the
following with respect to the patents and/or patent application described in sub-clauses (a) and/or (b) above: corresponding foreign patents and patent applications and any reissues, extensions,
substitutions, continuations, divisions, and continuation-in-part applications (to the extent that the CIP contains claims supported in the specification and entitled to
the priority date of the parent application) and any patents issuing from any of the foregoing.

			
	Patent Challenge	 		  	Any legal or administrative proceeding to revoke or challenge the validity of any of patent or patent application.
			
	Phase I Clinical Trial	 	-	  	A human clinical trial, the principal purpose of which is a preliminary determination of safety in healthy individuals or patients as required in 21 C.F.R. §312(a), or a similar clinical study prescribed by the regulatory
authorities in a country other than the United States.
			
	Phase II Clinical Trial	 	-	  	A study in humans of the safety, dose ranging and efficacy of a Licensed Product, which is prospectively designed to generate sufficient data (if successful) to commence pivotal clinical trials, as further defined in
21 C.F.R. § 312.21(b), or a similar study in a country other than the United States.
			
	Phase III Clinical Trial	 	-	  	A controlled study in humans of the efficacy and safety of a Licensed Product, which is prospectively designed to demonstrate statistically whether such Licensed Product is effective and safe for use in a
particular indication in a manner sufficient to file an application to obtain Regulatory Approval to market the Licensed Product, as further defined in 21 C.F.R. § 312.2l (c), or a similar study prescribed by the regulatory
authorities in a country other than the United States.
			
	Pre-approved Assignee	 		  	A company that (a) has capabilities to develop, manufacture and/or commercialize a bio - pharmaceutical product(s); (b) is not listed on the Consolidated Screening List; and (c) satisfies any of the following criteria
during the relevant period described below ending immediately prior to the

  

			
	

	  	Page 5 of 39

 EXECUTION COPY 

 

					
		 		  	effective date of the proposed assignment of this Agreement under Section 22.2: (i) has a market capitalization equal to or exceeding [***] for a period of at least [***]; (ii) has (together with its Related Companies) cash on
hand equal to or exceeding [***], as reflected in such company’s (or if applicable, its parent company’s) financial statements for [***]; or (iii) whose revenues from the sales of products in the life sciences sector (on a
consolidated basis for [***]) was in excess of [***]
			
	Preferred Stock	 		  	Duly authorized preferred stock of the Licensee having a par value of US$0.0001
			
	Qualified Sub-Licensee	 		  	 A Sub-Licensee that (a) has capabilities to develop, manufacture and/or commercialize a
bio - pharmaceutical product(s); (b) is not listed on the Consolidated Screening List; and (c) satisfies any of the following criteria during the relevant period described below ending immediately prior to the effective date of the
relevant sub license agreement: (i) has a market capitalization equal to or exceeding [***] for a period of at least [***]; (ii) has (together with its Related Companies) cash on hand and/or assets that, taken together, have a value equal to or
exceeding [***], as reflected in such company’s (or if applicable, its parent company’s) financial statements for [***];
 or

(iii) whose revenues from the sales of products in the life sciences sector (on a consolidated basis for [***] was in excess of [***]. For clarity, a company
that satisfies the criteria to be a Pre-approved Assignee also satisfies the foregoing criteria to be a Qualified Sub-Licensee.

			
	Related Company	 	-	  	Any person, corporation or other business entity which, directly or indirectly, controls, is controlled by, or is under common control with Licensee or for the purposes of Section 4.3, a Sub-Licensee, as applicable, including Licensee’s related corporations within the meaning of Section 6 of the Singapore Companies Act (Cap. 50). For such purposes, “control”
shall mean: (a) to possess, directly or indirectly, the power to affirmatively direct the management and policies of such person, corporation, or other business entity, whether through ownership
of

  

			
	

	  	Page 6 of 39

 EXECUTION COPY 

 

					
		 		  	voting securities or by contract relating to voting rights or corporate governance; or (b) direct or indirect beneficial ownership of fifty percent (50%) or more of the voting share capital in such person, corporation, or other
business entity, or, if applicable, such percentage that is the maximum allowed to be owned by a foreign person or corporation in the relevant jurisdiction.
			
	Series A Financing	 	-	  	A transaction or series of transactions pursuant to which Licensee issues and sells shares of a new series of Preferred Stock to be issued by Licensee with rights, privileges and preferences senior to the Licensee’s Common
Stock for aggregate gross proceeds of [***] with the principal purpose of raising capital.
			
	Sublicensing Revenue	 	-	  	 Any [***]. 
  

Sublicensing Revenue excludes: [***] shall also be excluded from Sublicensing Revenue. For clarity, such exclusions may be part of [***]
Patent Rights is granted, provided that such [***], based on their relative value.

  

			
	

	  	Page 7 of 39

 EXECUTION COPY 

 

					
	Sub-Licensee	 	-	  	A third party that obtains a sublicense to commercialize the Patent Rights or Licensed Products from Licensee, wherein the third party is not a Related Company.
			
	Term	 	-	  	The period during which this Agreement is in force pursuant to Section 5.
			
	Valid Claim	 	-	  	A claim in (a) an issued patent that (i) has not expired; (ii) has not been disclaimed; (iii) has not been cancelled or superseded, or if cancelled or superseded, has been reinstated; and (iv) has not been
revoked, held invalid, or otherwise declared unenforceable or not allowable by a tribunal or patent authority of competent jurisdiction over such claim in such country from which no further appeal
has or may be taken or (b) a pending patent application.

  

	2.	 INTERPRETATION 

 

	2.1	 In this Agreement: 

 

	 	(a)	 Words importing the singular shall include the plural and vice versa, and words that are gender specific or
neuter shall include the other gender and the neuter. 

  

	 	(b)	 References to a person shall be construed as references to an individual, corporation, company, firm,
incorporated body of persons of any country, or any agency, thereof. 

  

	 	(c)	 The headings in this Agreement are for convenience only and shall not affect its interpretation.

  

	 	(d)	 All references to Sections and Schedules refer, unless the context otherwise requires, to
Sections and Schedules of this Agreement. 

  

			
	

	  	Page 8 of 39

 EXECUTION COPY 

 

	 	(e)	 All references to statutes or statutory provisions shall be taken to be a reference to the statutes or
provisions as revised, amended, supplemented or re-enacted from time to time, and shall include any subsidiary legislation made thereunder.

  

	3.	 GRANT OF LICENSE 

 

	3.1	 Licensors hereby grant to Licensee, and Licensee accepts, subject to the terms and
conditions hereof, and subject to Licensors’ rights under Section 3.2 and retained governmental rights, including rights retained by the United States Government, if any, in accordance with the Bayh-Dole Act of
1980 (established by P.L. 96-517 and amended by P.L. 98-620, codified at 25USC § 200 et. seq. and implemented according to 37 CFR Part 401), an exclusive,
royalty-bearing worldwide license with rights to grant and authorize Sub-licensees to make, have made, use, sell, offer for sale and import Licensed Products and otherwise exploit the Patent Rights in the
Field of Use during the Term. 

  

	3.2	 Nothing in this Agreement shall prejudice Licensors’ right to practice itself, and to allow non-profit academic third parties to practice, the Patent Rights for Academic Purposes. 

  

	3.3	 Licensors shall not be obliged under this Agreement to render any technical assistance, or support, or
provide training to Licensee, for purposes of practicing any Patent Rights granted hereunder. 

  

	3.4	 Licensee shall own all rights, title and interests in and to all of Licensee Improvements and may
use the Licensee Improvements at its sole discretion. For clarity, improvements, inventions and other intellectual property generated by Dario Campana, alone or in collaboration with other employees or contractors of Licensee, shall be
Licensee Improvements or otherwise solely owned by Licensee (as between the Parties), if generated by Dario Campana acting in his capacity as a consultant for Licensee and without the use of any material resources of
Licensors. 

  

	3.5	 Licensee and NUS shall each [***] disclose to each other any Joint Improvements developed
or created. NUS and Licensee (to the extent Licensee becomes aware of any NUS Improvement) shall [***] disclose to each other any NUS Improvements developed or created. 

 

	3.6	 NUS hereby grants to Licensee, subject to the same terms and conditions as the practice of
Patent Rights under this Agreement as set forth in Section 3.1 [***], including but not limited to a clause substantially similar to Section 3.2 above in respect of Licensors’
right to practice for Academic Purposes: 

  

	 	(a)	 an exclusive license to NUS Improvements that are dominated by the claims of the Patent Rights
licensed under this Agreement; 

  

	 	(b)	 an exclusive license, limited to use [***], to NUS Improvements that are not dominated by the claims of
the Patent Rights licensed under this Agreement, but that relate to [***], and that are invented, and/or are disclosed in the first patent application claiming the same that is filed, [***]. For clarity, the exclusive
license under this Section 3.6(b) includes technology arising from research performed solely in the laboratory of Dario Campana that falls outside the scope of the Patent Rights but relates to [***], and is invented or filed [***]; and

  

			
	

	  	Page 9 of 39

 EXECUTION COPY 

 

	 	(c)	 An exclusive license, limited to use in connection with natural killer cells, to compositions comprising [***]
that were developed, [***], solely in the laboratory of Dario Campana; 

  

	 	(d)	 An exclusive license, limited to use in connection with natural killer cells, to compositions comprising [***]
that were developed, [***], solely in the laboratory of Dario Campana. 

 The licenses to the compositions described in
Section 3.6(c) and (d) above (collectively, “Additional NUS Compositions”) include [***] Additional NUS Compositions. Further, the licenses to a NUS Improvement and/or such
Additional NUS Composition, as applicable, in this Section 3.6 includes a license under all Other Patent Rights claiming or disclosing the same. 

For the purposes of this Section 3.6 and Section 3.7, inventions that relate to or
comprise [***] disclosed in the Patent Rights shall be deemed to be dominated by the claims of the Patent Rights. For purposes of the preceding sentence, “functional equivalence” shall mean [***]. 

 

	3.7	 NUS hereby grant to Licensee an option to negotiate in good faith for an exclusive license to
NUS Improvements that are not dominated by the claims of the Patent Rights exclusively licensed under this Agreement, but that relate to [***]; and that are invented, or are disclosed in the first patent
application claiming the same that is filed, [***], together with any Other Patent Rights claiming or disclosing such NUS Improvements (“Improvement Option”). The Improvement Option shall be
exercisable for a period of [***], unless extended by the mutual written agreement of the Parties, from the date on which such NUS Improvements are disclosed to Licensee by NUS (“Improvement Option
Period”). NUS shall provide to Licensee a copy of each invention disclosure received by NUS’ Industry Liaison Office disclosing a NUS Improvement that is subject to Licensee’s Improvement Option, and in any event shall
provide each such invention disclosure to Licensee [***] and prior to the time of [***]. Upon Licensee’s exercise of its NUS Option, NUS and Licensee will negotiate in good faith in an attempt to reach
a license agreement which shall be subject to the same terms and conditions as the practice of Patent Rights under this Agreement, including but not limited to a clause substantially similar to Section 3.2 above in
respect of Licensors’ right to practice for Academic Purpose, but on [***], the negotiation period not to exceed [***], unless extended by the

  

			
	

	  	Page 10 of 39

 EXECUTION COPY 

 

	 	
mutual written agreement of the Parties, from the date that Licensee exercises its Improvement Option (“Improvement Option Negotiation Period”). NUS
and Licensee agree that if Licensee does not exercise its Improvement Option [***], the Improvement Option (for such NUS Improvement only) shall be deemed to have lapsed. NUS and Licensee
further agree that if Licensee exercises its Improvement Option within the Improvement Option Period but [***], NUS and Licensee fail to conclude and execute a binding written license agreement
[***], the Improvement Option (for such NUS Improvement only) shall be deemed [***]; provided, however, that [***]. The provisions of this Section 3.7 shall also apply, mutatis mutandis, to NUS’s rights
under any Joint Improvements (and any Other Patent Rights claiming or disclosing the same), to the extent not already licensed exclusively to Licensee pursuant to Section 3.8 below. 

 

	3.8	 Licensee and NUS agree that all rights, title and interests in and to all Joint
Improvements shall be co-owned by NUS and Licensee as tenants in common in equal, undivided shares. NUS hereby grants an exclusive license to Licensee to NUS’s
rights, title and interest and joint share in any such Joint Improvements that are invented and/or disclosed in a patent application having an earliest priority date within [***], together with any Other Patent Rights
claiming or disclosing the same, subject to the same terms and conditions as the practice of Patent Rights under this Agreement as set forth in Section 3.1, including but not limited to a clause
substantially similar to Section 3.2 above in respect of the practice of Joint Improvements for Academic Purposes, [***]. 

  

	4.	 SUB-LICENSING 

 

	4.1	 Licensee shall have the right to grant written, sub-licenses
under all or any of the licenses granted under Section 3.1, 3.6 and 3.8 of this Agreement to any person, provided that: 

  

	 	(a)	 Licensee shall be responsible for the payment to Licensors of all amounts payable hereunder with respect to the
activities of any Related Company or Sub-Licensee; 

  

	 	(b)	 Any sublicense granted to a Related Company shall not grant to such Related Company any rights which are
inconsistent with the rights and obligations of Licensee hereunder; and Licensee shall remain responsible to the Licensors hereunder for all activities of its Related Companies to the same extent as if such activities had been undertaken by Licensee
itself; 

  

	 	(c)	 Licensee shall be responsible for its Sub-Licensees and
shall not grant any rights which are inconsistent with the rights and obligations of Licensee hereunder; 

  

	 	(d)	 any act or omission of a Sub-Licensee or of a Related Company
under a sublicense of the Patent Rights, which would be a breach of this Agreement if performed by Licensee, shall be deemed to be a breach by Licensee of this Agreement; it being
understood that the Licensors shall not have the right to terminate this Agreement as a result of any such act or omission of a Sub-Licensee if such act or omission is capable of remedy and, [***] below, the
applicable Sub-Licensee or Licensee itself cures such breach; 

  

			
	

	  	Page 11 of 39

 EXECUTION COPY 

 

	 	(e)	 each sub-license agreement granted by Licensee to a Related
Company or Sub-Licensee shall include a right to audit such Related Company or Sub-Licensee granted to Licensors of the same scope as provided in
Section 9.l(b) hereof with respect to Licensee; 

  

	 	(f)	 Licensee shall at all times indemnify and keep indemnified Licensors against all or any costs,
claims, damages or expenses incurred by Licensors, or for which Licensors may become liable, pursuant to any third party claim or proceedings to the extent the same is a result of the default or negligence of any Sub-Licensee or of a Related Company under a sublicense; and 

  

	 	(g)	 upon the termination of this Agreement under Section 18, all
sublicenses of Licensee’s rights hereunder granted to (i) a Qualified Sub-Licensee(s) shall survive automatically; and (ii) any Sub-Licensee that
is not a Qualified Sub-Licensee, shall survive at the Licensors’ option, in each case, with the same field, level of exclusivity and territorial scope as the
sub-license under the Patent Rights that had been granted by Licensee to such Sub-Licensee prior to the applicable termination of this Agreement, and Licensors and each
such Sub-Licensee shall negotiate in good faith and [***] enter into a direct license agreement between them, [***]. 

  

	4.2	 Licensee shall, within [***] with a Sub-Licensee, provide
Licensor with a certified true copy of the sub-license agreement [***]. 

  

	4.3	 The sub-licenses granted by Licensee to a Sub-Licensee under Licensee’s rights under Section 3.1 of this Agreement shall [***], provided that [***], as the case may be. 

 

	4.4	 For the purposes of this Agreement (including without limitation, Section 6 below), payments made
to Licensors directly by a Sub-Licensee or Related Company of Licensee and activities of Sub-Licensees, Licensee’s Related Companies and others
acting under Licensee’s authority, shall be deemed [***] for purposes of determining [***] under this Agreement. 

  

	5.	 COMMENCEMENT DATE AND TERM 

This Agreement shall come into effect on the Effective Date and shall continue in force until the expiration of the last to
expire of any patents under the Patent Rights unless terminated earlier in accordance with this Agreement (“Term”). 

  

			
	

	  	Page 12 of 39

 EXECUTION COPY 

 

	6.	 OBLIGATIONS OF LICENSEE 

 

	6.1	 Licensee hereby undertakes and agrees with Licensors that it will at all times during the Term
observe and perform the terms and conditions set out in this Agreement and in particular shall: 

  

	 	(a)	 use [***] to effect introduction of [***] into the commercial market [***]; and

  

	 	(b)	 deliver to Licensors the Licensee’s annual financial statements, within [***]
during the Term, the first annual financial statements being due to NUS [***]; and 

  

	 	(c)	 deliver to Licensors the Licensee’s technical development update including
[***], no later than [***]. 

  

	6.2	 Licensee also undertakes to meet the following Performance Objectives by the respective Dates of
Achievement: 

  

			
	 Performance Objectives:
	  	Date of Achievement
	 1. [***]
	  	[***]
		
	 2. [***]
	  	[***]
		
	 3. [***]
	  	[***]
		
	 4. [***]
	  	[***]
		
	 5. [***]
	  	[***]
		
	 6. [***]
	  	[***]

  

	6.3	 If Licensee fails to meet, or anticipates that it will fail to meet, any of the Performance Objectives
by the applicable Date of Achievement set out in Section 6.2:- 

  

	 	(a)	 the Parties shall, at Licensee’s written request (to be sent no later than [***]), have good faith
discussions, for a period of up to [***] from the date of the Licensee’s written request, on the reasons for such failure and any mutually agreeable extension of the then-current Dates of Achievement for any outstanding Performance Objectives.

  

			
	

	  	Page 13 of 39

 EXECUTION COPY 

 

	 	(b)	 Licensee may also obtain an extension of any Date of Achievement for a period of [***] in the case of [***]
listed in Section 6.2 above and [***] in the case of [***]. In order to obtain such an extension, Licensee shall, [***] for the applicable Performance Objective specified in Section 6.2 above: (i) [***] with respect to a request for an
extension of [***] and [***] with respect to a request for an extension of [***], and (ii) provide to Licensors a copy of [***]. Licensee may obtain no more than [***] extensions of the Date for Achievement for each Performance Objective [***].
Following [***], the Date of Achievement of the relevant Performance Objective will be deemed to be amended to incorporate the relevant [***] or [***] extension, as the case may be, and all other outstanding Performance Objectives shall be deemed
extended by the same time period. 

  

	 	(c)	 If Licensee fails to satisfy the Performance Objectives on or before the applicable Dates of Achievement (as
extended pursuant under Section 6.3(a) or (b) above, if applicable), Licensors shall, at their option, have the right, by notice in writing to Licensee, to: (i) terminate the exclusivity of the license granted under Section 3.1;
or (ii) terminate this Agreement pursuant to Section 18.1(a). 

  

	7.	 FINANCIAL PROVISIONS 

 

	7.1	 In consideration for the rights granted under Section 3, Licensee shall pay to
St. Jude a non-refundable upfront fee in US dollars equivalent to Singapore Dollars Forty Two Thousand Seven Hundred and Fifty Only (SGD 42,750) (“Upfront Fee”) [***]. 

 

	7.2	 In addition to the Upfront Fee under Section 7.1, Licensee shall pay to
Licensors during the Term of this Agreement, [***] royalties (“Royalty”) at the rate of 2.5% of Net Sales. The following Royalty shall be payable [***]; [***] until the
[***]. The Royalty shall be payable to Licensors no later than [***]. Licensors recognize that the Licensee may need to obtain additional patent rights and licenses to commercialize Licensed
Products. If Licensee, its Related Company or Sub-Licensee is obligated, with respect to any Licensed Product, to pay royalties or other amounts to any
third party in respect of any intellectual property rights that are reasonably required, or reasonably expected to be required, to make, use or sell any Licensed Product in such country, then Licensee shall have the right to credit
[***] against the Royalty owing to Licensors above for such year with respect to Net Sales of such Licensed Product [***]; provided, however, that Licensee shall not reduce the amount of the Royalty paid to
Licensors with respect to such Net Sales of such Licensed Product in a particular calendar year [***] to less than [***]% of Net Sales of such Licensed Product [***]. [***] royalty shall be due on Net
Sales of any Licensed Product, [***] if such Licensed Product is covered by multiple patents, patent applications or claims within the Patent Rights, NUS Improvements or Joint Improvements.

  

			
	

	  	Page 14 of 39

 EXECUTION COPY 

 

	7.3	 In addition to the Upfront Fee under Section 7.1 and in consideration of the
rights granted by Licensors under Section 3 to the Licensee, the Licensee, on behalf of itself and all its stockholders, shall, upon execution of this Agreement, issue to NUS or its nominee,
pursuant to the form of Common Stock Issuance Agreement attached hereto as Exhibit A, 250,000 fully paid-up common stock in the Licensee (“Common Stock”), which Licensee represents
being [***]% of Licensee’s [***] issued shares and [***] shares issued or reserved for future issuance pursuant to stock option plans or otherwise. The Common Stock shall have [***]. [***]. For purposes of clarity, upon the closing of
the Series A Financing, NUS or its nominee shall have no further rights to receive any additional shares of stock in Licensee. 

  

	7.4	 Licensee shall further pay to Licensors non-refundable
payments as follows and subject to the terms of this Section 7.4 below: 

  

	 	(a)	 a license maintenance fee within [***] of [***] during the Term of the Agreement commencing with January I,
2017 (“License Maintenance Fee”): 

  

					
	 Anniversary Date
	  	Fee	 
	 Years 1-2
	  	SGD $	25,000	 
	 Years 3+
	  	SGD $	50,000	 

 The License Maintenance Fee shall be paid in US dollars and [***]; 

 

	 	(b)	 [***]; 

  

	 	(c)	 [***]; 

  

	 	(d)	 [***]; 

  

	 	(e)	 [***]; 

  

			
	

	  	Page 15 of 39

 EXECUTION COPY 

 

	 	(f)	 [***]; 

  

	 	(g)	 [***]; 

  

	 	(h)	 [***]; and 

  

	 	(i)	 [***]. 

Notwithstanding the foregoing, in the event that a milestone stipulated in Sections 7.4(c) to (e) and (g) to
(i) above is first achieved by Licensee, or its Related Company or Sub -Licensee, as applicable, [***], the Licensee shall [***] and if such milestone is subsequently achieved by Licensee, its Related Company or Sub-Licensee, as applicable, [***], then [***]. For the avoidance of doubt, the Parties acknowledge and agree that in no event shall the amounts to be paid to Licensors under Sections 7.4(b) through 7.4(i) [***].

 [***] of milestone payments (b)-(i) shall be [***]. 
  

	7.5	 Licensee shall further pay to Licensors: 

 

	 	(a)	 [***]; 

  

	 	(b)	 [***]; 

  

	 	(c)	 [***]; and 

  

			
	

	  	Page 16 of 39

 EXECUTION COPY 

 

	 	(d)	 [***]. 

For the sole purpose of supporting research and development or infrastructure of Licensee, Licensee shall be allowed to
defer payment of Licensors’ share of any Sublicense Revenue received [***] for a period of up to [***]. 
  

	7.6	 All fees, royalties and all other sums payable under this Agreement shall be paid in US Dollars.
All such payments due in a particular accounting period computed in other currencies shall be converted into US dollars at the exchange rate for bank transfers from such currency to US dollars as quoted by the Wall Street Journal on the last day of
such accounting period. All fees, royalties and all other sums payable under this Agreement shall be made payable to “[***]”. Wire transfers may be made using the following information: 

Acct Name: [***] 
 Acct Number:
[***] 
 Bank Name: [***] 
 Bank
Swift: [***] 
 Bank ABA #: [***] 

Bank Address: [***] 
 [***] shall
be responsible for any and all costs associated with wire transfers and shall include a reference to this Agreement in any wire transfer payment. Payments made by check should be sent to the following address: 

[***] 
 or in such other manner as
Licensors may specify from time to time to Licensee. Where any fees, royalties or any other payments payable by Licensee to Licensors under this Agreement, including, but not limited to royalties, upfront fees and
patent costs reimbursements, are subject to goods and services taxes, value added taxes, withholding taxes and other applicable taxes or duties, these taxes and duties shall be borne [***]. Subject to Section 16.2 below, Licensee
agrees to hold harmless from, and indemnify Licensors against, all liabilities, costs, damages suffered by Licensors of whatever nature resulting from Licensee’s failure duly and timely to pay and discharge its
liability for any of the aforementioned taxes or duties. 
  

	7.7	 If Licensee fails to pay in full to Licensors any undisputed fees, royalties or other sums
payable under this Agreement by their respective due dates, the payment shall accrue interest beginning on the tenth day following the due date thereof, calculated at the rate of [***] the date said payment is due. 

 

	7.8	 For clarity, the payments made by Licensee to St. Jude, as required under
Section 7.6, shall satisfy in full Licensee’s payment obligations under this Agreement to both Licensors for the amounts paid. No duplicative payments shall be due to NUS, and
St. Jude shall be solely responsible for accounting to NUS for its portion (as determined as between the Licensors) of the amounts paid by Licensee to St. Jude. 

  

			
	

	  	Page 17 of 39

 EXECUTION COPY 

 

	8.	 ACCOUNTS 

  

	8.1	 Licensee shall: 

 

	 	(a)	 provide a statement accompanying all fees, royalties and other payments made under this Agreement,
showing all items of account from which such fees, royalties and other payment are calculated, such statements to be certified by an authorized officer of Licensee as properly reflecting all amounts due to Licensors in accordance with
the relevant provisions under this Agreement; 

  

	 	(b)	 keep true, accurate and complete accounts and records in sufficient detail to enable the amount of
royalties and other sums payable under this Agreement to be determined by Licensors; 

  

	 	(c)	 at the reasonable request of Licensors [***], and upon not less than [***] prior written notice,
allow an independent certified public accounting firm of internationally recognized standing selected by Licensors and reasonably acceptable to Licensee, at Licensors’ expense, during Licensee’s normal business
hours, to inspect, audit and copy those accounts and records pertaining to the items shown on the statements provided under Section 8.l(a) for [***] following the end of the [***] to which they pertain. Such accounting firm will be bound
to hold all information in confidence between the Parties except as necessary to communicate Licensee’s non-compliance (if any) with its reporting and payment obligations under this
Agreement to Licensors. 

  

	8.2	 If, following any inspection and audit pursuant to Section 8.l(c), Licensors’
independent accounting firm discovers a discrepancy, in Licensors’ disfavor, between the amount of fees, royalties and other sums actually paid by Licensee and those which should have been paid under this Agreement, which is
in excess of [***] of those that should have been paid under this Agreement, Licensee shall, within [***] of the date of Licensors’ notification thereof, reimburse St. Jude for any such deficiency [***]. 

 

	8.3	 The provisions of this Section 8 shall remain in full force and effect after the
termination of this Agreement for any reason for a period not to exceed [***] until the settlement of all subsisting claims of Licensors under this Agreement. 

 

	9.	 PROSECUTION OF PATENT APPLICATIONS AND MAINTENANCE OF PATENTS 

 

	9.1	 Licensee shall [***]. 

 

	9.2	 Licensors shall, from the Effective Date of this Agreement, control the management and further
prosecution and maintenance of the Patent Rights and the Other Patent Rights (collectively, the “Prosecuted Patent Rights”). Subject to Section 9.4 below, Licensors shall:

  

			
	

	  	Page 18 of 39

 EXECUTION COPY 

 

	 	(a)	 seek and maintain the strongest patent portfolio practicable with respect to the Prosecuted Patent
Rights and use patent attorneys (including foreign patent counsel) reasonably acceptable to Licensee, such acceptance not to be unreasonably withheld; 

 

	 	(b)	 instruct such patent attorneys to [***] copy Licensee on all written correspondence sent to or
received from any patent office (including all official actions) and give Licensee an opportunity and [***] to (i) comment on and advise Licensors with respect to all such correspondence and proposed responses to office actions, and
(ii) provide consultation and input on all strategic decisions with respect to the preparation, filing, prosecution and maintenance of all patent applications and patents within the Prosecuted Patent Rights; and 

 

	 	(c)	 consider in good faith and reasonably incorporate all such comments, input and advice provided by
Licensee and, without limiting the foregoing, Licensors shall file patent applications included the Prosecuted Patent Rights in each country requested by Licensee; 

 

	 	(d)	 not abandon or allow to lapse any such Prosecuted Patent Rights, or to amend or re-file the patent specifications of any patent applications within the scope of the Prosecuted Patent Rights, without first providing [***] prior written notice to Licensee. 

 

	9.3	 Licensee shall, [***], execute and do such assurances, acts and things, and execute such documents as
Licensors may reasonably require to prosecute patent applications within the Prosecuted Patent Rights and to grant and to maintain each of the Prosecuted Patent Rights in force. In addition, upon any Patty’s request,
NUS, St Jude and Licensee shall enter into a “commonality of interest” agreement to maintain attorney-client privilege and confidentiality with respect to the parties’ communications hereunder pertaining to the filing and/or
prosecution of any of the Prosecuted Patent Rights. 

  

	9.4	 It is hereby agreed and understood that, notwithstanding Section 9.2, Licensee shall,
by giving [***] to Licensors, [***]. If Licensee elects [***]: 

  

	 	(a)	 the license and/or rights granted pursuant to this Agreement in respect of the specific Prosecuted Patent
Rights for which Licensee has made the election, shall automatically terminate as of the expiration of [***] and such patent or patent application shall thereafter be deemed to be excluded from the definition of “Patent Rights”
or “Other Patent Rights,” as applicable, hereunder. 

  

	 	(b)	 [***] of such notice pursuant to Section 9.4, Licensors may continue to file for,
prosecute and/or maintain such specific Prosecuted Patent Rights in such country or countries in respect of which Licensee has made the election, [***], and notwithstanding Section 3, to thereafter deal with
the same with respect to such specific Prosecuted Patent Rights (or, if applicable, Licensors’ interest therein) in that country or countries as Licensors deem fit, without having to account to Licensee therefor; and

  

			
	

	  	Page 19 of 39

 EXECUTION COPY 

 

	 	(c)	 [***], Licensee shall have no further obligation [***]; 

 

	 	(d)	 For the avoidance of doubt, Licensors shall have and continue to retain their respective proprietary interests
in any Patent obtained pursuant to Section 9.4(b). 

  

	9.5	 Subject to Section 9.4 above and the terms of this
Section 9.5 below, Licensee shall reimburse Licensors for (a) [***] incurred by Licensors with respect to the preparation, filing, prosecution and maintenance of the Prosecuted Patent Rights (“Patent Costs”)
[***], and (b) [***] incurred by Licensors with respect to the preparation, filing, prosecution and maintenance of the Patent Rights [***]. 

  

	9.6	 [***], Licensee shall further pay to the Licensors an administrative charge of [***] of the [***] incurred by
NUS (“Administrative Fee”). 

  

	9.7	 Licensors shall provide to Licensee a detailed and itemized statement of the Patents Costs and Administrative
Fee incurred after the Effective Date on a [***] basis (but in no event less than [***] and Licensee’s payment of the undisputed Patent Costs and Administrative Fee reflected in each such statement shall be due within [***] after
Licensee’s [***]. 

  

	9.8	 To facilitate the smooth prosecution, processing and maintenance of Patent Rights by Licensors,
Licensee’s appointed representative for all patent matters shall be: 

 Name: [***] 

            [***] 

Email Add.:      [***] 

Phone No.:        [***] 

Fax No.:            [***] 

 

	10.	 FORMAL LICENSE FOR REGISTRATION 

 

	10.1	 Within [***] of a patent within Patent Rights or Other Patent Rights, each of the Parties
shall execute a separate formal license in respect of such patent for registration in all or any competent registries within such countries as may be determined by Licensee, each such license to be in the form set out in Schedule
3 or as nearly in such form as may be required under the laws of such country in which it is to be registered. 

  

	10.2	 Each of such formal licenses shall operate subject to and with the benefit of all the terms of this
Agreement, the terms of which shall be deemed to be incorporated in their entirety into each of such formal licenses. In the event of any conflict in meaning between any such formal license and the provisions of this Agreement, the
provisions of this Agreement shall prevail. 

  

	10.3	 The Parties shall [***] to ensure that, to the extent permitted or required by relevant authorities
(e.g., governmental or financial authorities), this Agreement shall not form part of any public record. 

  

			
	

	  	Page 20 of 39

 EXECUTION COPY 

 

	10.4	 Each of the Parties shall, at the request of the other Party, execute any further document
that may be necessary to: 

  

	 	(a)	 give effect to this Agreement; or 

 

	 	(b)	 procure or protect in any country the rights of the other Party under this Agreement and/or in
relation to the Patent Rights or Other Patent Rights. 

  

	11.	 INFRINGEMENT OF PATENTS 

 

	11.1	 Licensee shall forthwith notify Licensors in writing of any infringement, or suspected or
threatened infringement, of any of the Patent Rights or Other Patent Rights by any third party that shall at any time come to its knowledge. Each Licensor shall [***] notify Licensee and the other Licensor in
writing of any infringement, or suspected or threatened infringement, of any of the Patent Rights or Other Patent Rights by any third party that shall at any time come to its knowledge. 

 

	11.2	 Licensee (or, to the extent designated by Licensee, its Related Company or any Qualified Sublicensee)
shall have the [***], to enforce the Patent Rights and/or Other Patent Rights and/or to defend the Patent Rights and/or Other Patent Rights (e.g., in any declaratory judgment, opposition, post grant challenge,
inter partes review or biosimilar challenge) with respect to the same. 

  

	11.3	 In the event that any claims or counter-claims are issued or made by a third party against Licensors as
a result of such action taken by Licensee (or its designee described in Section 11.2 above) under Section 11.2, Licensee (or such designee) shall have control over, and shall take steps to defend Licensors
against such claims and/or counterclaims and shall have control over, and shall conduct [***], the defense of the Licensors in consultation with the Licensors. Licensee shall indemnify Licensors against all Liabilities (as
defined in Section 16.1 below) arising from such claims and counter-claims issued or made by a third party; provided that the indemnification procedures and other terms set out in Section 16.2 shall be deemed to apply mutatis mutandis
(and any references in Section 16.2 below to Section 16.1 shall be deemed to be replaced by Section 11.3 for such purposes). 

  

	11.4	 Licensors shall reasonably cooperate, [***] and at Licensee’s [***] request, in taking such steps,
including joining in any such action and cooperating with Licensee (or such designee described in Section 11.2 above) in connection therewith. 

  

	11.5	 Any recoveries pursuant to Section 11.2 shall be used [***] Licensee (and/or
its designee described in Section 11.2 above) [***], and any remainder shall be [***]. For clarity, [***] provision. 

  

	11.6	 If Licensee (or its designee described in Section 11.2 above) decides not to or fails, within [***]
pursuant to Section 11.1, to take steps to prevent or restrain any infringement by any third party of any of the Patent Rights, then Licensors shall be entitled to take action to prevent or restrain such
infringement. In the event that Licensors decides to take action under this Section: 

  

			
	

	  	Page 21 of 39

 EXECUTION COPY 

 

	 	(a)	 Licensors shall have control over, and shall conduct [***], any such action as it deems fit; provided
that Licensors shall not initiate any legal. 

 proceedings with respect to any such infringement unless such infringement
is, in the reasonable opinion of the Licensors, commercially significant and Licensors have first consulted with Licensee in good faith regarding whether to initiate such infringement proceedings; 

 

	 	(b)	 Licensee shall, [***], provide or procure the provision of such assistance as NUS shall
reasonably require in taking such action; and 

  

	 	(c)	 Licensors shall be entitled to [***] as a result of any such action [***] being taken by
Licensors. 

  

	12.	 INFRINGEMENT OF THIRD PARTY RIGHTS 

 

	12.1	 lf any proceedings are brought against Licensee on grounds that the use or exploitation by Licensee
of any of the Patent Rights infringes the rights of any third party, Licensee shall [***] notify Licensors of the same. Licensee shall have the exclusive control of the defense of such proceedings

  

	12.2	 With respect of such proceedings as described in Section 12.1, Licensors shall
reasonably cooperate with Licensee (or to the extent designated by Licensee, its Related Company or any Qualified Sublicensee), at Licensee’s (or such designee’s) [***]. 

 

	13.	 TRADE MARKS 

  

	13.1	 Licensee shall have the absolute right and discretion to make, have made, use, sell, offer for sale and
import Licensed Products under any trade marks designated by Licensee (“Licensee’s Trade Marks”) provided that the Licensee’s Trade Marks shall be readily distinguishable from, and not confusingly
similar to, any trade mark or trade name, whether registered or not, of Licensors. 

  

	13.2	 Licensors hereby agrees that it shall have no claim, right, title or interest in or to the
Licensee’s Trade Marks (except where any of such Licensee’s Trade Marks is not readily distinguishable from, or is confusingly similar to, any trade mark or trade name of Licensors), and that all goodwill accruing
thereto shall belong to Licensee absolutely. 

  

	13.3	 Licensee shall have the sole conduct of all proceedings relating to the Licensee’s Trade
Marks. 

  

	13.4	 Licensee shall have the sole right to decide what action, if any, to take in respect of any infringement
or alleged infringement of the Licensee’s Trade Marks or any other claim or counterclaim brought or threatened in respect of the use or registration of any of the Licensee’s Trade Marks. 

 

	13.5	 Licensee shall not be obliged to bring or defend any proceedings in relation to the Licensee’s
Trade Marks. 

  

	13.6	 Licensors shall not be entitled to bring any proceedings in respect of any infringement or alleged
infringement of any of the Licensee’s Trade Marks. 

  

			
	

	  	Page 22 of 39

 EXECUTION COPY 

 

	14.	 CONFIDENTIALITY 

 

	14.1	 Each Party hereby agrees to use all reasonable efforts to maintain the secrecy of any and all
Confidential Information disclosed to it by the other Party under the terms of this Agreement, or developed pursuant to this Agreement, and not to disclose, without the express, written consent of the
disclosing Party, such Confidential Information of another Party to any third party. 

  

	14.2	 The receiving Party agrees to maintain the Confidential information of the disclosing Party in
confidence with the same degree of care as it holds its own confidential and proprietary information and in any event with no less than a reasonable standard of care. The receiving Party will use such Confidential Information for the
performance of this Agreement only (including the exercise of such Party’s rights hereunder). The receiving Party may disclose such Confidential Information on a need-to-know basis only to its directors, officers, employees, contractors (including sublicensees and other collaboration partners or contractors), consultants, advisors, authorized representatives or agents
(each a “Representative”, and collectively “Representatives”) who have undertaken obligations of confidentiality for the benefit of receiving Party which are substantially similar to those contained in this
Section 14 and will not disclose such Confidential Information to any third party, or use the Confidential Information for any other purpose. The receiving Party undertakes that its Representatives shall make use of
such Confidential Information only for the performance of this Agreement and receiving Party shall be responsible for any unauthorized use or disclosure of disclosing Party’s Confidential Information by its
Representatives. 

  

	14.3	 The receiving Party shall take all reasonable steps, including, but not limited to, those steps taken to
protects its own information, data or other tangible or intangible property that it regards as proprietary or confidential, to ensure that the Confidential Information of the other Party is not disclosed or duplicated for the use of any third
party, and shall take all reasonable steps to prevent its Representatives having access to the Confidential Information, from disclosing or making unauthorized use of any Confidential Information, or from committing any acts or
omissions that may result in a violation of this Agreement. 

  

	14.4	 The preceding obligations of non-disclosure and the limitation on the
right to use the Confidential Information shall not apply to the extent that the receiving Party can demonstrate that the Confidential Information: 

 

	 	(a)	 was already in the possession or control of the receiving Party prior to the time of disclosure
by disclosing Party, as evidenced by written records; or 

  

	 	(b)	 was at the time of disclosure by the disclosing Party or thereafter becomes public knowledge
through no fault or omission of the receiving Party; or 

  

	 	(c)	 is lawfully obtained by the receiving Party from a third party under no obligation of
confidentiality to the disclosing Party; or 

  

	 	(d)	 is developed by the receiving Party independently of the Confidential
Information, as evidenced by written records; or 

  

	 	(e)	 is required to be disclosed by court rule or governmental law or regulation, including, without limitation, any
rules and regulations promulgated by the United States Securities and Exchange Commission, provided that the receiving Party gives the disclosing Party prompt notice of any such requirement and cooperated with the disclosing Party
in attempting to limit such disclosure; or 

  

			
	

	  	Page 23 of 39

 EXECUTION COPY 

 

	 	(f)	 was disclosed by the receiving Party with the disclosing Party’s prior written
approval. 

  

	14.5	 Title to, and all rights emanating from the ownership of, all Confidential Information disclosed under
this Agreement shall remain vested in the disclosing Party. Nothing herein shall be construed as granting any license or other right to use the Confidential Information of the other Party other than as specifically agreed
upon by the Parties. 

  

	14.6	 [***], the receiving Party shall [***] return to the disclosing Party all written
materials and documents, as well as other media, made available or supplied by the disclosing Party to the receiving Party that contains Confidential Information, together with any copies thereof, except that the receiving
Party may retain one copy each of such document or other media for archival purposes, subject to protection and nondisclosure in accordance with the terms of this Agreement. 

 

	14.7	 Notwithstanding anything to the contrary in this Section 14, each Party may
disclose the Confidential Information of the other Party to the extent such disclosure is reasonably necessary to prosecute or defend litigation. In addition, Licensee may disclose the Confidential Information of
Licensors to the extent such disclosure is reasonably necessary to facilitate discussions with prospective investors or acquirers or to prospective Sub-Licensees, provided that Licensee
has procured that such prospective investors or acquirers or prospective Sub-Licensees undertake obligations of confidentiality which are substantially similar to those contained in this
Section 14 and will not disclose such Confidential Information to any third party, or use the Confidential Information for any purpose other than discussions with Licensee. 

 

	15.	 WARRANTIES; DISCLAIMER OF WARRANTIES 

 

	15.1	 Neither Licensors nor any of their trustees, directors, employees, or agents assumes any responsibility
for the manufacture, production, specifications, sale or use of the Invention or Licensed Products, by Licensee or any Sub-licensees. 

 

	15.2	 Except as provided in Section 15.5, Licensors make no representations,
and provide no warranties, express or implied, including, but not limited to, warranties of fitness for purpose or merchantability or satisfactory quality or compliance with any description, or any implied warranty arising from course of
performance, course of dealing, usage of trade or otherwise, regarding or with respect to the Invention or Licensed Products, and to the fullest extent permitted by law, all such warranties and representations are hereby excluded.

  

	15.3	 Licensors make no representations, and provide no warranties, express or implied, on the patentability
of the Invention or Licensed Products or of the enforceability of any Patent Rights, if any, and to the fullest extent permitted by law, all such warranties and representations are hereby excluded. 

 

	15.4	 Licensors make no representations, and provide no warranties, express or implied, that the Invention
or Licensed Products are or shall be free from infringement of any patent or other rights of third parties or of St. Jude’s rights to chimeric antigen receptors containing [***], and to the fullest extent permitted by law, all such
warranties and representations are hereby excluded. 

  

	15.5	 St. Jude represents that no third party (i) has rights to [***] and [***] or (ii) eights to any
continuing pending applications to the extent that such pending applications 

  

			
	

	  	Page 24 of 39

 EXECUTION COPY 

 

	 	
issue with only claims directed to [***]. NUS represents that NUS has not entered into any agreement [***], nor is it otherwise bound by any obligations that would, limit
Licensee’s licenses to any NUS Inventions, Additional NUS Compositions and/or to NUS’ rights in any Joint Inventions pursuant to Sections 3.6 and/or 3.8, as applicable, nor to Licensee’s Improvement Option pursuant to
Section 3.7, at least with respect to any NUS Improvement or Joint Improvement, as applicable, that relates to natural killer cell technology; and NUS agrees that it shall not enter into any such agreement, or otherwise become bound by any such
obligations, during the term of this Agreement or, in the case of NUS Improvements or Joint Improvements, as applicable, to which Licensee’s Improvement Option applies pursuant to Section 3.7, until Licensee’s rights with respect to
each NUS Improvement or Joint Improvement, as applicable, that is subject to such Improvement Option terminate or expire in their entirety in accordance with Section 3.7 above. Licensors represent and warrant that Licensors have
the full power and authority to grant the rights and licenses granted herein. 

  

	16.	 INDEMNITIES; INSURANCE; LIMITATION OF LIABILITY 

 

	16.1	 Licensee hereby indemnifies, holds harmless and defends Licensors from and against any and all
losses, damages, costs (including, without limitation, reasonable attorneys’ fees and other legal costs (subject to Section 16.2 below)), expenses and liabilities (collectively, “Liabilities”) whatsoever which Licensors
may incur or suffer from any actions brought by a third party or, solely with respect to Section 16.1(e) below, any claims or demands, in each case, to the extent arising from: 

 

	 	(a)	 the manufacture, marketing, distribution and sale of the Licensed Products by Licensee or
through any of its Related Companies or Sub-Licensees; or 

  

	 	(b)	 the use or exploitation of any of the Patent Rights by Licensee or its
Sub-Licensees or Related Company(ies) infringes the rights of any third party; 

  

	 	(c)	 any other agreements entered into by Licensee or any of its Related Companies or Sub-licensees relating to the Licensed Products and Invention or the performance or non-performance of the terms of such agreements or any representations or
statements made by Licensee or any of its Related Companies or Sub-Licensees relating to the Invention or Licensed Products; or 

 

	 	(d)	 any claim that a use of any Licensee Improvement or Joint Improvement or any other modification(s) made
by or on behalf of Licensee or any of its Sub-Licensees or Related Companies to an invention claimed in the Patents Rights or Other Patent Rights as of the Effective Date infringes any trademark,
trade secret, confidential information, copyright or patent or any other proprietary rights of any third party; or 

  

	 	(e)	 all taxes of any kind (except income tax in respect of consideration received by Licensors under
this Agreement), payments in lieu of taxes, import duties, assessments, fees, charges and withholdings of any nature whatsoever, and all penalties, fines, additions to tax or interest thereon, however imposed, whether levied or asserted against
Licensors by any tax authority of any country to the extent based solely on any activities of Licensee or its Related Company(ies) in accordance with this Agreement; or 

 

	 	(f)	 all charges, fines or any liability arising from any default or failure by Licensee or any of its
Related Companies or Sub-Licensees to comply with and observe all laws and regulations referred to in Section 17; or 

  

			
	

	  	Page 25 of 39

 EXECUTION COPY 

 

	 	(g)	 any action or omission of Licensee or any of its Related Companies or Sub-Licensees, or
any of their employees, agents or contractors in the performance of its obligations or the exercise of any of its rights under this Agreement. 

  

	16.2	 In the event that a Licensor intends to claim indemnification under Section 16.1 above, such
Licensor shall [***] notify Licensee in writing of the alleged Liabilities. Licensee shall have the right to control the defense and/or settlement thereof with counsel of its choice as long as such counsel is reasonably acceptable to the applicable
Licensor(s); provided, however, that each Licensor shall have the right to retain its own counsel for any reason, provided further that the costs of such counsel retained by a Licensor shall [***]. Licensors shall cooperate with Licensee and its
legal representatives in the investigation of any Liability covered by Section 16.1 above. A Licensor shall not, except with the written consent of Licensee, such consent not to be unreasonably withheld, voluntarily make any payment or
otherwise settle or compromise any third party claim for which a Licensor wishes to claim indemnification under this Section 16. For the avoidance of doubt, circumstances in which Licensee may reasonably withhold its consent shall include, but
shall not be limited to, payment, settlement or compromise that [***]. In addition, notwithstanding Section 16.1 above, Licensee shall have no obligation to indemnify or hold harmless any Licensor from any Liabilities to the extent that such
Liabilities arise directly from the acts or omissions of that Licensor ( or its employees, agents and/or representatives) or from any breach of any representation, warranty or other term of this Agreement by that Licensor. 

 

	16.3	 Prior to the first use of a Licensed Product in a human being, Licensee shall obtain and
shall thereafter maintain adequate product liability insurance and shall ensure that Licensors are named as an additional insured on the policy. Licensee shall supply Licensors with a copy of such insurance policy upon written
request. 

  

	16.4	 Licensors shall not have any liability to Licensee for any indirect, consequential, special or
incidental loss, damage, expense or liability (including lost profit and loss of goodwill, opportunity costs, loss of business, damage to reputation, claims by third patties or customers), or any exemplary or punitive damages, regardless of the form
of action, whether in contract or tort (including negligence), arising under or relating to this Agreement, including from the Licensee’s use or exploitation of the Patent Rights or Invention; provided however that nothing in this
Section I 6.4 shall be deemed to limit the indemnification obligations of Licensee under Section 7.6, Section 11.3 or Section 16.1 above to the extent a third patty recovers any such indirect, consequential, special or incidental
loss, damage, expense or liability, or any such exemplary or punitive damages with respect to a claim for which Licensee is obligated to indemnify the Licensors thereunder. Licensors’ liability to the Licensee for direct damages
or losses for any cause arising from the acts or omission of NUS and/or St. Jude in the performance of this Agreement shall be limited [***]. 

  

			
	

	  	Page 26 of 39

 EXECUTION COPY 

 

	17.	 COMPLIANCE WITH LAW 

 

	17.1	 Licensee shall observe, and shall require that its Related Companies and Sub-Licensees observe, all applicable laws and regulations, and obtain all necessary licenses, consents and permissions required, in respect of the manufacture, storage, marketing, distribution, sale (including
export), and importation of the Licensed Products. 

  

	18.	 TERMINATION 

  

	18.1	 Licensors shall be entitled forthwith to terminate this Agreement [***] by notice in writing if:

  

	 	(a)	 Licensee fails, or refuses, to perform or comply with any one or more of its material obligations under
this Agreement, and Licensee fails to remedy such default within [***] by Licensee from Licensors; 

  

	 	(b)	 Licensee ceases to carry on its business; 

 

	 	(c)	 Licensee is declared insolvent by a court of competent jurisdiction or is unable to pay its debts as
they fall due or suspends making payments with respect to all or any class of its debts or enters into any composition or arrangement with its creditors or makes a general assignment for the benefit of its creditors; 

 

	 	(d)	 Licensee goes into liquidation or if an order is made or a resolution is passed for the winding up of
Licensee whether voluntarily or compulsorily (except for the purpose of a bona fide reconstruction or amalgamation); or 

  

	 	(e)	 Licensee has a receiver or receiver and manager or judicial manager appointed over any part of its
assets or undertaking. 

  

	18.2	 Licensee may terminate this Agreement by giving [***] advance written notice of termination to
Licensors. 

  

	18.3	 Termination or expiration of this Agreement howsoever caused shall not prejudice any other obligation,
right or remedy of the Parties, that at the time of such termination or expiration, has already accrued to another Party or that is attributable to a period prior to such termination or expiration, including without limitation in respect of
any antecedent breach. 

  

	18.4	 Upon the termination of this Agreement: 

 

	 	(a)	 Licensee shall be entitled to continue to exercise the rights granted to it under this Agreement to such
extent and for such further period, not exceeding [***] from the date of termination, [***] to enable Licensee to satisfy any orders placed prior to such termination date or scheduled for delivery within such [***] period; 

  

	 	(b)	 subject to Sections 4.1(g) and 18.4(a) above, Licensee shall [***] cease to manufacture, market,
distribute, sell, import or use, either directly or indirectly, the Invention or Licensed Products; 

  

			
	

	  	Page 27 of 39

 EXECUTION COPY 

 

	 	(c)	 subject to Sections 4.l(g) and 18.4(a) above, each Party shall [***] return or destroy all
Confidential Information pursuant to Section 14.6; 

  

	 	(d)	 Licensee shall [***] pay all amounts due under this Agreement to Licensors and shall
submit a declaration in writing signed by a duly authorized officer that it has complied with such payment obligations, along with a copy of all materials [***] to support such declaration. 

 

	 	(e)	 if termination occurs within [***], Licensee shall, in consideration of Licensors’
forbearance to claim damages against Licensee for lost opportunity cost, provide [***]; 

  

	 	(f)	 if termination occurs within [***], Licensee shall, in consideration of Licensors’
forbearance to claim damages against Licensee for lost opportunity cost, provide [***]; and 

  

	 	(g)	 if termination occurs within [***] and if Licensee has filed patent applications or obtained patents to
any Licensee Improvements to Licensed Product(s) within the scope of the Patent Rights, Licensee agrees upon request to enter into good faith negotiations with Licensors or Licensors’ future licensee(s) for the
purpose of granting licensing rights to said patent applications and/or patents to the extent controlled by Licensee [***] and under [***]; provided that such request to negotiate a license must be made by Licensors, if at all, [***].

  

	18.5	 Notwithstanding termination of this Agreement under any of its provision, Sections 3.4, 3.8 (first
sentence only), 4.1(g), 7.8, 8 (for the applicable periods specified in such section), 14, 15, 16.1, 16.2, 16.4, 18.3, 18.4, 19, 20, 21 through to and including 28 shall survive the Term or the termination of this Agreement and shall be deemed to
remain in full force and effect. 

  

	19.	 USE OF LICENSORS’ NAME 

Licensee agrees that it shall not use in any press release or other announcement made to the general public the name of NUS
and/or St. Jude and/or the name of an affiliate, a current or former staff member, employee, student of affiliated physician or faculty of St. Jude or any logotypes or symbols associated with NUS and/or St. Jude or
the names of any directors or employees of NUS and/or St. Jude without the prior written consent of NUS and/or St. Jude; provided that, for the avoidance of doubt, nothing in this Section 19 shall be deemed to
prevent Licensee from making factual statements regarding (a) the existence of this Agreement to existing or potential investors, (sub) licensees, collaboration partners, subcontractors, consultants, advisers, regulatory authorities and/or
other governmental authorities and/or (b) with respect to Dr. Dario Campana’s position as a scientific advisor to Licensee; provided further that no reference is made to Dr Dario Campana’s previous affiliation with St. Jude
without St. Jude’s consent or to Dr Dario Campana’s affiliation with NUS without NUS’s consent. 

  

			
	

	  	Page 28 of 39

 EXECUTION COPY 

 

	20.	 FORCE MAJEURE EVENTS 

Notwithstanding anything else in this Agreement, no default, delay or failure to perform its obligations under the Agreement on
the part of either Party shall be construed a breach of this Agreement to the extent such default delay or failure to perform is shown to be due to causes beyond the control of the Party charged with a default, delay or failure
to perform, including but not limited to, causes such as strikes, lockouts or other labor disputes to perform, including, without limitation, riots, civil disturbances, actions or inaction of governmental authorities, epidemics, war, embargoes,
severe weather, fire, earthquakes, acts or God or the public enemy and nuclear disasters (each a “Force Majeure Event”). 
  

	21.	 NO PARTNERSHIP OR AGENCY 

No agency, partnership or joint venture is created hereby. Licensee does not have any authority of any kind to bind Licensors in
any respect whatsoever. 
  

	22.	 ASSIGNMENT 

  

	22.1	 Except as provided in Section 22.2 below, no Party shall assign any of its rights under this
Agreement, or novate its rights and obligations hereunder to any third party, without the prior consent in writing of the other Parties on terms to be agreed by the Parties. Where such consent is given, the Party, which is the
assignor, shall procure that such third party assignee covenants with the other Parties to be bound by the terms of this Agreement as if it had been a party hereto in place of the assignor. 

 

	22.2	 Notwithstanding Section 22.1, Licensee may assign this Agreement and/or its rights and/or
obligations hereunder, without the consent of Licensors, to (a) a Related Company or (b) a Pre-approved Assignee; provided that such assignment is in connection with a restructuring or other
corporate reorganization or merger or sale of Licensee or any business or assets or similar transaction. [***] and subject to the terms of Section 7 .5, if applicable. No assignment fee or other amounts shall be due hereunder with respect to
any consideration received by Licensee and/or its shareholders in connection with any of the Excluded Activities and/or an assignment of this Agreement and/or Licensee’s rights and/or obligations under this Agreement in connection with
any of the Excluded Activities. 

  

	22.3	 [***]. 

  

			
	

	  	Page 29 of 39

 EXECUTION COPY 

 

	23.	 NO WAIVER 

The failure or delay by a Party in enforcing an obligation, or exercising a right or remedy under this Agreement shall not be
construed or deemed to be a waiver of that obligation, right or remedy. A waiver of a breach of a term under this Agreement shall not amount to a waiver of a breach of any other term in this Agreement and a waiver of a particular
obligation in one circumstance will not prevent a Party from subsequently requiring compliance with the obligation on other occasions. Any waiver by a Party of any right under this Agreement shall be made in writing and signed
by the authorized representative of such Party. 
  

	24.	 NOTICES 

  

	24.1	 All notices, demands or other communications required or permitted to be given or made hereunder shall
be in writing and delivered personally, sent by internationally recognized priority carrier (e.g., FedEx), email correspondence (delivery receipt confirmed) or by telefax, addressed to the intended recipient thereof at its address or telefax number
as set out below (or to such other address or telefax number as any Party may from time to time notify the other Party). Any such notice, demand or communication shall be deemed to have been duly served on and received by the
addressee: 

  

	 	(a)	 if delivered by hand, at the time of delivery; 

 

	 	(b)	 if sent by priority carrier, within 3 business days of dispatch; or 

 

	 	(c)	 if sent by email at the time of delivery as shown by delivery and read receipts, or on the next business
day if received after the recipient’s normal business hours; or 

  

	 	(d)	 if transmitted by way of telefax, at the time of transmission, or on the next business day if received
after the recipient’s normal business hours. 

  

	24.2	 In proving the giving of a notice or other communication, it shall be sufficient to show:

  

	 	(a)	 in the case of communication via priority carrier, that the notice or other communication was contained
in an envelope which was duly addressed, sufficient carrier fees paid and posted; or 

  

	 	(b)	 in the case of telefax that the telefax transmission was duly transmitted from the dispatching terminal
as evidenced by a transmission report generated by the transmitting equipment. 

  

			
	NUS:	  	Licensee:
		
	[***]	  	[***]
	[***]	  	[***]
	Fax: [***] 	  	Email: [***]
	Email:[***]	  	Fax: [***]

  

			
	

	  	Page 30 of 39

 EXECUTION COPY 

 

 
			
	St. Jude	  	
		
	[***]	  	
	 St. Jude Children’s Research Hospital
 262
Danny Thomas Place
	  	
	 Memphis, TN 38105
 Email: [***]
	  	
	Fax: [***]	  	

  

	25.	 ENTIRE AGREEMENT 

This Agreement contains the entire agreement between the Parties hereto regarding the subject matter hereof, and supersedes all
prior agreements, understandings and negotiations regarding the same. No modification, variation or amendment shall be made to this Agreement unless made in writing, specifically referring to this Agreement and signed by the authorized
representatives of all of the Parties. 
  

	26.	 SEVERABILITY 

Should any one or more of the provisions of this Agreement be held to be invalid or unenforceable by a court of competent jurisdiction,
it shall be considered severed from this Agreement and shall not serve to invalidate the remaining provisions hereof. The Parties shall make a good faith effort to replace any invalid or unenforceable provision with a valid and
enforceable one such that the objectives contemplated by them when entering into this Agreement may be realized. 
  

	27.	 DISPUTE RESOLUTION 

 

	27.1	 Informal Resolution 

Any dispute, controversy or claim arising out of or in connection with this Agreement shall be resolved in the following manner: 

 

	 	(a)	 the aggrieved Party (“Claimant”) shall notify the responding Party
(“Respondent”) in writing (“Resolution Notice”) (and provide a copy of such notice to the other Party to this Agreement), setting forth in detail the nature of its dispute, controversy or claim
(“Claim”) and requesting a meeting (“Resolution Meeting”) of a senior representative from each Party to be held on a date not less than [***] nor more than [***] (“Resolution Period”) for the
purpose of resolving such Claim; 

  

	 	(b)	 the Respondent shall issue and deliver a written response to Claimant (and provide a copy
of such response to the other Party to this Agreement) not later than [***], setting forth in detail its response to such Claim, failing which the Resolution Meeting shall not proceed and the Claimant shall be entitled to
submit the dispute to arbitration as provided under Section 27.2 below; 

  

			
	

	  	Page 31 of 39

 EXECUTION COPY 

 

  

	 	(c)	 the senior representative from each Party shall meet to seek to resolve such Claim amicably between the
Claimant and the Respondent in good faith; and 

  

	 	(d)	 if such Claim is not resolved by the end of [***], then either Claimant or Respondent
shall be entitled to submit the dispute to arbitration, as provided under Section 27.2 below. 

  

	27.2	 Arbitration 

 

	 	(a)	 If, and to the extent that, any dispute has not been settled pursuant to
Section 27.1 above, then, upon written notice by any Party to the other Party(ies), any dispute with respect to the breach, performance or interpretation of this Agreement shall be referred to and finally resolved by
binding arbitration conducted by the Judicial Arbitration and Mediation Services International, Inc. (or any successor entity thereto) (“JAMS”) under the JAMS lnternational Arbitration Rules then in effect, except as modified in
this Agreement. The arbitration shall be conducted in the English language, by a panel of three (3) arbitrators, who shall be selected as described in this Section 27.2(a) below and the each of whom meet the qualifications described in
this Section 27.2(a). One of the arbitrators shall be selected by Licensee, one of the arbitrators shall be selected by the Licensors jointly, and the third (3rd) arbitrator shall be jointly selected by the two (2) Party-appointed
arbitrators. Each of the arbitrators shall be a lawyer admitted to practice in the United Kingdom with at least fifteen (15) years’ experience handling commercial contract disputes with respect to agreements governed by the law of England
and Wales. The arbitration panel may also engage an independent expert with experience in the subject matter of the Dispute and at least ten (10) years’ experience at a senior executive level in a pharmaceutical or biotechnology company,
or in an academic technology transfer office, to advise the arbitration panel. 

  

	 	(b)	 The Parties and the arbitration panel shall use [***] to complete any such arbitration within [***]. The
arbitration panel shall determine what discovery will be permitted, consistent with the goal of limiting the cost and time which the Patties must expend for discovery; provided that the arbitration panel shall permit such discovery as they deem
necessary to permit an equitable resolution of the dispute and shall [***] for the completion of discovery, which time period shall be determined by the arbitration panel based on the issues in dispute, the discovery requested by each of the
Parities and the overall goal of the Parties to complete any arbitration within [***]. 

  

	 	(c)	 The Parties agree that the decision of the arbitration panel shall be the sole, exclusive and binding
remedy between them regarding the dispute presented to the arbitration panel. Any decision of the arbitration panel may be entered in a court of competent jurisdiction for judicial recognition of the decision and an order of enforcement. The
arbitration proceedings and the decision of the arbitration panel shall not be made public without the joint consent of the Parties and each Party shall maintain the confidentiality of such proceedings and decision unless each Patty otherwise agrees
in writing; provided that either Party may make such disclosures as are permitted for Confidential Information of another Party under Section 14 above. 

  

			
	

	  	Page 32 of 39

 EXECUTION COPY 

 

	 	(d)	 Unless otherwise mutually agreed upon by the Parties, the arbitration proceedings shall be conducted in San
Francisco, CA, U.S.A. The Parties agree that they [***]. 

  

	 	(e)	 Pending the selection of the arbitration panel or pending the arbitration panel’s determination of the
merits of any dispute, any Party may seek appropriate interim or provisional relief from any court of competent jurisdiction as necessary to protect the rights or property of that Party.

  

	28.	 GOVERNING LAW 

This Agreement shall be governed by, interpreted and construed in accordance with the laws of England and Wales. 

 

	29.	 GENERAL 

  

	29.1	 Stamp duty or fees, if any, payable in respect of this Agreement shall be [***].

  

	29.2	 Each Party shall from time to time do all acts and execute all documents as may be reasonable necessary
in order to give effect to the provisions of this Agreement. 

  

	29.3	 Except as otherwise provided in this Agreement, the Parties shall [***] of this Agreement.

  

	29.4	 This Agreement may be executed in one or more counterparts by the Parties by signature of a
person having authority to bind the Party, each of which when executed and delivered, by facsimile transmission or other electronic modes of delivery, will be an original and all of which will constitute but one and the same Agreement.

 AS WITNESS the hands of the Parties hereto the day and year first above written. 

 

							
	SIGNED by for and on behalf of	  	)	  	SIGNED by for and on behalf of	  	
	NATIONAL UNIVERSITY OF	  	)	  	NKARTA, INC.	  	
	SINGAPORE	  	)	  		  	
				
	 /s/ Lily CHAN
	  		  	 /s/ Ali Behbahani
	  	
	Lily CHAN	  	)	  	Ali Behbahani	  	
	CEO, NUS Enterprise	  	)	  	President, Nkarta	  	
				
	SIGNED by for and on behalf of	  	)	  		  	
	ST. JUDE CHILDREN’S RESEARCH	  	)	  		  	
	HOSPITAL, INC.	  	)	  		  	
				
	 /s/ J. Scott Elmer
	  		  		  	
	J. Scott Elmer	  	)	  		  	
	Director of Technology Licensing	  	)	  		  	

  

			
	

	  	Page 33 of 39

 EXECUTION COPY 

 

 SCHEDULE 1 

The Invention covers: 
 [***] 

  

			
	

	  	Page 34 of 39

 EXECUTION COPY 

 

 SCHEDULE 3 

FORMAL LICENSE 

PATENT LICENSE FOR REGISTRATION 

[***] 

  

			
	

	  	Page 35 of 39

 EXECUTION COPY 

 

 Exhibit A 

Form of Common Stock Issuance Agreement 

(See attached.) 
 [***] 

  

			
	

	  	Page 36 of 39EX-10.10

 Exhibit 10.10 

 
 LEASE 

6000 SHORELINE COURT 

HCP LIFE SCIENCE REIT, INC., 

a Maryland corporation, 
 as
Landlord, 
 and 
 NKARTA,
INC., 
 a Delaware corporation, 

as Tenant. 

  

					
		  		  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 TABLE OF CONTENTS 

 

							
	 	  	 	  	Page	 
	 1.
	  	PREMISES, BUILDING, PROJECT, AND COMMON AREAS	  	 	4	 
	 2.
	  	LEASE TERM; OPTION TERM	  	 	5	 
	 3.
	  	BASE RENT	  	 	7	 
	 4.
	  	ADDITIONAL RENT	  	 	7	 
	 5.
	  	USE OF PREMISES	  	 	13	 
	 6.
	  	SERVICES AND UTILITIES	  	 	17	 
	 7.
	  	REPAIRS	  	 	19	 
	 8.
	  	ADDITIONS AND ALTERATIONS	  	 	19	 
	 9.
	  	COVENANT AGAINST LIENS	  	 	20	 
	 10.
	  	INSURANCE	  	 	21	 
	 11.
	  	DAMAGE AND DESTRUCTION	  	 	23	 
	 12.
	  	NONWAIVER	  	 	23	 
	 13.
	  	CONDEMNATION	  	 	24	 
	 14.
	  	ASSIGNMENT AND SUBLETTING	  	 	24	 
	 15.
	  	SURRENDER OF PREMISES; OWNERSHIP AND REMOVAL OF TRADE FIXTURES	  	 	27	 
	 16.
	  	HOLDING OVER	  	 	28	 
	 17.
	  	ESTOPPEL CERTIFICATES	  	 	28	 
	 18.
	  	SUBORDINATION	  	 	28	 
	 19.
	  	DEFAULTS; REMEDIES	  	 	29	 
	 20.
	  	COVENANT OF QUIET ENJOYMENT	  	 	30	 
	 21.
	  	SECURITY DEPOSIT	  			
	 22.
	  	COMMUNICATIONS AND COMPUTER LINE	  	 	34	 
	 23.
	  	SIGNS	  	 	34	 
	 24.
	  	COMPLIANCE WITH LAW	  	 	34	 
	 25.
	  	LATE CHARGES	  	 	35	 
	 26.
	  	LANDLORD’S RIGHT TO CURE DEFAULT; PAYMENTS BY TENANT	  	 	35	 
	 27.
	  	ENTRY BY LANDLORD	  	 	36	 
	 28.
	  	TENANT PARKING	  	 	36	 
	 29.
	  	MISCELLANEOUS PROVISIONS	  	 	36	 
		
	 EXHIBITS
	  			
			
	 A
	  	OUTLINE OF PREMISES	  			
	 B
	  	TENANT WORK LETTER	  			
	 C
	  	FORM OF NOTICE OF LEASE TERM DATES	  			
	 D
	  	FORM OF TENANT’S ESTOPPEL CERTIFICATE	  			
	 E
	  	ENVIRONMENTAL QUESTIONNAIRE	  			
	 F
	  	TENANTS PROPERTY	  			

  

					
		  	(i)	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 INDEX 

 

			
	 	  	 Page(s)

	 Accountant
	  	14
	 Advocate Arbitrators
	  	7
	 Alterations
	  	23
	 Applicable Laws
	  	37
	 Base Rent
	  	9
	 Brokers
	  	43
	 Building
	  	5
	 Closure Letter
	  	18
	 Common Areas
	  	6
	 Comparable Buildings
	  	7
	 Contemplated Effective Date
	  	31
	 Contemplated Transfer Space
	  	31
	 Direct Expenses
	  	9
	 Disputed Amounts
	  	40
	 Environmental Assessment
	  	18
	 Estimate
	  	14
	 Estimate Statement
	  	14
	 Estimated Direct Expenses
	  	14
	 Excepted Matters
	  	43
	 Expense Year
	  	9
	 Force Majeure
	  	41
	 Hazardous Materials
	  	15
	 Intention to Transfer Notice
	  	31
	 Landlord
	  	1
	 Landlord Parties
	  	25
	 Lease
	  	1
	 Lease Commencement Date
	  	6
	 Lease Expiration Date
	  	6
	 Lease Term
	  	6
	 Lease Year
	  	6
	 Lines
	  	36
	 Mail
	  	41
	 Net Worth
	  	32
	 Neutral Arbitrator
	  	8
	 Nine Month Period
	  	31
	 Notices
	  	41
	 Objectionable Name
	  	37
	 Operating Expenses
	  	9
	 Option Conditions
	  	6
	 Option Rent
	  	7
	 Option Term
	  	6
	 Outside Agreement Date
	  	7
	 Permitted Transferee
	  	32
	 Premises
	  	5
	 Project,
	  	5
	 Security Deposit
	  	36
	 Sign Specifications
	  	37
	 Statement
	  	13
	 Subject Space
	  	29
	 Summary
	  	1

  

					
		  	(ii)	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

			
	 	  	 Page(s)

	 Tax Expenses
	  	12
	 Tenant
	  	1
	 Tenant Work Letter
	  	5
	 Tenant’s Accountant
	  	14
	 Tenant’s Property
	  	24
	 Tenant’s Share
	  	13
	 Transfer Notice
	  	29
	 Transferee
	  	29
	 Transfers
	  	29

  

					
		  	(iii)	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 6000 SHORELINE COURT 

LEASE 
 This Lease
(the “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by and between HCP LIFE SCIENCE REIT, INC., a
Maryland corporation (“Landlord”), and NKARTA, INC., a Delaware corporation (“Tenant”). 

SUMMARY OF BASIC LEASE INFORMATION 
  

			
	TERMS OF LEASE	  	DESCRIPTION
		
	 1.  Date:
	  	May 29, 2018
		
	 2.  Premises

(Article 1).
	  	
		
	 2.1  Building:
	  	 6000 Shoreline Court
 South San Francisco,
California 94080
 Containing 136,372 rentable square feet of space

		
	 2.2  Premises:
	  	Suite 102, consisting of approximately 7,163 rentable square feet of space on the first (1st) floor of the Building, as further set forth in Exhibit A to
the Lease.
		
	 3.  Lease Term

(Article 2).
	  	
		
	 3.1  Length of Term:
	  	Approximately seven (7) years.
		
	 3.2  Lease Commencement Date:
	  	The later to occur of (i) the date the Premises are “Ready for Occupancy”, as defined in the Tenant Work Letter attached hereto as Exhibit B, which date is anticipated to be June 1, 2018, and
(ii) June 1, 2018.
		
	 3.3  Lease Expiration Date:
	  	If the Lease Commencement Date shall be the first day of a calendar month, then the day immediately preceding the seventh (7th) anniversary of the Lease Commencement Date; or,
if the Lease Commencement Date shall be other than the first day of a calendar month, then the last day of the month in which the seventh (7th) anniversary of the Lease Commencement Date
occurs.

  
  
  

 
  
  

 
  
  

 
  

  

					
		  		  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

			
		
	 4.  Base Rent (Article 3):
	  	

  

													
	 Lease Year
	  	Annual
Base Rent	 	  	Monthly
Installment
of Base Rent	 	  	Approximate
Monthly Base
Rent per Rentable
Square Foot	 
	 1
	  	$	438,375.60	 	  	$	36,531.30	 	  	$	5.10	 
	 2
	  	$	453,718.75	 	  	$	37,809.90	 	  	$	5.28	 
	 3
	  	$	469,598.90	 	  	$	39,133.24	 	  	$	5.46	 
	 4
	  	$	486,034.86	 	  	$	40,502.91	 	  	$	5.65	 
	 5
	  	$	503,046.08	 	  	$	41,920.51	 	  	$	5.85	 
	 6
	  	$	520,652.70	 	  	$	43,387.72	 	  	$	6.06	 
	 7
	  	$	538,875.54	 	  	$	44,906.30	 	  	$	6.27	 

 *Note: Tenant shall have no obligation to pay any Base Rent for the Premises attributable to the first three
(3) full calendar months of the Lease Term (the “Base Rent Abatement Period”); provided, however, Tenant shall be required to pay Tenant’s Share of Direct Expenses attributable to such period, as well as for all utilities
and other services. 
  

			
	 5.  Tenant Improvements (Exhibit B):
	  	Tenant Improvements to be constructed on a turn-key basis pursuant to the Work Letter attached hereto as Exhibit B.
		
	 6.  Tenant’s Share

(Article 4):
	  	5.2525%.
		
	 7.  Permitted Use

(Article 5):
	  	The Premises shall be used only for general office, research and development, engineering, laboratory, storage and/or warehouse uses, including, but not limited to, administrative offices and other lawful uses reasonably related
to or incidental to such specified uses, all (i) consistent with first class life sciences projects in South San Francisco, California (“First Class Life Sciences Projects”), and (ii) in compliance with,
and subject to, applicable laws and the terms of this Lease.
		
	 8.  Letter of Credit

(Article 21):
	  	$89,812.60.
		
	 9.  Parking

(Article 28):
	  	Three (3) unreserved parking spaces for every 1,000 rentable square feet of the Premises, subject to the terms of Article 28 of the Lease.

  

					
		  	-6-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

			
		
	 10.  Address of Tenant

(Section 29.18):
	  	 329 Oyster Point Blvd., 34th Floor

South San Francisco, CA 94080
 Attention: Chief Executive
Officer
 (Prior to Lease Commencement Date)
  

and
  

The Premises
 Attention: Chief Executive Officer

(After Lease Commencement Date)

		
	 11.  Address of Landlord

(Section 29.18):
	  	See Section 29.18 of the Lease.
		
	 12.  Broker(s)

(Section 29.24):
	  	CBRE, Inc.

  
  
  

  

					
		  	-7-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

	1.	 PREMISES, BUILDING, PROJECT, AND COMMON AREAS 

1.1    Premises, Building, Project and Common Areas. 

1.1.1    The Premises. Landlord hereby leases to Tenant and Tenant hereby leases from Landlord the premises
set forth in Section 2.2 of the Summary (the “Premises”). The outline of the Premises is set forth in Exhibit A attached hereto. The outline of the “Building” and the
“Project,” as those terms are defined in Section 1.1.2 below, are also further depicted on the Site Plan attached hereto as Exhibit A. The parties hereto agree that the lease of the Premises is upon
and subject to the terms, covenants and conditions herein set forth, and Tenant covenants as a material part of the consideration for this Lease to keep and perform each and all of such terms, covenants and conditions by it to be kept and performed.
The parties hereto hereby acknowledge that the purpose of Exhibit A is to show the approximate location of the Premises only, and such Exhibit is not meant to constitute an agreement, representation or warranty as to the
construction of the Premises, the precise area thereof or the specific location of the “Common Areas,” as that term is defined in Section 1.1.3, below, or the elements thereof or of the accessways to the Premises
or the “Project,” as that term is defined in Section 1.1.2, below. Except as specifically set forth in this Lease and in the Tenant Work Letter attached hereto as Exhibit B (the
“Tenant Work Letter”), Landlord shall not be obligated to provide or pay for any improvement work or services related to the improvement of the Premises. Tenant also acknowledges that neither Landlord nor any agent of Landlord has
made any representation or warranty regarding the condition of the Premises, the Building or the Project or with respect to the suitability of any of the foregoing for the conduct of Tenant’s business, except as specifically set forth in this
Lease and the Tenant Work Letter. Landlord shall deliver the Premises to Tenant fully decommissioned, in good, vacant, broom clean condition, and otherwise in substantially the same condition as of the date of this Lease, in compliance with all
laws, with the roof water-tight and shall cause the plumbing, electrical systems, fire sprinkler system, lighting, and all other building systems serving the Premises in good operating condition and repair on or before the Lease Commencement Date.
Notwithstanding anything in this Lease to the contrary, in connection with the foregoing Landlord shall, at Landlord’s sole cost and expense (which shall not be deemed an “Operating Expense,” as that term is defined in
Section 4.2.4), repair or replace any failed or inoperable portion of the HVAC systems, plumbing, electrical systems, fire sprinkler system, lighting, and all other building systems serving the Premises during the first two (2) years of
the initial Lease term (“Warranty Period”), provided that the need to repair or replace was not caused by the misuse, misconduct, damage, destruction, omissions, and/or negligence of Tenant, its subtenants and/or assignees, if any,
or any company which is acquired, sold or merged with Tenant (collectively, “Tenant Damage”), or by any modifications, Alterations or improvements constructed by or on behalf of Tenant. Landlord shall coordinate such work with
Tenant and shall utilize commercially reasonable efforts to perform the same in a manner designed to minimize interference with Tenant’s use of the Premises. To the extent repairs which Landlord is required to make pursuant to this
Section 1.1.1 are necessitated in part by Tenant Damage, then Tenant shall reimburse Landlord for an equitable proportion of the cost of such repair. Landlord will be responsible for causing the exterior of the Building, the existing Building
entrances, and all exterior Common Areas (including required striping and handicapped spaces in the parking areas) to be in compliance with Applicable Laws, to the extent required to allow the legal occupancy of the Premises or completion of the
Tenant Improvements. 
 1.1.2    The Building and The Project. The Premises constitutes a portion of the
building set forth in Section 2.1 of the Summary (the “Building”). The Building is part of the office/laboratory project currently known as “6000 Shoreline Court.” The term
“Project,” as used in this Lease, shall mean (i) the Building and the Common Areas, (ii) the land (which is improved with landscaping, parking facilities and other improvements) upon which the Building and the Common Areas
are located, and (iii) at Landlord’s discretion, any additional real property, areas, land, buildings or other improvements added thereto outside of the Project (provided that any such additions do not increase Tenant’s obligations
under this Lease). 
 1.1.3    Common Areas. Tenant shall have the
non-exclusive right to use in common with other tenants in the Project, and subject to the rules and regulations referred to in Article 5 of this Lease, those portions of the Project which are provided,
from time to time, for use in common by Landlord, Tenant and any other tenants of the Project (such areas, together with such other portions of the Project designated by Landlord, in its discretion, are collectively referred to herein as the
“Common Areas”). Landlord shall maintain and operate the Common Areas, including all sprinkler and other systems serving the Common Areas, in a first class manner, and the use thereof shall

  

					
		  	-8-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 
be subject to such rules, regulations and restrictions as Landlord may reasonably make from time to time. Landlord reserves the right to close temporarily, make alterations or additions to, or
change the location of elements of the Project and the Common Areas, provided that in connection therewith Landlord will use commercially reasonable efforts to minimize any interference with Tenant’s use of and access to the Premises and
parking areas. 
 1.2    Rentable Square Feet of Premises. The rentable square footage of the Premises is
hereby deemed to be as set forth in Section 2.2 of the Summary, and shall not be subject to measurement or adjustment during the Lease Term. 
  

	2.	 LEASE TERM; OPTION TERM 

2.1    Lease Term. The terms and provisions of this Lease shall be effective as of the date of this Lease.
The term of this Lease (the “Lease Term”) shall be as set forth in Section 3.1 of the Summary, shall commence on the date set forth in Section 3.2 of the Summary (the
“Lease Commencement Date”), and shall terminate on the date set forth in Section 3.3 of the Summary (the “Lease Expiration Date”) unless this Lease is sooner terminated as hereinafter
provided. For purposes of this Lease, the term “Lease Year” shall mean each consecutive twelve (12) month period during the Lease Term. At any time during the Lease Term, Landlord may deliver to Tenant a notice in the form as
set forth in Exhibit C, attached hereto, as a confirmation only of the information set forth therein, which Tenant shall execute and return to Landlord within five (5) business days of receipt thereof. Notwithstanding the
foregoing, if Landlord has not delivered possession of the Premises in the condition required by Section 1.1.1, above, (1) on or before October 1, 2018, then, as Tenant’s sole remedy for such delay, the date Tenant is otherwise obligated
to commence payment of rent shall be delayed by one day for each day that the delivery date is delayed beyond such date, or (2) February 1, 2019, then, Tenant shall also have the right to terminate this Lease by written notice thereof to
Landlord, whereupon any monies previously paid by Tenant to Landlord shall be reimbursed to Tenant. The foregoing dates shall be extended to the extent of any delays in delivery of possession caused by (i) Tenant Delay, as provided in
Section 1(j) of the Tenant Work Letter, or (ii) war, terrorism, acts of God, natural disaster, civil unrest, governmental strike or area-wide or industry-wide labor disputes, inability to obtain services, labor, or materials or reasonable
substitutes therefor, or delays due to utility companies that are not the result of any action or inaction of Landlord (provided that any such delay in this item (ii) shall not extend any such date by more than ninety (90) days). 

2.2    Option Term. 

2.2.1    Option Right. Landlord hereby grants to the Tenant originally named in this Lease (the
“Original Tenant”), and its “Permitted Assignees”, as that term is defined in Section 14.8, below, one (1) option to extend the Lease Term for a period of five (5) years (the
“Option Term”), which option shall be irrevocably exercised only by written notice delivered by Tenant to Landlord not more than twelve (12) months nor less than nine (9) months prior to the expiration of the initial Lease
Term, provided that the following conditions (the “Option Conditions”) are satisfied: (i) as of the date of delivery of such notice, Tenant is not in default under this Lease, after the expiration of any applicable
notice and cure period; (ii) Tenant has not previously been in default under this Lease, after the expiration of any applicable notice and cure period, more than twice in the twelve (12) month period prior to the date of Tenant’s
attempted exercise; and (iii) the Lease then remains in full force and effect. Landlord may, at Landlord’s option, exercised in Landlord’s sole and absolute discretion, waive any of the Option Conditions in which case the option, if
otherwise properly exercised by Tenant, shall remain in full force and effect. Upon the proper exercise of such option to extend, and provided that Tenant satisfies all of the Option Conditions (except those, if any, which are waived by Landlord),
the Lease Term, as it applies to the Premises, shall be extended for a period of five (5) years. The rights contained in this Section 2.2 shall be personal to Original Tenant and any Permitted Assignees, and may be
exercised by Original Tenant or such Permitted Assignees (and not by any other assignee, sublessee or other “Transferee,” as that term is defined in Section 14.1 of this Lease, of Tenant’s interest in this
Lease). 
 2.2.2    Option Rent. The annual Rent payable by Tenant during the Option Term (the
“Option Rent”) shall be equal to the “Fair Rental Value,” as that term is defined below, for the Premises as of the commencement date of the Option Term. The “Fair Rental Value,” as used in this Lease,
shall be equal to the annual rent per rentable square foot (including additional rent and considering any “base year” or “expense stop” applicable thereto), including all escalations, at which tenants (pursuant to leases
consummated within the twelve (12) month period preceding the first day of the Option Term), are leasing non-sublease, non-encumbered, non-equity space which 

  

					
		  	-9-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 
is not significantly greater or smaller in size than the subject space, with a comparable level of improvements (excluding any property that Tenant would be allowed to remove from the Premises at
the termination of the Lease), for a comparable lease term, in an arm’s length transaction, which comparable space is located in the “Comparable Buildings,” as that term is defined in this Section 2.2.2,
below (transactions satisfying the foregoing criteria shall be known as the “Comparable Transactions”), taking into consideration the following concessions (the “Concessions”): (a) rental abatement concessions, if
any, being granted such tenants in connection with such comparable space; (b) tenant improvements or allowances provided or to be provided for such comparable space, and taking into account the value, if any, of the existing improvements in the
subject space (other than improvements installed by Tenant at Tenant’s sole cost and expense), such value to be based upon the age, condition, design, quality of finishes and layout of the improvements and the extent to which the same can be
utilized by a general office/lab user other than Tenant; and (c) other reasonable monetary concessions being granted such tenants in connection with such comparable space; provided, however, that in calculating the Fair Rental Value, no
consideration shall be given to the fact that Landlord is or is not required to pay a real estate brokerage commission in connection with Tenant’s exercise of its right to extend the Lease Term, or the fact that landlords are or are not paying
real estate brokerage commissions in connection with such comparable space. The Concessions shall be reflected in the effective rental rate (which effective rental rate shall take into consideration the total dollar value of such Concessions as
amortized on a straight-line basis over the applicable term of the Comparable Transaction (in which case such Concessions evidenced in the effective rental rate shall not be granted to Tenant)) payable by Tenant. The term “Comparable
Buildings” shall mean the Building and those other life sciences buildings which are comparable to the Building in terms of age (based upon the date of completion of construction or major renovation of to the building), quality of
construction, level of services and amenities, size and appearance, and are located in South San Francisco, California and the surrounding commercial area. 

2.2.3    Determination of Option Rent. In the event Tenant timely and appropriately exercises an option to
extend the Lease Term, Landlord shall notify Tenant of Landlord’s determination of the Option Rent within thirty (30) days thereafter. If Tenant, on or before the date which is ten (10) business days following the date upon which
Tenant receives Landlord’s determination of the Option Rent, in good faith objects to Landlord’s determination of the Option Rent, then Landlord and Tenant shall attempt to agree upon the Option Rent using their best good-faith efforts. If
Landlord and Tenant fail to reach agreement within ten (10) business days following Tenant’s objection to the Option Rent (the “Outside Agreement Date”), then Tenant shall have the right to withdraw its exercise of the
option by delivering written notice thereof to Landlord within five (5) days thereafter, in which event Tenant’s right to extend the Lease pursuant to this Section 2.2 shall be of no further force or effect. If
Tenant does not withdraw its exercise of the extension option, each party shall make a separate determination of the Option Rent, as the case may be, within ten (10) days after the Outside Agreement Date, and such determinations shall be
submitted to arbitration in accordance with Sections 2.2.3.1 through 2.2.3.7, below. If Tenant fails to object to Landlord’s determination of the Option Rent within the time period set forth herein, then Tenant shall be deemed to
have accepted Landlord’s determination of Option Rent. 
 2.2.3.1    Landlord and Tenant shall each appoint one
arbitrator who shall be a real estate appraiser who shall have been active over the five (5) year period ending on the date of such appointment in the appraisal of other class A life sciences buildings located in the South San Francisco market
area. The determination of the arbitrators shall be limited solely to the issue of whether Landlord’s or Tenant’s submitted Option Rent is the closest to the actual Option Rent, taking into account the requirements of
Section 2.2.2 of this Lease, as determined by the arbitrators. Each such arbitrator shall be appointed within fifteen (15) days after the Outside Agreement Date. Landlord and Tenant may consult with their selected
arbitrators prior to appointment and may select an arbitrator who is favorable to their respective positions. The arbitrators so selected by Landlord and Tenant shall be deemed “Advocate Arbitrators.” 

2.2.3.2    The two (2) Advocate Arbitrators so appointed shall be specifically required pursuant to an engagement
letter within ten (10) days of the date of the appointment of the last appointed Advocate Arbitrator to agree upon and appoint a third arbitrator (“Neutral Arbitrator”) who shall be qualified under the same criteria set forth
hereinabove for qualification of the two Advocate Arbitrators, except that neither the Landlord or Tenant or either parties’ Advocate Arbitrator may, directly or indirectly, consult with the Neutral Arbitrator prior or subsequent to his or her
appearance. The Neutral Arbitrator shall be retained via an engagement letter jointly prepared by Landlord’s counsel and Tenant’s counsel. 

  

					
		  	-10-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 2.2.3.3    The three arbitrators shall, within thirty (30) days of
the appointment of the Neutral Arbitrator, reach a decision as to whether the parties shall use Landlord’s or Tenant’s submitted Option Rent, and shall notify Landlord and Tenant thereof. 

2.2.3.4    The decision of the majority of the three arbitrators shall be binding upon Landlord and Tenant. 

2.2.3.5    If either Landlord or Tenant fails to appoint an Advocate Arbitrator within fifteen (15) days after the
Outside Agreement Date, then either party may petition the presiding judge of the Superior Court of San Mateo County to appoint such Advocate Arbitrator subject to the criteria in Section 2.2.3.1 of this Lease, or if he or
she refuses to act, either party may petition any judge having jurisdiction over the parties to appoint such Advocate Arbitrator. 

2.2.3.6    If the two (2) Advocate Arbitrators fail to agree upon and appoint the Neutral Arbitrator, then either
party may petition the presiding judge of the Superior Court of San Mateo County to appoint the Neutral Arbitrator, subject to criteria in Section 2.2.3.1 of this Lease, or if he or she refuses to act, either party may
petition any judge having jurisdiction over the parties to appoint such arbitrator. 
 2.2.3.7    The cost of the
arbitration shall be paid by Landlord and Tenant equally. 
 2.2.3.8    In the event that the Option Rent shall not
have been determined pursuant to the terms hereof prior to the commencement of the Option Term, Tenant shall be required to pay the Option Rent initially provided by Landlord to Tenant, and upon the final determination of the Option Rent, the
payments made by Tenant shall be reconciled with the actual amounts of Option Rent due, and the appropriate party shall make any corresponding payment to the other party. 

3.    BASE RENT Tenant shall pay, without prior notice or demand, to Landlord or Landlord’s agent at the management
office of the Project, or, at Landlord’s option, at such other place as Landlord may from time to time designate in writing, by a check for currency which, at the time of payment, is legal tender for private or public debts in the United States
of America, base rent (“Base Rent”) as set forth in Section 4 of the Summary, payable in equal monthly installments as set forth in Section 4 of the Summary in advance on or before the first day of each and every calendar
month during the Lease Term, without any setoff or deduction whatsoever. The Base Rent for the fourth (4th) full month of the Lease Term shall be paid at the time of Tenant’s execution of this Lease. If any Rent payment date (including the
Lease Commencement Date) falls on a day of the month other than the first day of such month or if any payment of Rent is for a period which is shorter than one month, the Rent for any fractional month shall accrue on a daily basis for the period
from the date such payment is due to the end of such calendar month or to the end of the Lease Term at a rate per day which is equal to 1/365 of the applicable annual Rent. All other payments or adjustments required to be made under the terms of
this Lease that require proration on a time basis shall be prorated on the same basis. 
  

	4.	 ADDITIONAL RENT 

4.1    General Terms. 

4.1.1    Direct Expenses; Additional Rent. In addition to paying the Base Rent specified in Article 3
of this Lease, Tenant shall pay during the Lease Term “Tenant’s Share” of the annual “Direct Expenses,” as those terms are defined in Sections 4.2.6 and 4.2.2 of this Lease, respectively, allocable to
the Building as described in Section 4.3. Such payments by Tenant, together with any and all other amounts payable by Tenant to Landlord pursuant to the terms of this Lease, are hereinafter collectively referred to as the
“Additional Rent”, and the Base Rent and the Additional Rent are herein collectively referred to as “Rent.” All amounts due under this Article 4 as Additional Rent shall be payable for the same periods and in
the same manner as the Base Rent. Without limitation on other obligations of Tenant which survive the expiration of the Lease Term, the obligations of Tenant to pay the Additional Rent provided for in this Article 4 shall survive the
expiration of the Lease Term. 

  

					
		  	-11-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 4.1.2    Triple Net Lease. Landlord and Tenant acknowledge
that, to the extent provided in this Lease, it is their intent and agreement that this Lease be a “TRIPLE NET” lease and that as such, the provisions contained in this Lease are intended to pass on to Tenant or reimburse Landlord
for the costs and expenses reasonably associated with this Lease, the Building and the Project, and Tenant’s operation therefrom to the extent provided in this Lease. To the extent such costs and expenses payable by Tenant cannot be charged
directly to, and paid by, Tenant, such costs and expenses shall be paid by Landlord but reimbursed by Tenant as Additional Rent. 

4.2    Definitions of Key Terms Relating to Additional Rent. As used in this Article 4, the following
terms shall have the meanings hereinafter set forth: 
 4.2.1    Intentionally Deleted. 

4.2.2 “Direct Expenses” shall mean “Operating Expenses” and “Tax Expenses.” 

4.2.3    ”Expense Year” shall mean each calendar year in which any portion of the Lease Term falls,
through and including the calendar year in which the Lease Term expires, provided that Landlord, upon notice to Tenant, may change the Expense Year from time to time to any other twelve (12) consecutive month period, and, in the event of any
such change, Tenant’s Share of Direct Expenses shall be equitably adjusted for any Expense Year involved in any such change. 

4.2.4    ”Operating Expenses” shall mean all expenses, costs and amounts of every kind and nature which
Landlord pays or accrues during any Expense Year because of or in connection with the ownership, management, maintenance, security, repair, replacement, restoration or operation of the Project, or any portion thereof. Without limiting the generality
of the foregoing, Operating Expenses shall specifically include any and all of the following: (i) the cost of supplying all utilities, the cost of operating, repairing and maintaining the utility, telephone, mechanical, sanitary, storm
drainage, and elevator systems, and the cost of maintenance and service contracts in connection therewith; (ii) the cost of licenses, certificates, permits and inspections and the cost of contesting any governmental enactments which are
reasonably likely to increase Operating Expenses during the Lease Term, and the costs incurred in connection with a governmentally mandated transportation system management program or similar program; (iii) the cost of all insurance carried by
Landlord in connection with the Project and Premises as reasonably determined by Landlord and reasonably consistent with the insurance generally carried by owners of Comparable Buildings; (iv) the cost of landscaping, relamping, and all
supplies, tools, equipment and materials used in the operation, repair and maintenance of the Project, or any portion thereof; (v) the cost of parking area operation, repair, restoration, and maintenance; (vi) management and/or incentive
fees, consulting fees, legal fees and accounting fees, of all contractors and consultants in connection with the management, operation, maintenance and repair of the Project; (vii) payments under any equipment rental agreements; (viii) subject
to item (f), below, wages, salaries and other compensation and benefits, including taxes levied thereon, of all persons engaged in the operation, maintenance and security of the Project; (ix) costs under any easement pertaining to the sharing
of costs by the Project; (x) operation, repair, maintenance and replacement of all systems and equipment and components thereof of the Project; (xi) the cost of janitorial, alarm, security and other services, replacement of wall and floor
coverings, ceiling tiles and fixtures in Common Areas, maintenance and replacement of curbs and walkways, repair to roofs and re-roofing; (xii) amortization (including commercially reasonable interest on
the unamortized cost) over such period of time as Landlord shall reasonably determine, of the cost of acquiring or the rental expense of personal property used in the maintenance, operation and repair of the Project, or any portion thereof;
(xiii) the cost of capital improvements or other costs incurred in connection with the Project (A) which are intended to effect economies in the operation or maintenance of the Project, or any portion thereof, or to reduce current or
future Operating Expenses or to enhance the safety or security of the Project or its occupants, (B) which are required to comply with present or anticipated conservation programs, (C) which are replacements or modifications of
nonstructural items located in the Common Areas required to keep the Common Areas in good order or condition, or (D) which are required under any governmental law or regulation; provided, however, notwithstanding anything to the contrary
herein, that any capital expenditure shall be amortized (including reasonable interest on the amortized cost) over the reasonable useful life of such capital item before being included in Operating Expenses; (xiv) costs, fees, charges or
assessments imposed by, or resulting from any mandate imposed on Landlord by, any federal, state or local government for fire and police protection, trash removal, community services, or other services which do not constitute “Tax
Expenses” as that term is defined in Section 4.2.5, below; and (xv) payments under any easement, license, operating agreement, declaration, 

  

					
		  	-12-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 
restrictive covenant, or instrument pertaining to the sharing of costs by the Building, including, without limitation, any covenants, conditions and restrictions affecting the property, and
reciprocal easement agreements affecting the property, any parking licenses, and any agreements with transit agencies affecting the Property (collectively, “Underlying Documents”). Notwithstanding the foregoing, for purposes of this
Lease, Operating Expenses shall not, however, include: 
 (a)    costs, including legal fees, space
planners’ fees, advertising and promotional expenses (except as otherwise set forth above), and brokerage fees incurred in connection with the original construction or development, or original or future leasing of the Project, and costs,
including permit, license and inspection costs, incurred with respect to the installation of tenant improvements made for new tenants initially occupying space in the Project after the Lease Commencement Date or incurred in renovating or otherwise
improving, decorating, painting or redecorating vacant space for tenants or other occupants of the Project (excluding, however, such costs relating to any common areas of the Project or parking facilities); 

(b)    except as set forth in items (xii), (xiii), and (xiv) above, depreciation, interest and
principal payments on mortgages and other debt costs, if any, penalties and interest; 
 (c)    costs for
which the Landlord is reimbursed by any tenant or occupant of the Project or by insurance by its carrier or any tenant’s carrier or by anyone else, electric power costs for which any tenant directly contracts with the local public service
company and costs of utilities and services provided to other tenants that are not provided to Tenant; 

(d)    any bad debt loss, rent loss, or reserves for bad debts or rent loss or other reserves to the extent
not used in the same year; 
 (e)    costs associated with the operation of the business of the
partnership or entity which constitutes the Landlord, as the same are distinguished from the costs of operation of the Project (which shall specifically include, but not be limited to, accounting costs associated with the operation of the Project).
Costs associated with the operation of the business of the partnership or entity which constitutes the Landlord include costs of partnership accounting and legal matters, costs of defending any lawsuits with any mortgagee (except as the actions of
the Tenant may be in issue), costs of selling, syndicating, financing, mortgaging or hypothecating any of the Landlord’s interest in the Project, and costs incurred in connection with any disputes between Landlord and its employees, between
Landlord and Project management, or between Landlord and other tenants or occupants; 
 (f)    the wages
and benefits of any employee who does not devote substantially all of his or her employed time to the Project unless such wages and benefits are prorated to reflect time spent on operating and managing the Project vis-a-vis time spent on matters unrelated to operating and managing the Project; provided, that in no event shall Operating Expenses for purposes of this Lease include wages and/or benefits attributable to
personnel above the level of Project manager; 
 (g)    amount paid as ground rental for the Project by
the Landlord; 
 (h)    except for a property management fee not to exceed three percent (3%) of gross
revenues, overhead and profit increment paid to the Landlord, and any amounts paid to the Landlord or to subsidiaries or affiliates of the Landlord for services in the Project to the extent the same exceeds the costs of such services rendered by
qualified, first-class unaffiliated third parties on a competitive basis; 
 (i)    any compensation paid
to clerks, attendants or other persons in commercial concessions operated by the Landlord; 

(j)    rentals and other related expenses incurred in leasing air conditioning systems, elevators or other
equipment which if purchased the cost of which would be excluded from Operating Expenses as a capital cost, except equipment not affixed to the Project which is used in providing engineering, janitorial or similar services and, further excepting
from this exclusion such equipment rented or leased to remedy or ameliorate an emergency condition in the Project ; 

  

					
		  	-13-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 (k)    all items and services for which Tenant or any
other tenant in the Project reimburses Landlord or which Landlord provides selectively to one or more tenants (other than Tenant) without reimbursement; 

(l)    any costs expressly excluded from Operating Expenses elsewhere in this Lease; 

(m)    rent for any office space occupied by Project management personnel; 

(n)    costs arising from the gross negligence or willful misconduct of Landlord or its agents, employees
or contractors in connection with this Lease; 
 (o)    costs incurred to comply with laws relating to
the removal or remediation of hazardous material (as defined under applicable law), and any costs of fines or penalties relating to the presence of hazardous material, in each case to the extent not brought into the Building or Premises by Tenant or
any Tenant Parties; 
 (p)    costs to correct any construction defect in the Project or to remedy any
violation of a covenant, condition, restriction, underwriter’s requirement or law that exists as of the Lease Commencement Date; 

(q)    capital costs occasioned by casualties or condemnation; 

(r)    legal fees, accountants’ fees (other than normal bookkeeping expenses) and other expenses
incurred in connection with disputes of tenants or other occupants of the Project or associated with the enforcement of the terms of any leases with tenants or the defense of Landlord’s title to or interest in the Project or any part thereof;

 (s)    costs incurred due to a violation by Landlord or any other tenant of the Project of the terms
and conditions of a lease; 
 (t)    self-insurance retentions and premiums for insurance coverage not
customarily paid by tenants of similar projects in the vicinity of the Premises and insurance deductibles; and 

(u)    expenses associated with all structural elements, including the foundations, load bearing walls,
columns, structural steel, exterior walls and roof structure. 
 4.2.5    Taxes. 

4.2.5.1    ”Tax Expenses” shall mean all federal, state, county, or local governmental or municipal
taxes, fees, charges or other impositions of every kind and nature, whether general, special, ordinary or extraordinary (including, without limitation, real estate taxes, general and special assessments, transit taxes, leasehold taxes or taxes based
upon the receipt of rent, including gross receipts or sales taxes applicable to the receipt of rent, unless required to be paid by Tenant, personal property taxes imposed upon the fixtures, machinery, equipment, apparatus, systems and equipment,
appurtenances, furniture and other personal property used in connection with the Project, or any portion thereof), which shall be paid or accrued during any Expense Year (without regard to any different fiscal year used by such governmental or
municipal authority) because of or in connection with the ownership, leasing and operation of the Project, or any portion thereof. 

4.2.5.2    Tax Expenses shall include, without limitation: (i) Any tax on the rent, right to rent or other income
from the Project, or any portion thereof, or as against the business of leasing the Project, or any portion thereof; (ii) Any assessment, tax, fee, levy or charge in addition to, or in substitution, partially or totally, of any assessment, tax,
fee, levy or charge previously included within the definition of real property tax; (iii) Any 

  

					
		  	-14-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 
assessment, tax, fee, levy, or charge allocable to or measured by the area of the Premises or the Rent payable hereunder, including, without limitation, any business or gross income tax or excise
tax with respect to the receipt of such rent, or upon or with respect to the possession, leasing, operating, management, maintenance, alteration, repair, use or occupancy by Tenant of the Premises, or any portion thereof; and (iv) Any
assessment, tax, fee, levy or charge, upon this transaction or any document to which Tenant is a party, creating or transferring an interest or an estate in the Premises or the improvements thereon. 

4.2.5.3    Any costs and expenses (including, without limitation, reasonable attorneys’ and consultants’ fees)
incurred in attempting to protest, reduce or minimize Tax Expenses shall be included in Tax Expenses in the Expense Year such expenses are incurred. Tax refunds shall be credited against Tax Expenses and refunded to Tenant regardless of when
received, based on the Expense Year to which the refund is applicable, provided that in no event shall the amount to be refunded to Tenant for any such Expense Year exceed the total amount paid by Tenant as Additional Rent under this Article 4 for
such Expense Year. If Tax Expenses for any period during the Lease Term or any extension thereof are increased after payment thereof for any reason, including, without limitation, error or reassessment by applicable governmental or municipal
authorities, Tenant shall pay Landlord upon demand Tenant’s Share of any such increased Tax Expenses. Notwithstanding anything to the contrary contained in this Section 4.2.5, there shall be excluded from Tax Expenses
(i) all excess profits taxes, franchise taxes, gift taxes, capital stock taxes, inheritance and succession taxes, transfer taxes, estate taxes, federal and state income taxes, and other taxes to the extent applicable to Landlord’s net
income (as opposed to rents, receipts or income attributable to operations at the Project), (ii) any items included as Operating Expenses, (iii) any items paid by Tenant under Section 4.5 of this Lease,
(iv) assessments in excess of the amount which would be payable if such assessment expense were paid in installments over the longest permitted term, (v) taxes imposed on land and improvements other than the Project and (vi) tax
increases resulting from the improvement of any of the Project for the sole use of other occupants. 
 4.2.6 “Tenant’s
Share” shall mean the percentage set forth in Section 6 of the Summary. 

4.3    Allocation of Direct Expenses. The parties acknowledge that, if the Building is a part of a
multi-building project, the costs and expenses incurred in connection with the Project (i.e., the Direct Expenses) should be shared between the Building and the other buildings in the Project. Accordingly, in such case, as set forth in Section
4.2 above, Direct Expenses (which consist of Operating Expenses and Tax Expenses) are determined annually for the Project as a whole, and a portion of the Direct Expenses, which portion shall be determined by Landlord on an equitable basis,
shall be allocated to the Building (as opposed to other buildings in the Project). Such portion of Direct Expenses allocated to the Building shall include all Direct Expenses attributable solely to the Building and a pro rata portion of the Direct
Expenses attributable to the Project as a whole, and shall not include Direct Expenses attributable solely to other buildings in the Project. 

4.4    Calculation and Payment of Additional Rent. Commencing on the Lease Commencement Date, Tenant shall
pay to Landlord, in the manner set forth in Section 4.4.1, below, and as Additional Rent, Tenant’s Share of Direct Expenses for each Expense Year during the Lease Term. 

4.4.1    Statement of Actual Direct Expenses and Payment by Tenant. Landlord shall give to Tenant within
five (5) months following the end of each Expense Year (provided that Landlord agrees to utilize commercially reasonable efforts to deliver such Statement to Tenant as soon as practicable following the end of each Expense Year), a statement
(the “Statement”) which shall state the Direct Expenses incurred or accrued for such preceding Expense Year, and which shall indicate the amount of Tenant’s Share of Direct Expenses. Upon receipt of the Statement for each
Expense Year commencing or ending during the Lease Term, Tenant shall pay, with its next installment of Base Rent due that is at least thirty (30) days thereafter, the full amount of Tenant’s Share of Direct Expenses for such Expense Year,
less the amounts, if any, paid during such Expense Year as “Estimated Direct Expenses,” as that term is defined in Section 4.4.2, below, and if Tenant paid more as Estimated Direct Expenses than the actual
Tenant’s Share of Direct Expenses, Tenant shall receive a credit in the amount of Tenant’s overpayment against Rent next due under this Lease. The failure of Landlord to timely furnish the Statement for any Expense Year shall not prejudice
Landlord or Tenant from enforcing its rights under this Article 4. Even though the Lease Term has expired and Tenant has vacated the Premises, when the final determination is made of Tenant’s Share of Direct Expenses for the Expense Year
in which this Lease terminates, Tenant shall within thirty (30) days of delivery of such determination pay to Landlord such amount, and if Tenant paid more as Estimated Direct Expenses than the actual

  

					
		  	-15-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 
Tenant’s Share of Direct Expenses, Landlord shall, within thirty (30) days, deliver a check payable to Tenant in the amount of the overpayment. The provisions of this
Section 4.4.1 shall survive the expiration or earlier termination of the Lease Term. Notwithstanding the immediately preceding sentence, Tenant shall not be responsible for Tenant’s Share of any Direct Expenses
attributable to any Expense Year which are first billed to Tenant more than two (2) calendar years after the earlier of the expiration of the applicable Expense Year or the Lease Expiration Date, provided that in any event Tenant shall be
responsible for Tenant’s Share of Direct Expenses levied by any governmental authority or by any public utility companies at any time following the Lease Expiration Date which are attributable to any Expense Year (provided that Landlord
delivers Tenant a bill for such amounts within two (2) years following Landlord’s receipt of the bill therefor). 

4.4.2    Statement of Estimated Direct Expenses. In addition, Landlord shall give Tenant a yearly expense
estimate statement (the “Estimate Statement”) which shall set forth Landlord’s reasonable estimate (the “Estimate”) of what the total amount of Direct Expenses for the then-current Expense Year shall be and the
estimated Tenant’s Share of Direct Expenses (the “Estimated Direct Expenses”). Landlord shall utilize commercially reasonable efforts to deliver such Estimate Statement within five (5) months following the end of each
Expense Year. The failure of Landlord to timely furnish the Estimate Statement for any Expense Year shall not preclude Landlord from enforcing its rights to collect any Estimated Direct Expenses under this Article 4, nor shall Landlord be
prohibited from revising any Estimate Statement or Estimated Direct Expenses theretofore delivered to the extent necessary. Thereafter, Tenant shall pay, with its next installment of Base Rent due that is at least thirty (30) days thereafter, a
fraction of the Estimated Direct Expenses for the then-current Expense Year (reduced by any amounts paid pursuant to the last sentence of this Section 4.4.2). Such fraction shall have as its numerator the number of months
which have elapsed in such current Expense Year, including the month of such payment, and twelve (12) as its denominator. Until a new Estimate Statement is furnished (which Landlord shall have the right to deliver to Tenant at any time), Tenant
shall pay monthly, with the monthly Base Rent installments, an amount equal to one-twelfth (1/12) of the total Estimated Direct Expenses set forth in the previous Estimate Statement delivered by Landlord to
Tenant. 
 4.5    Taxes and Other Charges for Which Tenant Is Directly Responsible. Tenant shall be liable
for and shall pay ten (10) days before delinquency, taxes levied against Tenant’s equipment, furniture, fixtures and any other personal property located in or about the Premises. If any such taxes on Tenant’s equipment, furniture,
fixtures and any other personal property are levied against Landlord or Landlord’s property or if the assessed value of Landlord’s property is increased by the inclusion therein of a value placed upon such equipment, furniture, fixtures or
any other personal property and if Landlord pays the taxes based upon such increased assessment, which Landlord shall have the right to do regardless of the validity thereof but only under proper protest if requested by Tenant, Tenant shall upon
demand repay to Landlord the taxes so levied against Landlord or the proportion of such taxes resulting from such increase in the assessment, as the case may be. 

4.6    Landlord’s Books and Records. Within one hundred twenty (120) days after receipt by Tenant
of a Statement, if Tenant disputes the amount of Additional Rent set forth in the Statement, a member of Tenant’s finance department, or an independent certified public accountant (which accountant is a member of a nationally recognized
accounting firm and is not working on a contingency fee basis) (“Tenant’s Accountant”), designated and paid for by Tenant, may, after reasonable notice to Landlord and at reasonable times, inspect Landlord’s records with
respect to the Statement at Landlord’s offices, provided that there is no existing Event of Default and Tenant has paid all amounts required to be paid under the applicable Estimate Statement and Statement, as the case may be. In connection
with such inspection, Tenant and Tenant’s agents must agree in advance to follow Landlord’s reasonable rules and procedures regarding inspections of Landlord’s records, and shall execute a commercially reasonable confidentiality
agreement regarding such inspection. Tenant’s failure to dispute the amount of Additional Rent set forth in any Statement within one hundred twenty (120) days of Tenant’s receipt of such Statement shall be deemed to be Tenant’s
approval of such Statement and Tenant, thereafter, waives the right or ability to dispute the amounts set forth in such Statement. If after such inspection, Tenant still disputes such Additional Rent, a determination as to the proper amount shall be
made, at Tenant’s expense, by an independent certified public accountant (the “Accountant”) selected by Landlord and subject to Tenant’s reasonable approval; provided that if such Accountant determines that Direct Expenses
were overstated by more than five percent (5%), then the cost of the Accountant and the cost of such determination shall be paid for by Landlord, and Landlord shall reimburse Tenant for the cost of the Tenant’s Accountant (provided that such
cost shall be a reasonable market cost for such services). Tenant hereby acknowledges that Tenant’s sole right to inspect Landlord’s books and records and to contest the amount of Direct Expenses payable by Tenant shall be as set forth in
this Section 4.6, and Tenant hereby waives any and all other rights pursuant to applicable law to inspect such books and records and/or to contest the amount of Direct Expenses payable by Tenant. 

  

					
		  	-16-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

	5.	 USE OF PREMISES 

5.1    Permitted Use. Tenant shall use the Premises solely for the Permitted Use set forth in
Section 7 of the Summary and Tenant shall not use or permit the Premises or the Project to be used for any other purpose or purposes whatsoever without the prior written consent of Landlord, which may be withheld in
Landlord’s sole discretion. 
 5.2    Prohibited Uses. Tenant further covenants and agrees that
Tenant shall not use or permit any person or persons to use, the Premises or any part thereof for any use or purpose in violation of the laws of the United States of America, the State of California, or the ordinances, regulations or requirements of
the local municipal or county governing body or other lawful authorities having jurisdiction over the Project) including, without limitation, any such laws, ordinances, regulations or requirements relating to hazardous materials or substances, as
those terms are defined by applicable laws now or hereafter in effect. Landlord shall have the right to impose reasonable, nondiscriminatory and customary rules and regulations regarding the use of the Project that do not unreasonably interfere with
Tenant’s use of the Premises, as reasonably deemed necessary by Landlord with respect to the orderly operation of the Project, and Tenant shall comply with such reasonable rules and regulations. Tenant shall not do or permit anything to be done
in or about the Premises which will in any way obstruct or interfere with the rights of other tenants or occupants of the Project, or injure or annoy them or use or allow the Premises to be used for any improper, unlawful or objectionable purpose,
nor shall Tenant cause, maintain or permit any nuisance in, on or about the Premises. Tenant shall comply with, and Tenant’s rights and obligations under the Lease and Tenant’s use of the Premises shall be subject and subordinate to, all
recorded easements, covenants, conditions, and restrictions now or hereafter affecting the Project, so long as the same do not unreasonably interfere with Tenant’s use of the Premises or parking rights or materially increase Tenant’s
obligations or decrease Tenant’s rights under this Lease. 
 5.3    Hazardous Materials. 

 

	 	5.3.1    Tenant’s	 Obligations. 

5.3.1.1    Prohibitions. As a material inducement to Landlord to enter into this Lease with Tenant, Tenant
has fully and accurately completed Landlord’s Pre-Leasing Environmental Exposure Questionnaire (the “Environmental Questionnaire”), which is attached as Exhibit E. Tenant
agrees that except for those chemicals or materials, and their respective quantities, specifically listed on the Environmental Questionnaire (as the same may be updated from time to time as provided below), neither Tenant nor Tenant’s
employees, contractors and subcontractors of any tier, entities with a contractual relationship with Tenant (other than Landlord), or any entity acting as an agent or sub-agent of Tenant (collectively,
“Tenant’s Agents”) will produce, use, store or generate any “Hazardous Materials,” as that term is defined below, on, under or about the Premises, nor cause any Hazardous Material to be brought upon, placed, stored,
manufactured, generated, blended, handled, recycled, used or “Released,” as that term is defined below, on, in, under or about the Premises. If any information provided to Landlord by Tenant on the Environmental Questionnaire, or otherwise
relating to information concerning Hazardous Materials is intentionally false, incomplete, or misleading in any material respect, the same shall be deemed a default by Tenant under this Lease. Upon Landlord’s request, or in the event of any
material change in Tenant’s use of Hazardous Materials in the Premises, Tenant shall deliver to Landlord an updated Environmental Questionnaire at least once a year. Tenant shall notify Landlord prior to using any Hazardous Materials in the
Premises not described on the initial Environmental Questionnaire, and, to the extent such use would, in Landlord’s reasonable judgment, cause a material increase in the risk of liability compared to the uses previously allowed in the Premises,
such additional use shall be subject to Landlord’s prior consent, which may be withheld in Landlord’s reasonable discretion. Tenant shall not install or permit Tenant’s Agents to install any underground storage tank on the Premises.
For purposes of this Lease, “Hazardous Materials” means all flammable explosives, petroleum and petroleum products, waste oil, radon, radioactive materials, toxic pollutants, asbestos, polychlorinated biphenyls
(“PCBs”), medical waste, chemicals known to cause cancer or reproductive toxicity, pollutants, contaminants, hazardous wastes, toxic substances or related materials, including without limitation any chemical, element, compound,
mixture, solution, substance, object, waste or any combination thereof, which is or may be hazardous to human health, safety or to the environment due to its 

  

					
		  	-17-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 
radioactivity, ignitability, corrosiveness, reactivity, explosiveness, toxicity, carcinogenicity, infectiousness or other harmful or potentially harmful properties or effects, or defined as,
regulated as or included in, the definition of “hazardous substances,” “hazardous wastes,” “hazardous materials,” or “toxic substances” under any Environmental Laws. For purposes of this Lease,
“Release” or “Released” or “Releases” shall mean any release, deposit, discharge, emission, leaking, spilling, seeping, migrating, injecting, pumping, pouring, emptying, escaping, dumping,
disposing, or other movement of Hazardous Materials into the environment. Landlord acknowledges that Tenant may be installing and using fume hoods in the Premises and that emissions of Hazardous Materials into the air in compliance with all
Environmental Laws shall not be considered Releases. 
 5.3.1.2    Notices to Landlord. Tenant shall
notify Landlord in writing as soon as possible but in no event later than five (5) days after (i) the occurrence of any actual, alleged or threatened Release of any Hazardous Material in, on, under, from, about or in the vicinity of the
Premises (whether past or present), regardless of the source or quantity of any such Release, or (ii) Tenant becomes aware of any regulatory actions, inquiries, inspections, investigations, directives, or any cleanup, compliance, enforcement or
abatement proceedings (including any threatened or contemplated investigations or proceedings) relating to or potentially affecting the Premises, or (iii) Tenant becomes aware of any claims by any person or entity relating to any Hazardous Materials
in, on, under, from, about or in the vicinity of the Premises, whether relating to damage, contribution, cost recovery, compensation, loss or injury. Collectively, the matters set forth in clauses (i), (ii) and (iii) above are hereinafter
referred to as “Hazardous Materials Claims”. Tenant shall promptly forward to Landlord copies of all orders, notices, permits, applications and other communications and reports in connection with any Hazardous Materials Claims.
Additionally, Tenant shall promptly advise Landlord in writing of Tenant’s discovery of any occurrence or condition on, in, under or about the Premises that could subject Tenant or Landlord to any liability, or restrictions on ownership,
occupancy, transferability or use of the Premises under any “Environmental Laws,” as that term is defined below. Tenant shall not enter into any legal proceeding or other action, settlement, consent decree or other compromise with respect
to any Hazardous Materials Claims without first notifying Landlord of Tenant’s intention to do so and affording Landlord the opportunity to join and participate, as a party if Landlord so elects, in such proceedings and in no event shall Tenant
enter into any agreements which are binding on Landlord or the Premises without Landlord’s prior written consent. Landlord shall have the right to appear at and participate in, any and all legal or other administrative proceedings concerning
any Hazardous Materials Claim. For purposes of this Lease, “Environmental Laws” means all applicable present and future laws relating to the protection of human health, safety, wildlife or the environment, including, without
limitation, (i) all requirements pertaining to reporting, licensing, permitting, investigation and/or remediation of emissions, discharges, Releases, or threatened Releases of Hazardous Materials, whether solid, liquid, or gaseous in nature,
into the air, surface water, groundwater, or land, or relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport, or handling of Hazardous Materials; and (ii) all requirements pertaining to the health
and safety of employees or the public. Environmental Laws include, but are not limited to, the Comprehensive Environmental Response, Compensation and Liability Act of 1980, 42 USC § 9601, et seq., the Hazardous Materials Transportation
Authorization Act of 1994, 49 USC § 5101, et seq., the Solid Waste Disposal Act, as amended by the Resource Conservation and Recovery Act of 1976, and Hazardous and Solid Waste Amendments of 1984, 42 USC § 6901, et seq., the Federal Water
Pollution Control Act, as amended by the Clean Water Act of 1977, 33 USC § 1251, et seq., the Clean Air Act of 1966, 42 USC § 7401, et seq., the Toxic Substances Control Act of 1976, 15 USC § 2601, et seq., the Safe Drinking Water Act
of 1974, 42 USC §§ 300f through 300j, the Occupational Safety and Health Act of 1970, as amended, 29 USC § 651 et seq., the Oil Pollution Act of 1990, 33 USC § 2701 et seq., the Emergency Planning and Community Right-To-Know Act of 1986, 42 USC § 11001 et seq., the National Environmental Policy Act of 1969, 42 USC § 4321 et seq., the Federal Insecticide, Fungicide and
Rodenticide Act of 1947, 7 USC § 136 et seq., California Carpenter-Presley-Tanner Hazardous Substance Account Act, California Health & Safety Code §§ 25300 et seq., Hazardous Materials Release Response Plans and Inventory
Act, California Health & Safety Code, §§ 25500 et seq., Underground Storage of Hazardous Substances provisions, California Health & Safety Code, §§ 25280 et seq., California Hazardous Waste Control Law,
California Health & Safety Code, §§ 25100 et seq., and any other state or local law counterparts, as amended, as such applicable laws, are in effect as of the Lease Commencement Date, or thereafter adopted, published, or
promulgated. 
 5.3.1.3    Releases of Hazardous Materials. If any Release of any Hazardous Material in,
on, under, from or about the Premises shall occur at any time during the Lease by Tenant or Tenant’s Agents, in addition to notifying Landlord as specified above, Tenant, at its own sole cost and expense, shall (i) immediately comply with
any and all reporting requirements imposed pursuant to any and all Environmental Laws, (ii) provide a 

  

					
		  	-18-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 
written certification to Landlord indicating that Tenant has complied with all applicable reporting requirements, (iii) take any and all necessary investigation, corrective and remedial action in
accordance with any and all applicable Environmental Laws, utilizing an environmental consultant approved by Landlord, all in accordance with the provisions and requirements of this Section 5.3, including, without
limitation, Section 5.3.4, and (iv) take any such additional investigative, remedial and corrective actions as Landlord shall in its reasonable discretion deem necessary such that the Premises are remediated to the
condition existing prior to such Release. 
 5.3.1.4    Indemnification. 

5.3.1.4.1    In General. Without limiting in any way Tenant’s obligations under any
other provision of this Lease, Tenant shall be solely responsible for and shall protect, defend, indemnify and hold the Landlord Parties harmless from and against any and all claims, judgments, losses, damages, costs, expenses, penalties,
enforcement actions, taxes, fines, remedial actions, liabilities (including, without limitation, actual attorneys’ fees, litigation, arbitration and administrative proceeding costs, expert and consultant fees and laboratory costs) including,
without limitation, consequential damages and sums paid in settlement of claims, which arise during or after the Lease Term, whether foreseeable or unforeseeable, that arise during or after the Lease Term in whole or in part, foreseeable or
unforeseeable, directly or indirectly arising out of or attributable to the Release of Hazardous Materials in, on, under or about the Premises by Tenant or Tenant’s Agents. 

5.3.1.4.2    Limitations. Notwithstanding anything in
Section 5.3.1.4, above, to the contrary, Tenant’s indemnity of Landlord as set forth in Section 5.3.1.4, above, shall not be applicable to claims based upon Hazardous Materials not Released by
Tenant or Tenant’s Agents. 
 5.3.1.4.3    Landlord Indemnity. Under no circumstance
shall Tenant be liable for, and Landlord shall indemnify, defend, protect and hold harmless Tenant and Tenant’s Agents from and against, all losses, costs, claims, liabilities and damages (including attorneys’ and consultants’ fees)
arising out of any Hazardous Materials that exist in, on or about the Project as of the date hereof, or Hazardous Material Released by Landlord or any Landlord Parties. Landlord shall provide Tenant with any environmental reports relating to the
Project in Landlord’s immediate possession. The provision of such reports shall be for informational purposes only, and Landlord does not make any representation or warranty as to the correctness or completeness of any such reports. 

5.3.1.5    Compliance with Environmental Laws. Without limiting the generality of Tenant’s obligation
to comply with applicable laws as otherwise provided in this Lease, Tenant shall, at its sole cost and expense, comply with all Environmental Laws related to the use of Hazardous Materials by Tenant and Tenant’s Agents. Tenant shall obtain and
maintain any and all necessary permits, licenses, certifications and approvals appropriate or required for the use, handling, storage, and disposal of any Hazardous Materials used, stored, generated, transported, handled, blended, or recycled by
Tenant on the Premises. Landlord shall have a continuing right, without obligation, to require Tenant to obtain, and to review and inspect any and all such permits, licenses, certifications and approvals, together with copies of any and all
Hazardous Materials management plans and programs, any and all Hazardous Materials risk management and pollution prevention programs, and any and all Hazardous Materials emergency response and employee training programs respecting Tenant’s use
of Hazardous Materials. Upon request of Landlord, Tenant shall deliver to Landlord a narrative description explaining the nature and scope of Tenant’s activities involving Hazardous Materials and showing to Landlord’s satisfaction
compliance with all Environmental Laws and the terms of this Lease. 
 5.3.2    Assurance of Performance.

 5.3.2.1    Environmental Assessments In General. Landlord may, but shall not be required to, engage
from time to time such contractors as Landlord determines to be appropriate (and which are reasonably acceptable to Tenant) to perform environmental assessments of a scope reasonably determined by Landlord (an “Environmental
Assessment”) to ensure Tenant’s compliance with the requirements of this Lease with respect to Hazardous Materials. 

  

					
		  	-19-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 5.3.2.2    Costs of Environmental Assessments. All costs
and expenses incurred by Landlord in connection with any such Environmental Assessment initially shall be paid by Landlord; provided that if any such Environmental Assessment shows that Tenant has failed to comply with the provisions of this
Section 5.3, then all of the costs and expenses of such Environmental Assessment shall be reimbursed by Tenant as Additional Rent within thirty (30) days after receipt of written demand therefor. 

5.3.3    Tenant’s Obligations upon Surrender. At the expiration or earlier termination of the Lease
Term, Tenant, at Tenant’s sole cost and expense, shall: (i) cause an Environmental Assessment of the Premises to be conducted in accordance with Section 15.3; (ii) cause all Hazardous Materials brought onto the
Premises by Tenant or Tenant’s Agents to be removed from the Premises and disposed of in accordance with all Environmental Laws and as necessary to allow the Premises to be used for the purposes allowed as of the date of this Lease; and (iii)
cause to be removed all containers installed or used by Tenant or Tenant’s Agents to store any Hazardous Materials on the Premises, and cause to be repaired any damage to the Premises caused by such removal. 

5.3.4    Clean-up. 

5.3.4.1    Environmental Reports; Clean-Up. If any written report,
including any report containing results of any Environmental Assessment (an “Environmental Report”) shall indicate (i) the presence of any Hazardous Materials as to which Tenant has a removal or remediation obligation under
this Section 5.3, and (ii) that as a result of same, the investigation, characterization, monitoring, assessment, repair, closure, remediation, removal, or other clean-up (the
“Clean-up”) of any Hazardous Materials is required, Tenant shall immediately prepare and submit to Landlord within thirty (30) days after receipt of the Environmental Report a
comprehensive plan, subject to Landlord’s written approval, specifying the actions to be taken by Tenant to perform the Clean-up so that the Premises are restored to the conditions required by this Lease.
Upon Landlord’s approval of the Clean-up plan, Tenant shall, at Tenant’s sole cost and expense, without limitation on any rights and remedies of Landlord under this Lease, immediately implement such
plan with a consultant reasonably acceptable to Landlord and proceed to Clean-Up Hazardous Materials in accordance with all applicable laws. If, within thirty (30) days after receiving a copy of such
Environmental Report, Tenant fails either (a) to complete such Clean-up, or (b) with respect to any Clean-up that cannot be completed within such thirty-day period, fails to proceed with diligence to prepare the Clean-up plan and complete the Clean-up as promptly as practicable,
then Landlord shall have the right, but not the obligation, and without waiving any other rights under this Lease, to carry out any Clean-up recommended by the Environmental Report or required by any
governmental authority having jurisdiction over the Premises, and recover all of the costs and expenses thereof from Tenant as Additional Rent, payable within ten (10) days after receipt of written demand therefor. 

5.3.4.2    No Rent Abatement. Tenant shall continue to pay all Rent due or accruing under this Lease during
any Clean-up, and shall not be entitled to any reduction, offset or deferral of any Base Rent or Additional Rent due or accruing under this Lease during any such
Clean-up. 
 5.3.4.3    Surrender of Premises. Tenant shall
complete any Clean-up prior to surrender of the Premises upon the expiration or earlier termination of this Lease. Tenant shall obtain and deliver to Landlord a letter or other written determination from the
overseeing governmental authority confirming that the Clean-up has been completed in accordance with all requirements of such governmental authority and that no further response action of any kind is required
for the unrestricted use of the Premises (“Closure Letter”). Upon the expiration or earlier termination of this Lease, Tenant shall also be obligated to close all permits obtained in connection with Hazardous Materials used by
Tenant or Tenant’s Agents in accordance with applicable laws. 
 5.3.4.4    Failure to Timely Clean-Up. Should any Clean-up for which Tenant is responsible not be completed, or should Tenant not receive the Closure Letter and any governmental approvals required
under Environmental Laws in conjunction with such Clean-up prior to the expiration or earlier termination of this Lease, then, commencing on the later of the termination of this Lease and three
(3) business days after Landlord’s delivery of notice of such failure and that it elects to treat such failure as a holdover, Tenant shall be liable to Landlord as a holdover tenant (as more particularly provided in Article 16)
until Tenant has fully complied with its obligations under this Section 5.3. 

  

					
		  	-20-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 5.3.5    Confidentiality. Unless compelled to do so by
applicable law, Tenant agrees that Tenant shall not disclose, discuss, disseminate or copy any information, data, findings, communications, conclusions and reports regarding the environmental condition of the Premises to any Person (other than
Tenant’s consultants, attorneys, property managers, employees, shareholders and potential and actual investors, lenders, business and merger partners, subtenants and assignees that have a need to know such information), including any
governmental authority, without the prior written consent of Landlord. In the event Tenant reasonably believes that disclosure is compelled by applicable law, it shall provide Landlord ten (10) days’ advance notice of disclosure of
confidential information so that Landlord may attempt to obtain a protective order. Tenant may additionally release such information to bona fide prospective purchasers or lenders, subject to any such parties’ written agreement to be bound by
the terms of this Section 5.3. 
 5.3.6    Copies of Environmental
Reports. Within thirty (30) days of receipt thereof, Tenant shall provide Landlord with a copy of any and all environmental assessments, audits, studies and reports regarding Tenant’s activities with respect to the Premises, or
ground water beneath the Land, or the environmental condition or Clean-up thereof. Tenant shall be obligated to provide Landlord with a copy of such materials without regard to whether such materials are
generated by Tenant or prepared for Tenant, or how Tenant comes into possession of such materials. 

5.3.7    Intentionally Omitted. 

5.3.8    Signs, Response Plans, Etc. Tenant shall be responsible for posting on the Premises any signs
required under applicable Environmental Laws with respect to the use of Hazardous Materials by Tenant or Tenant’s Agents. Tenant shall also complete and file any business response plans or inventories required by any applicable laws. Tenant
shall concurrently file a copy of any such business response plan or inventory with Landlord. 

5.3.9    Survival. Each covenant, agreement, representation, warranty and indemnification made by Tenant set
forth in this Section 5.3 shall survive the expiration or earlier termination of this Lease and shall remain effective until all of Tenant’s obligations under this
Section 5.3 have been completely performed and satisfied. 
  

	6.	 SERVICES AND UTILITIES 

6.1    In General. Landlord will be responsible, at Tenant’s sole cost and expense (subject to the terms
of Section 4.2.4, above), for the furnishing of heating, ventilation and air-conditioning, electricity, water, and interior Building security services to the Premises. Landlord shall
not provide janitorial or telephone services for the Premises. Tenant shall be solely responsible for performing all janitorial services and other cleaning of the Premises, all in compliance with applicable laws. The janitorial and cleaning of the
Premises shall be adequate to maintain the Premises in a manner consistent with First Class Life Sciences Projects. 
 Tenant shall
cooperate fully with Landlord at all times and abide by all regulations and requirements that Landlord may reasonably prescribe for the proper functioning and protection of the HVAC, electrical, mechanical and plumbing systems. Provided that
Landlord agrees to provide and maintain and keep in continuous service utility connections to the Project, including electricity, water and sewage connections, Landlord shall have no obligation to provide any services or utilities to the Building,
including, but not limited to heating, ventilation and air-conditioning, electricity, water, telephone, janitorial and interior Building security services, except as set forth in this
Section 6.1, above. 
 6.2    Allocation of Utilities Costs. To the extent that
any utilities (including without limitation, electricity, gas, sewer and water) to the Building are separately metered to the Premises, such utilities shall be contracted for and paid directly by Tenant to the applicable utility provider. To the
extent that any utilities (including without limitation, electricity, gas, sewer and water) to the Building are not separately metered to the Premises, then Tenant shall pay to Landlord, within thirty (30) days after billing, an equitable
portion of the Building utility costs, based on Tenant’s proportionate use thereof. 
 6.3    Interruption of
Use. Tenant agrees that Landlord shall not be liable for damages, by abatement of Rent or otherwise, for failure to furnish or delay in furnishing any service (including telephone and telecommunication

  

					
		  	-21-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 
services), or for any diminution in the quality or quantity thereof, when such failure or delay or diminution is occasioned, in whole or in part, by breakage, repairs, replacements, or
improvements, by any strike, lockout or other labor trouble, by inability to secure electricity, gas, water, or other fuel at the Building or Project after reasonable effort to do so, by any riot or other dangerous condition, emergency, accident or
casualty whatsoever, by act or default of Tenant or other parties, or by any other cause; and such failures or delays or diminution shall never be deemed to constitute an eviction or disturbance of Tenant’s use and possession of the Premises or
relieve Tenant from paying Rent or performing any of its obligations under this Lease. Notwithstanding the foregoing, Landlord may be liable for damages to the extent caused by the negligence or willful misconduct of Landlord or the Landlord Parties
or Landlord’s violation of this Lease, provided that Landlord shall not be liable under any circumstances for injury to, or interference with, Tenant’s business, including, without limitation, loss of profits, however occurring, through or
in connection with or incidental to a failure to furnish any of the services or utilities as set forth in this Article 6. 

6.4    Energy Performance Disclosure Information. Tenant hereby acknowledges that Landlord may be required
to disclose certain information concerning the energy performance of the Building pursuant to California Public Resources Code Section 25402.10 and the regulations adopted pursuant thereto (collectively the “Energy Disclosure
Requirements”). Tenant hereby acknowledges prior receipt of the Data Verification Checklist, as defined in the Energy Disclosure Requirements (the “Energy Disclosure Information”), and agrees that Landlord has timely
complied in full with Landlord’s obligations under the Energy Disclosure Requirements. Tenant acknowledges and agrees that (i) Landlord makes no representation or warranty regarding the energy performance of the Building or the accuracy or
completeness of the Energy Disclosure Information, (ii) the Energy Disclosure Information is for the current occupancy and use of the Building and that the energy performance of the Building may vary depending on future occupancy and/or use of
the Building, and (iii) Landlord shall have no liability to Tenant for any errors or omissions in the Energy Disclosure Information. If and to the extent not prohibited by applicable laws, Tenant hereby waives any right Tenant may have to
receive the Energy Disclosure Information, including, without limitation, any right Tenant may have to terminate this Lease as a result of Landlord’s failure to disclose such information. Further, Tenant hereby releases Landlord from any and
all losses, costs, damages, expenses and/or liabilities relating to, arising out of and/or resulting from the Energy Disclosure Requirements, including, without limitation, any liabilities arising as a result of Landlord’s failure to disclose
the Energy Disclosure Information to Tenant prior to the execution of this Lease. Tenant’s acknowledgment of the AS-IS condition of the Premises to the extent provided in this Lease shall be deemed to
include the energy performance of the Building. Tenant further acknowledges that pursuant to the Energy Disclosure Requirements, Landlord may be required in the future to disclose information concerning Tenant’s energy usage to certain third
parties, including, without limitation, prospective purchasers, lenders and tenants of the Building (the “Tenant Energy Use Disclosure”). Tenant hereby (A) consents to all such Tenant Energy Use Disclosures, and (B)
acknowledges that Landlord shall not be required to notify Tenant of any Tenant Energy Use Disclosure. Further, Tenant hereby releases Landlord from any and all losses, costs, damages, expenses and liabilities relating to, arising out of and/or
resulting from any Tenant Energy Use Disclosure. The terms of this Section 6.3 shall survive the expiration or earlier termination of this Lease. 

6.5    Emergency Generator. Landlord and Tenant hereby acknowledge that there is an existing generator
currently serving the Premises (“Emergency Generator”), and Tenant shall have the right to connect to the Emergency Generator for up to Tenant’s Share of the electrical capacity provided by such Emergency Generator.
Tenant’s use of the Emergency Generator shall be at Tenant’s sole risk. Landlord represents that the Emergency Generator is currently in place and shall be in good operating condition on the Lease Commencement Date, and during the Lease
Term Landlord shall maintain the Generator in good condition and repair, and Tenant shall be responsible for a share of the costs of such maintenance and repair based on the proportion of the Generator capacity allocated to the Premises. Except to
the extent caused by the gross negligence or willful misconduct of Landlord, or any Landlord Parties, or Landlord’s violation of this Lease, Tenant hereby waives any claims against Landlord or any Landlord Parties resulting from Tenant’s
use of the Emergency Generator, or any failure of the Emergency Generator to operate as designed, and agrees that Landlord shall not be liable for any damages resulting from any failure in operation of the Emergency Generator, including, without
limitation any injury or damage to, or interference with, Tenant’s business, including but not limited to, loss of profits, loss of rents or other revenues, loss of business opportunity, loss of goodwill or loss of use, or loss to equipment,
inventory, scientific research, scientific experiments, laboratory animals, products, specimens, samples, and/or scientific, business, accounting and other records of every kind and description kept at the Premises and any and all income derived or
derivable therefrom. Tenant acknowledges that Operating Expenses shall include Landlord’s costs incurred in maintaining and operating the Emergency Generator (including all permit costs and fees), but shall not include any Hazardous Materials
remediation costs incurred in connection with the Generator. 

  

					
		  	-22-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

	7.	 REPAIRS 

7.1    Tenant Repair Obligations. Tenant shall, throughout the Term, at its sole cost and expense, maintain,
repair or replace as required, the Premises in a good standard of maintenance, repair and replacement as required, and in good and sanitary condition, all in accordance with the standards of First Class Life Sciences Projects, except for the
Landlord Repair Obligations, whether or not such maintenance, repair, replacement or improvement is required in order to comply with applicable Laws (“Tenant’s Repair Obligations”), including without limitation, all electrical
facilities and equipment, including lighting fixtures, lamps, fans and any exhaust equipment and systems, electrical motors and all other appliances and equipment of every kind and nature located in the Premises; all communications systems serving
the Premises; all of Tenant’s security systems in or about or serving the Premises; Tenant’s signage; interior demising walls and partitions (including painting and wall coverings), equipment, floors. Tenant shall additionally be
responsible, at Tenant’s sole cost and expense, to furnish all expendables, including light bulbs, paper goods and soaps, used in the Premises. 

7.2    Landlord Repair Obligations. Landlord shall be responsible, as a part of Operating Expenses, for
repairs to and routine maintenance of the Building including without limitation: (1) exterior windows, window frames, window casements (including the repairing, resealing, cleaning and replacing of exterior windows); (2) exterior doors, door
frames and door closers; (3) the Building (as opposed to the Premises) and Project plumbing, sewer, drainage, electrical, fire protection, life safety and security systems and equipment, existing heating, ventilation and air- conditioning systems, and all other mechanical and HVAC systems and equipment (including rebalancing thereof to the extent deemed reasonably necessary by Landlord) (collectively, the “Building
Systems”), (4) the exterior glass, exterior walls, foundation and roof of the Building, the structural portions of the floors of the Building, including, without limitation, any painting, sealing, patching and waterproofing of exterior
walls, and (5) repairs to the elevator in the Building and underground utilities, except to the extent that any such repairs are required due to the negligence or willful misconduct of Tenant (the “Landlord Repair
Obligations”); provided, however, that if such repairs are due to the negligence or willful misconduct of Tenant, Landlord shall nevertheless make such repairs at Tenant’s expense, or, if covered by Landlord’s insurance, Tenant
shall only be obligated to pay any deductible in connection therewith. Costs expended by Landlord in connection with the Landlord Repair Obligations shall be included in Operating Expenses to the extent allowed pursuant to the terms of Article
4, above. Landlord shall cooperate with Tenant to enforce any warranties that Landlord holds that could reduce Tenant’s maintenance obligations under this Lease. 
  

	8.	 ADDITIONS AND ALTERATIONS 

8.1    Landlord’s Consent to Alterations. Tenant may not make any improvements, alterations, additions
or changes to the Premises or any mechanical, plumbing or HVAC facilities or systems pertaining to the Premises (collectively, the “Alterations”) without first procuring the prior written consent of Landlord to such Alterations,
which consent shall be requested by Tenant not less than ten (10) business days prior to the commencement thereof, and which consent shall not be unreasonably withheld by Landlord, provided it shall be deemed reasonable for Landlord to withhold
its consent to any Alteration which adversely affects the structural portions or the systems or equipment of the Building or is visible from the exterior of the Building. Notwithstanding the foregoing, Tenant shall be permitted to make Alterations
following ten (10) business days’ notice to Landlord (as to Alterations costing more than $10,000 only), but without Landlord’s prior consent, to the extent that such Alterations (i) do not affect the building systems or equipment
(other than minor changes such as adding or relocating electrical outlets and thermostats), (ii) are not visible from the exterior of the Building, and (iii) cost less than $50,000.00 for a particular job of work. The construction of the Tenant
Improvements to the Premises shall be governed by the terms of the Tenant Work Letter and not the terms of this Article 8. 

8.2    Manner of Construction. Landlord may impose, as a condition of its consent to any and all Alterations
or repairs of the Premises or about the Premises, such requirements as Landlord in its reasonable discretion may deem desirable, including, but not limited to, the requirement that upon Landlord’s request, Tenant shall, at Tenant’s
expense, remove such Alterations upon the expiration or any early termination of the Lease Term. Tenant 

  

					
		  	-23-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 
shall construct such Alterations and perform such repairs in a good and workmanlike manner, in conformance with any and all applicable federal, state, county or municipal laws, rules and
regulations and pursuant to a valid building permit, issued by the city in which the Building is located (or other applicable governmental authority). Tenant shall not use (and upon notice from Landlord shall cease using) contractors, services,
workmen, labor, materials or equipment that, in Landlord’s reasonable judgment, would disturb labor harmony with the workforce or trades engaged in performing other work, labor or services in or about the Building or the Common Areas. Upon
completion of any Alterations, Tenant shall deliver to Landlord final lien waivers from all contractors, subcontractors and materialmen who performed such work. In addition to Tenant’s obligations under Article 9 of this Lease, upon
completion of any Alterations, Tenant agrees to cause a Notice of Completion to be recorded in the office of the Recorder of the County of San Mateo in accordance with Section 3093 of the Civil Code of the State of California or any successor
statute, and Tenant shall deliver to the Project construction manager a reproducible copy of the “as built” drawings of the Alterations as well as all permits, approvals and other documents issued by any governmental agency in
connection with the Alterations. 
 8.3    Payment for Improvements. In connection with any Alterations
that affect the Building systems (other than minor changes such as adding or relocating electrical outlets and thermostats), or which have a cost in excess of $100,000, Tenant shall reimburse Landlord for Landlord’s reasonable, actual, out-of-pocket costs and expenses actually incurred in connection with Landlord’s review of such work. 

8.4    Construction Insurance. In addition to the requirements of Article 10 of this Lease, in the
event that Tenant makes any Alterations as to which Tenant is required to obtain Landlord’s consent or provide Landlord with notice, prior to the commencement of such Alterations, Tenant shall provide Landlord with evidence that Tenant or
Tenant’s contractor carries “Builder’s All Risk” insurance (to the extent that the cost of such work shall exceed $50,000) in an amount approved by Landlord covering the construction of such Alterations, and such other
insurance as Landlord may reasonably require, it being understood and agreed that all of such Alterations shall be insured by Landlord pursuant to Article 10 of this Lease immediately upon completion thereof. In addition, Tenant’s
contractors and subcontractors shall be required to carry Commercial General Liability Insurance in an amount approved by Landlord and otherwise in accordance with the requirements of Article 10 of this Lease. In connection with Alterations with a
cost in excess of $250,000, Landlord may, in its reasonable discretion, require Tenant to obtain a lien and completion bond or some alternate form of security satisfactory to Landlord in an amount sufficient to ensure the lien- free completion of
such Alterations and naming Landlord as a co-obligee. 

8.5    Landlord’s Property. All Alterations, improvements, fixtures, equipment and/or appurtenances
which may be installed or placed in or about the Premises, from time to time, shall be at the sole cost of Tenant and all Alterations and improvements, shall be and become the property of Landlord and remain in place at the Premises following the
expiration or earlier termination of this Lease. Notwithstanding the foregoing, Landlord may, by written notice to Tenant given at the time it consents to an Alteration, require Tenant, at Tenant’s expense, to remove any Alterations within the
Premises and to repair any damage to the Premises and Building caused by such removal. If Tenant fails to complete such removal and/or to repair any damage caused by the removal of any Alterations, Landlord may do so and may charge the cost thereof
to Tenant. Tenant hereby protects, defends, indemnifies and holds Landlord harmless from any liability, cost, obligation, expense or claim of lien in any manner relating to the installation, placement, removal or financing of any such Alterations,
improvements, fixtures and/or equipment in, on or about the Premises, which obligations of Tenant shall survive the expiration or earlier termination of this Lease. Tenant shall not be required to remove the initial Tenant Improvements constructed
pursuant to the Tenant Work Letter. Notwithstanding the foregoing, except to the extent the same are paid for by the Tenant Improvement Allowance, the items set forth in Exhibit F attached hereto (the “Tenant’s
Property”) shall at all times be and remain Tenant’s property. Exhibit F may be updated from time to time by agreement of the parties. Tenant may remove the Tenant’s Property from the Premises at any time,
provided that Tenant repairs all damage caused by such removal. Landlord shall have no lien or other interest in the Tenant’s Property. 

9.    COVENANT AGAINST LIENS Tenant shall keep the Project and Premises free from any liens or encumbrances arising out of the
work performed, materials furnished or obligations incurred by or on behalf of Tenant, and shall protect, defend, indemnify and hold Landlord harmless from and against any claims, liabilities, judgments or costs (including, without limitation,
reasonable attorneys’ fees and costs) arising out of same or in connection therewith. Except as to Alterations as to which no notice is required under the second sentence 

  

					
		  	-24-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 
of Section 8.1, Tenant shall give Landlord notice at least ten (10) business days prior to the commencement of any such work on the Premises (or such additional time as may be
necessary under applicable laws) to afford Landlord the opportunity of posting and recording appropriate notices of non-responsibility (to the extent applicable pursuant to then applicable laws). Tenant shall
remove any such lien or encumbrance by bond or otherwise within ten (10) business days after notice by Landlord, and if Tenant shall fail to do so, Landlord may pay the amount necessary to remove such lien or encumbrance, without
being responsible for investigating the validity thereof. 
  

	10.	 INSURANCE 

10.1    Indemnification and Waiver. Except as provided in Section 10.5 or to the
extent due to the negligence, willful misconduct or violation of this Lease by Landlord or the Landlord Parties, Tenant hereby assumes all risk of damage to property in, upon or about the Premises from any cause whatsoever (including, but not
limited to, any personal injuries resulting from a slip and fall in, upon or about the Premises) and agrees that Landlord, its partners, subpartners and their respective officers, agents, servants, employees, and independent contractors
(collectively, “Landlord Parties”) shall not be liable for, and are hereby released from any responsibility for, any damage either to person or property or resulting from the loss of use thereof, which damage is sustained by Tenant
or by other persons claiming through Tenant. Tenant shall indemnify, defend, protect, and hold harmless the Landlord Parties from any and all loss, cost, damage, expense and liability (including without limitation court costs and reasonable
attorneys’ fees) incurred in connection with or arising from any cause in or on the Premises (including, but not limited to, a slip and fall), any acts, omissions or negligence of Tenant or of any person claiming by, through or under Tenant, or
of the contractors, agents, servants, employees, invitees, guests or licensees of Tenant or any such person, in, on or about the Project or any breach of the terms of this Lease, either prior to, during, or after the expiration of the Lease Term,
provided that the terms of the foregoing indemnity and release shall not apply to the negligence or willful misconduct of Landlord or its agents, employees, contractors, licensees or invitees, or Landlord’s violation of this Lease. Should
Landlord be named as a defendant in any suit brought against Tenant in connection with or arising out of Tenant’s occupancy of the Premises, Tenant shall pay to Landlord its costs and expenses incurred in such suit, including without
limitation, its actual professional fees such as reasonable appraisers’, accountants’ and attorneys’ fees. Notwithstanding anything to the contrary in this Lease, Landlord shall not be released or indemnified from, and shall
indemnify, defend, protect and hold harmless Tenant from, all losses, damages, liabilities, claims, attorneys’ fees, costs and expenses arising from the gross negligence or willful misconduct of Landlord or its agents, contractors, licensees or
invitees, or a violation of Landlord’s obligations or representations under this Lease. The provisions of this Section 10.1 shall survive the expiration or sooner termination of this Lease with respect to any claims or
liability arising in connection with any event occurring prior to such expiration or termination. 

10.2    Tenant’s Compliance With Landlord’s Property Insurance. Landlord shall insure the
Building, Tenant Improvements and any Alterations during the Lease Term against loss or damage under an “all risk” property insurance policy. Such coverage shall be in such amounts, from such companies, and on such other terms and
conditions, as Landlord may from time to time reasonably determine. Additionally, at the option of Landlord, such insurance coverage may include the risks of earthquakes and/or flood damage and additional hazards, a rental loss endorsement and one
or more loss payee endorsements in favor of the holders of any mortgages or deeds of trust encumbering the interest of Landlord in the Building or the ground or underlying lessors of the Building, or any portion thereof. The costs of such insurance
shall be included in Operating Expenses, subject to the terms of Section 4.2.4. Tenant shall, at Tenant’s expense, comply with all insurance company requirements pertaining to the use of the Premises. If Tenant’s
conduct or use of the Premises causes any increase in the premium for such insurance policies then Tenant shall reimburse Landlord for any such increase. Tenant, at Tenant’s expense, shall comply with all rules, orders, regulations or
requirements of the American Insurance Association (formerly the National Board of Fire Underwriters) and with any similar body. Notwithstanding anything to the contrary in this Lease, Tenant shall not be required to comply with or cause the
Premises to comply with any laws, rules, regulations or insurance requirements requiring the construction of alterations unless such compliance is necessitated solely due to Tenant’s particular use of the Premises. 

10.3    Tenant’s Insurance. Tenant shall maintain the following coverages in the following amounts.

  

					
		  	-25-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 10.3.1    Commercial General Liability Insurance on an occurrence form
covering the insured against claims of bodily injury and property damage (including loss of use thereof) arising out of Tenant’s operations, and contractual liabilities including a contractual coverage for limits of liability (which limits may
be met together with umbrella liability insurance) of not less than: 
  

			
	Bodily Injury and Property Damage Liability	  	 $4,000,000 each occurrence
 $4,000,000 annual
aggregate

		
	Personal Injury Liability	  	 $3,000,000 each occurrence
 $3,000,000 annual
aggregate

 10.3.2    Property Insurance covering all office furniture, business and trade fixtures,
office and lab equipment, free-standing cabinet work, movable partitions, merchandise and all other items of Tenant’s property on the Premises installed by, for, or at the expense of Tenant. Such insurance shall be written on an “all
risks” of physical loss or damage basis, for the full replacement cost value (subject to reasonable deductible amounts) new without deduction for depreciation of the covered items and in amounts that meet any
co-insurance clauses of the policies of insurance and shall include coverage for damage or other loss caused by fire or other peril including, but not limited to, vandalism and malicious mischief, theft, water
damage (excluding flood), including sprinkler leakage, bursting or stoppage of pipes, and explosion, and providing business interruption coverage for a period of ninety (90) days. 

10.3.3    Business Income Interruption for ninety (90) days plus Extra Expense insurance in such amounts as will
reimburse Tenant for actual direct or indirect loss of earnings attributable to the risks outlined in Section 10.3.2 above. 

10.3.4    Worker’s Compensation and Employer’s Liability or other similar insurance pursuant to all applicable
state and local statutes and regulations. The policy shall include a waiver of subrogation in favor of Landlord, its employees, Lenders and any property manager or partners. 

10.4    Form of Policies. The minimum limits of policies of insurance required of Tenant under this Lease
shall in no event limit the liability of Tenant under this Lease. Such insurance shall (i) name Landlord, its subsidiaries and affiliates, its property manager (if any) and any other party the Landlord so specifies, as an additional insured on
the liability insurance, including Landlord’s managing agent, if any; (ii) be issued by an insurance company having a rating of not less than A-:VII in Best’s Insurance Guide or which is
otherwise acceptable to Landlord and authorized to do business in the State of California; and (iv) be primary insurance as to all claims thereunder and provide that any insurance carried by Landlord is excess and is non-contributing with any insurance required of Tenant. Tenant shall not cause said insurance to be canceled or coverage changed unless thirty (30) days’ prior written notice shall have been given to
Landlord and any mortgagee of Landlord (unless such cancellation is the result of non-payment of premiums, in which case not less than five (5) days’ notice shall be provided). Tenant shall deliver
said policy or policies or certificates thereof to Landlord on or before the Lease Commencement Date and at least ten (10) days before the expiration dates thereof. In the event Tenant shall fail to procure such insurance, or to deliver such
policies or certificate, Landlord may, at its option, procure such policies for the account of Tenant, and the cost thereof shall be paid to Landlord within five (5) days after delivery to Tenant of bills therefor. 

10.5    Subrogation. Landlord and Tenant hereby agree to look solely to, and seek recovery only from, their
respective insurance carriers in the event of a property or business interruption loss to the extent that such coverage is agreed to be provided hereunder, notwithstanding the negligence of either party. Notwithstanding anything to the contrary in
this Lease, the parties each hereby waive all rights and claims against each other for such losses, and waive all rights of subrogation of their respective insurers. The parties agree that their respective insurance policies do now, or shall,
contain the waiver of subrogation. 
 10.6    Additional Insurance Obligations. Tenant shall carry and
maintain during the entire Lease Term, at Tenant’s sole cost and expense, increased amounts of the insurance required to be carried by Tenant pursuant to this Article 10 and such other reasonable types of insurance coverage and in such
reasonable amounts covering the Premises and Tenant’s operations therein, as may be reasonably requested by Landlord or Landlord’s lender, but in no event in excess of the amounts and types of insurance then being required by landlords of
buildings comparable to and in the vicinity of the Building. 

  

					
		  	-26-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

	11.	 DAMAGE AND DESTRUCTION 

11.1    Repair of Damage to Premises by Landlord. Tenant shall promptly notify Landlord of any damage to the
Premises resulting from fire or any other casualty. If the Premises or any Common Areas serving or providing access to the Premises shall be damaged by fire or other casualty, Landlord shall promptly and diligently, subject to reasonable delays for
insurance adjustment or other matters beyond Landlord’s reasonable control, and subject to all other terms of this Article 11, restore the Premises and such Common Areas. Such restoration shall be to substantially the same condition of
the Premises and the Common Areas prior to the casualty, except for modifications required by zoning and building codes and other laws or any other modifications to the Common Areas deemed desirable by Landlord, which are consistent with the
character of the Project, provided that access to the Premises shall not be materially impaired. Landlord shall not be liable for any inconvenience or annoyance to Tenant or its visitors, or injury to Tenant’s business resulting in any way from
such damage or the repair thereof; provided however, that if such fire or other casualty shall have damaged the Premises or Common Areas necessary to Tenant’s occupancy, and the damaged portions of the Premises are not occupied by Tenant as a
result thereof, then during the time and to the extent the Premises are unfit for occupancy, the Rent shall be abated in proportion to the ratio that the amount of rentable square feet of the Premises which is unfit for occupancy for the purposes
permitted under this Lease bears to the total rentable square feet of the Premises. 
 11.2    Landlord’s
Option to Repair. Notwithstanding the terms of Section 11.1 of this Lease, Landlord may elect not to rebuild and/or restore the Premises, Building and/or Project, and instead terminate this Lease, by notifying
Tenant in writing of such termination within sixty (60) days after the date of discovery of the damage, such notice to include a termination date giving Tenant sixty (60) days to vacate the Premises, but Landlord may so elect only if the
Building shall be damaged by fire or other casualty or cause, and one or more of the following conditions is present: (i) in Landlord’s reasonable judgment, repairs cannot reasonably be completed within one (1) year after the date of
discovery of the damage (when such repairs are made without the payment of overtime or other premiums); (ii) the damage is due to a risk that Landlord is not required to insure under this Lease, and the cost of restoration exceed five percent (5%)
of the replacement cost of the Building (unless Tenant agrees to pay any uninsured amount in excess of such five percent (5%)); or (iii) the damage occurs during the last twelve (12) months of the Lease Term and will take more than sixty
(60) days to restore; provided, however, that if Landlord does not elect to terminate this Lease pursuant to Landlord’s termination right as provided above, and the repairs cannot, in the reasonable opinion of Landlord, be completed within
seven (7) months after the date of discovery of the damage (or are not in fact completed within eight (8) months after the date of discovery of the damage), Tenant may elect, no earlier than sixty (60) days after the date of the
damage and not later than ninety (90) days after the date of such damage, or within thirty (30) days after such repairs are not timely completed, to terminate this Lease by written notice to Landlord effective as of the date specified in
the notice, which date shall not be less than thirty (30) days nor more than sixty (60) days after the date such notice is given by Tenant. 

11.3    Waiver of Statutory Provisions. The provisions of this Lease, including this Article 11,
constitute an express agreement between Landlord and Tenant with respect to any and all damage to, or destruction of, all or any part of the Premises, the Building or the Project, and any statute or regulation of the State of California, including,
without limitation, Sections 1932(2) and 1933(4) of the California Civil Code, with respect to any rights or obligations concerning damage or destruction in the absence of an express agreement between the parties, and any other statute or
regulation, now or hereafter in effect, shall have no application to this Lease or any damage or destruction to all or any part of the Premises, the Building or the Project. 

12.    NONWAIVER No provision of this Lease shall be deemed waived by either party hereto unless expressly waived in a
writing signed thereby. The waiver by either party hereto of any breach of any term, covenant or condition herein contained shall not be deemed to be a waiver of any subsequent breach of same or any other term, covenant or condition herein
contained. The subsequent acceptance of Rent hereunder by Landlord shall not be deemed to be a waiver of any preceding breach by Tenant of any term, covenant or condition of this Lease, other than the failure of Tenant to pay the particular Rent so
accepted, regardless of Landlord’s knowledge of such preceding breach at the time of acceptance of such Rent. No acceptance of a lesser amount than the Rent herein stipulated shall be deemed a 

  

					
		  	-27-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 
waiver of Landlord’s right to receive the full amount due, nor shall any endorsement or statement on any check or payment or any letter accompanying such check or payment be deemed an accord
and satisfaction, and Landlord may accept such check or payment without prejudice to Landlord’s right to recover the full amount due. No receipt of monies by Landlord from Tenant after the termination of this Lease shall in any way alter the
length of the Lease Term or of Tenant’s right of possession hereunder, or after the giving of any notice shall reinstate, continue or extend the Lease Term or affect any notice given Tenant prior to the receipt of such monies, it being agreed
that after the service of notice or the commencement of a suit, or after final judgment for possession of the Premises, Landlord may receive and collect any Rent due, and the payment of said Rent shall not waive or affect said notice, suit or
judgment. 
 13.    CONDEMNATION If the whole or any part of the Premises shall be taken by power of eminent domain or
condemned by any competent authority for any public or quasi-public use or purpose, or if any adjacent property or street shall be so taken or condemned, or reconfigured or vacated by such authority in such manner as to require the use or
reconstruction of any part of the Premises, or if Landlord shall grant a deed or other instrument in lieu of such taking by eminent domain or condemnation, Landlord shall have the option to terminate this Lease effective as of the date possession is
required to be surrendered to the authority. Tenant shall not because of such taking assert any claim against Landlord or the authority for any compensation because of such taking and Landlord shall be entitled to the entire award or payment in
connection therewith, except that Tenant shall have the right to file any separate claim available to Tenant for any taking of Tenant’s personal property and fixtures belonging to Tenant and removable by Tenant upon expiration of the Lease Term
pursuant to the terms of this Lease, for moving expenses, for the unamortized value of any improvements paid for by Tenant and for the Lease “bonus value”, so long as such claims are payable separately to Tenant. All Rent shall be
apportioned as of the date of such termination. If any part of the Premises shall be taken, and this Lease shall not be so terminated, the Rent shall be proportionately abated. Tenant hereby waives any and all rights it might otherwise have pursuant
to Section 1265.130 of The California Code of Civil Procedure. Notwithstanding anything to the contrary contained in this Article 13, in the event of a temporary taking of all or any portion of the Premises for a period of one hundred and
eighty (180) days or less, then this Lease shall not terminate but the Base Rent and the Additional Rent shall be abated for the period of such taking in proportion to the ratio that the amount of rentable square feet of the Premises taken
bears to the total rentable square feet of the Premises. Landlord shall be entitled to receive the entire award made in connection with any such temporary taking. 
  

	14.	 ASSIGNMENT AND SUBLETTING 

14.1    Transfers. Tenant shall not, without the prior written consent of Landlord, assign, mortgage, pledge,
hypothecate, encumber, or permit any lien to attach to, or otherwise transfer, this Lease or any interest hereunder, permit any assignment, or other transfer of this Lease or any interest hereunder by operation of law, sublet the Premises or any
part thereof, or enter into any license or concession agreements or otherwise permit the occupancy or use of the Premises or any part thereof by any persons other than Tenant and its employees and contractors (all of the foregoing are hereinafter
sometimes referred to collectively as “Transfers” and any person to whom any Transfer is made or sought to be made is hereinafter sometimes referred to as a “Transferee”). If Tenant desires Landlord’s consent
to any Transfer, Tenant shall notify Landlord in writing, which notice (the “Transfer Notice”) shall include (i) the proposed effective date of the Transfer, which shall not be less than thirty (30) days nor more than one
hundred eighty (180) days after the date of delivery of the Transfer Notice, (ii) a description of the portion of the Premises to be transferred (the “Subject Space”), (iii) all of the terms of the proposed Transfer and
the consideration therefor, including calculation of the “Transfer Premium”, as that term is defined in Section 14.3 below, in connection with such Transfer, the name and address of the proposed Transferee,
and a copy of all existing executed and/or proposed documentation pertaining to the proposed Transfer, and (iv) current financial statements of the proposed Transferee certified by an officer, partner or owner thereof, and any other information
reasonably required by Landlord which will enable Landlord to determine the financial responsibility, character, and reputation of the proposed Transferee, nature of such Transferee’s business and proposed use of the Subject Space. Any Transfer
made without Landlord’s prior written consent shall, at Landlord’s option, be null, void and of no effect, and shall, at Landlord’s option, constitute a default by Tenant under this Lease. Whether or not Landlord consents to any
proposed Transfer, Tenant shall pay Landlord’s reasonable review and processing fees, as well as any reasonable professional fees (including, without limitation, attorneys’, accountants’, architects’, engineers’ and
consultants’ fees) incurred by Landlord (not to exceed $3,500 in the aggregate for any particular Transfer), within thirty (30) days after written request by Landlord. 

  

					
		  	-28-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 14.2    Landlord’s Consent. Landlord shall not
unreasonably withhold or delay its consent to any proposed Transfer of the Subject Space to the Transferee on the terms specified in the Transfer Notice and shall respond to Tenant’s consent request within forty-five (45) days following
receipt of such request and the documentation required by this Lease in connection therewith. Without limitation as to other reasonable grounds for withholding consent, the parties hereby agree that it shall be reasonable under this Lease and under
any applicable law for Landlord to withhold consent to any proposed Transfer where one or more of the following apply: 

14.2.1    The Transferee is of a character or reputation or engaged in a business which is not consistent with the quality
of the Building or the Project; 
 14.2.2    The Transferee is either a governmental agency or instrumentality thereof;

 14.2.3    The Transferee is not a party of reasonable financial worth and/or financial stability in light of the
responsibilities to be undertaken in connection with the Transfer on the date consent is requested; or 
 14.2.4    The
proposed Transfer would cause a violation of another lease for space in the Project, or would give an occupant of the Project a right to cancel its lease. 

If Landlord consents to any Transfer pursuant to the terms of this Section 14.2 (and does not exercise any recapture
rights Landlord may have under Section 14.4 of this Lease), Tenant may within six (6) months after Landlord’s consent, but not later than the expiration of said six-month
period, enter into such Transfer of the Premises or portion thereof, upon substantially the same terms and conditions as are set forth in the Transfer Notice furnished by Tenant to Landlord pursuant to Section 14.1 of this
Lease, provided that if there are any changes in the terms and conditions from those specified in the Transfer Notice such that Landlord would initially have been entitled to refuse its consent to such Transfer under this
Section 14.2, Tenant shall again submit the Transfer to Landlord for its approval and other action under this Article 14 (including Landlord’s right of recapture, if any, under
Section 14.4 of this Lease). Notwithstanding anything to the contrary in this Lease, if Tenant or any proposed Transferee claims that Landlord has unreasonably withheld or delayed its consent under
Section 14.2 or otherwise has breached or acted unreasonably under this Article 14, their sole remedies shall be a suit for contract damages (other than damages for injury to, or interference with, Tenant’s
business including, without limitation, loss of profits, however occurring) or declaratory judgment and an injunction for the relief sought, and Tenant hereby waives all other remedies, including, without limitation, any right at law or equity to
terminate this Lease, on its own behalf and, to the extent permitted under all applicable laws, on behalf of the proposed Transferee. 

14.3    Transfer Premium. If Landlord consents to a Transfer, as a condition thereto which the parties
hereby agree is reasonable, Tenant shall pay to Landlord fifty percent (50%) of any “Transfer Premium,” as that term is defined in this Section 14.3, received by Tenant from such Transferee.
“Transfer Premium” shall mean all rent, additional rent or other consideration payable by such Transferee in connection with the Transfer in excess of the Rent and Additional Rent payable by Tenant under this Lease during the term
of the Transfer on a per rentable square foot basis if less than all of the Premises is transferred, and after deduction of (i) any costs of improvements made to the Subject Space in connection with such Transfer, (ii) brokerage
commissions paid in connection with such Transfer, and (iii) reasonable legal fees incurred in connection with such Transfer. “Transfer Premium” shall also include, but not be limited to, key money, bonus money or other cash
consideration paid by Transferee to Tenant in connection with such Transfer, and any payment in excess of fair market value for services rendered by Tenant to Transferee or for assets, fixtures, inventory, equipment, or furniture transferred by
Tenant to Transferee in connection with such Transfer. The determination of the amount of Landlord’s applicable share of the Transfer Premium shall be made on a monthly basis as rent or other consideration is received by Tenant under the
Transfer. 
 14.4    Landlord’s Option as to Subject Space. Notwithstanding anything to the contrary
contained in this Article 14, in the event Tenant contemplates a Transfer other than to a Permitted Transferee which, together with all prior Transfers then remaining in effect, would cause fifty percent (50%) or more of the Premises to be
Transferred for more than fifty percent (50%) of the then remaining Lease Term (taking into account any extension of the Lease Term which has irrevocably exercised by Tenant), Tenant shall give Landlord notice (the “Intention to Transfer
Notice”) of such contemplated Transfer (whether or not the contemplated Transferee or the terms of such contemplated Transfer have been determined). The Intention to Transfer Notice shall specify the portion of and amount of rentable

  

					
		  	-29-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 
square feet of the Premises which Tenant intends to Transfer in the subject Transfer (the “Contemplated Transfer Space”), the contemplated date of commencement of the
Contemplated Transfer (the “Contemplated Effective Date”), and the contemplated length of the term of such contemplated Transfer. Thereafter, Landlord shall have the option, by giving written notice to Tenant within thirty
(30) days after receipt of any Intention to Transfer Notice, to recapture the Contemplated Transfer Space. Such recapture shall cancel and terminate this Lease with respect to such Contemplated Transfer Space as of the Contemplated Effective
Date. In the event of a recapture by Landlord, if this Lease shall be canceled with respect to less than the entire Premises, the Rent reserved herein shall be prorated on the basis of the number of rentable square feet retained by Tenant in
proportion to the number of rentable square feet contained in the Premises, and this Lease as so amended shall continue thereafter in full force and effect, and upon request of either party, the parties shall execute written confirmation of the
same. If Landlord declines, or fails to elect in a timely manner, to recapture such Contemplated Transfer Space under this Section 14.4, then, subject to the other terms of this Article 14, for a period of nine
(9) months (the “Nine Month Period”) commencing on the last day of such thirty (30) day period, Landlord shall not have any right to recapture the Contemplated Transfer Space with respect to any Transfer made during the
Nine Month Period, provided that any such Transfer is substantially on the terms set forth in the Intention to Transfer Notice, and provided further that any such Transfer shall be subject to the remaining terms of this Article 14. If such a
Transfer is not so consummated within the Nine Month Period (or if a Transfer is so consummated, then upon the expiration of the term of any Transfer of such Contemplated Transfer Space consummated within such Nine Month Period), Tenant shall again
be required to submit a new Intention to Transfer Notice to Landlord with respect any contemplated Transfer, as provided above in this Section 14.4. Tenant shall not be required to provide a separate Intention to Transfer
Notice and Tenant’s request for Landlord’s consent to a Transfer shall satisfy Tenant’s obligations in this Section 14.4. 

14.5    Effect of Transfer. If Landlord consents to a Transfer, (i) the terms and conditions of this
Lease shall in no way be deemed to have been waived or modified, (ii) such consent shall not be deemed consent to any further Transfer by either Tenant or a Transferee, (iii) Tenant shall deliver to Landlord, promptly after execution, an
original executed copy of all documentation pertaining to the Transfer in form reasonably acceptable to Landlord, (iv) Tenant shall furnish upon Landlord’s request a complete statement, certified by an independent certified public
accountant, or Tenant’s chief financial officer, setting forth in detail the computation of any Transfer Premium Tenant has derived and shall derive from such Transfer, and (v) no Transfer relating to this Lease or agreement entered into
with respect thereto, whether with or without Landlord’s consent, shall relieve Tenant or any guarantor of the Lease from any liability under this Lease, including, without limitation, in connection with the Subject Space. Landlord or its
authorized representatives shall have the right at all reasonable times to audit the books, records and papers of Tenant relating to any Transfer, and shall have the right to make copies thereof. If the Transfer Premium respecting any Transfer shall
be found understated, Tenant shall, within thirty (30) days after demand, pay the deficiency, and if understated by more than two percent (2%), Tenant shall pay Landlord’s costs of such audit. 

14.6    Additional Transfers. For purposes of this Lease, the term “Transfer” shall also
include if Tenant is a partnership, the withdrawal or change, voluntary, involuntary or by operation of law, of fifty percent (50%) or more of the partners, or transfer of fifty percent (50%) or more of partnership interests, within a twelve
(12)-month period, or the dissolution of the partnership without immediate reconstitution thereof. 

14.7    Occurrence of Default. Any Transfer hereunder shall be subordinate and subject to the provisions of
this Lease, and if this Lease shall be terminated during the term of any Transfer, Landlord shall have the right to: (i) treat such Transfer as cancelled and repossess the Subject Space by any lawful means, or (ii) require that such Transferee
attorn to and recognize Landlord as its landlord under any such Transfer. If Tenant shall be in default under this Lease, Landlord is hereby irrevocably authorized, as Tenant’s agent and attorney-in-fact, to direct any Transferee to make all payments under or in connection with the Transfer directly to Landlord (which Landlord shall apply towards Tenant’s obligations under this Lease)
until such default is cured. Such Transferee shall rely on any representation by Landlord that Tenant is in default hereunder, without any need for confirmation thereof by Tenant. Upon any assignment, the assignee shall assume in writing all
obligations and covenants of Tenant thereafter to be performed or observed under this Lease. No collection or acceptance of rent by Landlord from any Transferee shall be deemed a waiver of any provision of this Article 14 or the approval of
any Transferee or a release of Tenant from any obligation under this Lease, whether theretofore or thereafter accruing. In no event shall Landlord’s enforcement of any provision of this Lease against any Transferee be deemed a waiver of
Landlord’s right to enforce any term of this Lease against Tenant or any other person. If Tenant’s obligations hereunder have been guaranteed, Landlord’s consent to any Transfer shall not be effective unless the guarantor also
consents to such Transfer. 

  

					
		  	-30-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

14.8    Non-Transfers. Notwithstanding anything to the contrary
contained in this Article 14, (i) an assignment or subletting of all or a portion of the Premises to an affiliate of Tenant (an entity which is controlled by, controls, or is under common control with, Tenant), (ii) an assignment of the
Premises to an entity which acquires all or substantially all of the assets or interests (partnership, stock or other) of Tenant, (iii) an assignment of the Premises to an entity which is the resulting entity of a merger or consolidation of
Tenant with another entity, or (iv) a change of Control or the sale of corporate shares of capital stock in Tenant in connection with a private financing or public offering of Tenant’s stock on a nationally-recognized stock exchange
(collectively, a “Permitted Transferee”), shall not be deemed a Transfer under this Article 14, provided that (A) Tenant notifies Landlord of any such assignment or sublease and promptly supplies Landlord with any
documents or information requested by Landlord regarding such assignment or sublease or such affiliate, (B) such assignment or sublease is not a subterfuge by Tenant to avoid its obligations under this Lease, (C) such Permitted Transferee
shall be of a character and reputation consistent with the quality of the Building, and (D) such Permitted Transferee described in subpart (ii) or (iii) above shall have a tangible net worth (not including goodwill as an asset) computed in
accordance with generally accepted accounting principles (“Net Worth”) at least equal to the Net Worth of Tenant on the day immediately preceding the effective date of such assignment or sublease. An assignee of Tenant’s entire
interest that is also a Permitted Transferee may also be known as a “Permitted Assignee”. “Control,” as used in this Section 14.8, shall mean the ownership, directly or indirectly, of at
least fifty-one percent (51%) of the voting securities of, or possession of the right to vote, in the ordinary direction of its affairs, of at least fifty-one percent
(51%) of the voting interest in, any person or entity. No such permitted assignment or subletting shall serve to release Tenant from any of its obligations under this Lease. 
  

	15.	 SURRENDER OF PREMISES; OWNERSHIP AND REMOVAL OF TRADE FIXTURES 

15.1    Surrender of Premises. No act or thing done by Landlord or any agent or employee of Landlord during
the Lease Term shall be deemed to constitute an acceptance by Landlord of a surrender of the Premises unless such intent is specifically acknowledged in writing by Landlord. The delivery of keys to the Premises to Landlord or any agent or employee
of Landlord shall not constitute a surrender of the Premises or effect a termination of this Lease, whether or not the keys are thereafter retained by Landlord, and notwithstanding such delivery Tenant shall be entitled to the return of such keys at
any reasonable time upon request until this Lease shall have been properly terminated. The voluntary or other surrender of this Lease by Tenant, whether accepted by Landlord or not, or a mutual termination hereof, shall not work a merger, and at the
option of Landlord shall operate as an assignment to Landlord of all subleases or subtenancies affecting the Premises or terminate any or all such sublessees or subtenancies. 

15.2    Removal of Tenant Property by Tenant. Upon the expiration of the Lease Term, or upon any earlier
termination of this Lease, Tenant shall, subject to the provisions of this Article 15, quit and surrender possession of the Premises to Landlord in as good order and condition as when Tenant took possession and as thereafter improved by
Landlord and/or Tenant, reasonable wear and tear, damage caused by casualty, repairs required as a result of condemnation, and repairs which are specifically made the responsibility of Landlord hereunder excepted. Upon such expiration or
termination, Tenant shall, without expense to Landlord, remove or cause to be removed from the Premises all debris and rubbish, and such items of furniture, equipment, free-standing cabinet work, movable partitions (but not demountable walls) and
other articles of personal property owned by Tenant or installed or placed by Tenant at its expense in the Premises, and such similar articles of any other persons claiming under Tenant, as Landlord may, in its sole discretion, require to be
removed, and Tenant shall repair at its own expense all damage to the Premises and Building resulting from such removal. 

15.3    Environmental Assessment. In connection with its surrender of the Premises, Tenant shall submit to
Landlord, at least fifteen (15) days prior to the expiration date of this Lease (or in the event of an earlier termination of this Lease, as soon as reasonably possible following such termination), an environmental Assessment of the Premises by
a competent and experienced environmental engineer or engineering firm reasonably satisfactory to Landlord (pursuant to a contract approved by Landlord and providing that Landlord can rely on the Environmental Assessment). If such Environmental
Assessment reveals that remediation or Clean-up is required under any Environmental Laws that Tenant is responsible for under this Lease, Tenant shall submit a remediation plan prepared by a recognized
environmental consultant and shall be responsible for all costs of remediation and Clean-up, as more particularly provided in Section 5.3, above. 

 

  

					
		  	-31-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 15.4    Condition of the Building and Premises Upon
Surrender. In addition to the above requirements of this Article 15, upon the expiration of the Lease Term, or upon any earlier termination of this Lease, Tenant shall, surrender the Premises and Building with Tenant having complied
with all of Tenant’s obligations under this Lease, including those relating to improvement, repair, maintenance, compliance with law, testing and other related obligations of Tenant set forth in Article 7 of this Lease. In the event that
the Building and Premises shall be surrendered in a condition which does not comply with the terms of this Section 15.4, because Tenant failed to comply with its obligations set forth in Lease, then following thirty
(30) days’ notice to Tenant, during which thirty (30) day period Tenant shall have the right to cure such noncompliance, Landlord shall be entitled to expend all reasonable costs in order to cause the same to comply with the required
condition upon surrender and Tenant shall immediately reimburse Landlord for all such costs upon notice and, commencing on the later of the termination of this Lease and three (3) business days after Landlord’s delivery of notice of such
failure and that it elects to treat such failure as a holdover, Tenant shall be deemed during the period that Tenant or Landlord, as the case may be, perform obligations relating to the Surrender Improvements to be in holdover under
Article 16 of this Lease. 
 16.    HOLDING OVER If Tenant holds over after the expiration of the Lease Term
or earlier termination thereof, with the express or implied consent of Landlord, such tenancy shall be from month-to-month only, and shall not constitute a renewal
hereof or an extension for any further term. If Tenant holds over after the expiration of the Lease Term of earlier termination thereof, without the express or implied consent of Landlord, such tenancy shall be deemed to be a tenancy by sufferance
only, and shall not constitute a renewal hereof or an extension for any further term. In either case, Base Rent shall be payable at a monthly rate equal to one hundred fifty percent (150%) of the Base Rent applicable during the last rental period of
the Lease Term under this Lease. Such month-to-month tenancy or tenancy by sufferance, as the case may be, shall be subject to every other applicable term, covenant and
agreement contained herein. Nothing contained in this Article 16 shall be construed as consent by Landlord to any holding over by Tenant, and Landlord expressly reserves the right to require Tenant to surrender possession of the Premises to Landlord
as provided in this Lease upon the expiration or other termination of this Lease. The provisions of this Article 16 shall not be deemed to limit or constitute a waiver of any other rights or remedies of Landlord provided herein or at law. If Tenant
fails to surrender the Premises upon the termination or expiration of this Lease, in addition to any other liabilities to Landlord accruing therefrom, Tenant shall protect, defend, indemnify and hold Landlord harmless from all loss, costs (including
reasonable attorneys’ fees) and liability resulting from such failure, including, without limiting the generality of the foregoing, any claims made by any succeeding tenant founded upon such failure to surrender and any lost profits to Landlord
resulting therefrom. 
 17.    ESTOPPEL CERTIFICATES Within ten (10) business days following a request in writing by
Landlord, Tenant shall execute, acknowledge and deliver to Landlord an estoppel certificate, which, as submitted by Landlord, shall be substantially in the form of Exhibit D, attached hereto (or such other form as may be reasonably
required by any prospective mortgagee or purchaser of the Project, or any portion thereof), indicating therein any exceptions thereto that may exist at that time, and shall also contain any other information reasonably requested by Landlord or
Landlord’s mortgagee or prospective mortgagee. Any such certificate may be relied upon by any prospective mortgagee or purchaser of all or any portion of the Project. Tenant shall execute and deliver whatever other instruments may be reasonably
required for such purposes. At any time during the Lease Term, in connection with a sale or financing of the Building by Landlord, Landlord may require Tenant to provide Landlord with its most recent annual financial statement and annual financial
statements of the preceding two (2) years. Such statements shall be prepared in accordance with generally accepted accounting principles and, if such is the normal practice of Tenant, shall be audited by an independent certified public
accountant. Landlord shall hold such statements confidential. Failure of Tenant to timely execute, acknowledge and deliver such estoppel certificate or other instruments shall constitute an acceptance of the Premises and an acknowledgment by Tenant
that statements included in the estoppel certificate are true and correct, without exception. 
 18.    SUBORDINATION
Landlord hereby represents and warrants to Tenant that the Project is not currently subject to any ground lease, or to the lien of any mortgage or deed of trust. This Lease shall be subject and subordinate to all future ground or underlying
leases of the Building or Project and to the lien of any mortgage, trust deed or other encumbrances now or hereafter in force against the Building or Project or any part thereof, if any, and to all renewals,

  

					
		  	-32-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 
extensions, modifications, consolidations and replacements thereof, and to all advances made or hereafter to be made upon the security of such mortgages or trust deeds, unless the holders of such
mortgages, trust deeds or other encumbrances, or the lessors under such ground lease or underlying leases, require in writing that this Lease be superior thereto. The subordination of this Lease to any such future ground or underlying leases of the
Building or Project or to the lien of any mortgage, trust deed or other encumbrances, shall be subject to Tenant’s receipt of a commercially reasonable subordination, non-disturbance, and attornment
agreement in favor of Tenant. Tenant covenants and agrees in the event any proceedings are brought for the foreclosure of any such mortgage or deed in lieu thereof (or if any ground lease is terminated), to attorn, without any deductions or set-offs whatsoever, to the lienholder or purchaser or any successors thereto upon any such foreclosure sale or deed in lieu thereof (or to the ground lessor), if so requested to do so by such purchaser or
lienholder or ground lessor, and to recognize such purchaser or lienholder or ground lessor as the lessor under this Lease, provided such lienholder or purchaser or ground lessor shall agree to accept this Lease and not disturb Tenant’s
occupancy, so long as Tenant timely pays the rent and observes and performs the terms, covenants and conditions of this Lease to be observed and performed by Tenant. Landlord’s interest herein may be assigned as security at any time to any
lienholder. Tenant shall, within ten (10) days of request by Landlord, execute such further instruments or assurances as Landlord may reasonably deem necessary to evidence or confirm the subordination or superiority of this Lease to any such
mortgages, trust deeds, ground leases or underlying leases. Tenant waives the provisions of any current or future statute, rule or law which may give or purport to give Tenant any right or election to terminate or otherwise adversely affect this
Lease and the obligations of the Tenant hereunder in the event of any foreclosure proceeding or sale. 
  

	19.	 DEFAULTS; REMEDIES 

19.1    Events of Default. The occurrence of any of the following shall constitute a default of this Lease by
Tenant: 
 19.1.1    Any failure by Tenant to pay any Rent or any other charge required to be paid under this Lease, or
any part thereof, when due unless such failure is cured within five (5) business days after notice; or 

19.1.2    Except where a specific time period is otherwise set forth for Tenant’s performance in this Lease, in which
event the failure to perform by Tenant within such time period shall be a default by Tenant under this Section 19.1.2, any failure by Tenant to observe or perform any other provision, covenant or condition of this Lease to
be observed or performed by Tenant where such failure continues for thirty (30) days after written notice thereof from Landlord to Tenant; provided that if the nature of such default is such that the same cannot reasonably be cured within a
thirty (30) day period, Tenant shall not be deemed to be in default if it diligently commences such cure within such period and thereafter diligently proceeds to rectify and cure such default; or 

19.1.3    Abandonment or vacation of all or a substantial portion of the Premises by Tenant while Tenant is in default
under the Lease; or 
 19.1.4    The failure by Tenant to observe or perform according to the provisions of Articles
5, 14, 17 or 18 of this Lease where such failure continues for more than five (5) business days after notice from Landlord. 

19.2    Remedies Upon Default. Upon the occurrence of any event of default by Tenant, Landlord shall have,
in addition to any other remedies available to Landlord at law or in equity (all of which remedies shall be distinct, separate and cumulative), the option to pursue any one or more of the following remedies, each and all of which shall be cumulative
and nonexclusive, without any notice or demand whatsoever. 
 19.2.1    Terminate this Lease, in which event Tenant
shall immediately surrender the Premises to Landlord, and if Tenant fails to do so, Landlord may, without prejudice to any other remedy which it may have for possession or arrearages in rent, enter upon and take possession of the Premises and expel
or remove Tenant and any other person who may be occupying the Premises or any part thereof, without being liable for prosecution or any claim or damages therefor; and Landlord may recover from Tenant the following: 

(i)    The worth at the time of award of the unpaid rent which has been earned at the time of such
termination; plus 

  

					
		  	-33-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 (ii)    The worth at the time of award of the amount by
which the unpaid rent which would have been earned after termination until the time of award exceeds the amount of such rental loss that Tenant proves could have been reasonably avoided; plus 

(iii)    The worth at the time of award of the amount by which the unpaid rent for the balance of the Lease
Term after the time of award exceeds the amount of such rental loss that Tenant proves could have been reasonably avoided; plus 

(iv)    Any other amount necessary to compensate Landlord for all the detriment proximately caused by
Tenant’s failure to perform its obligations under this Lease or which in the ordinary course of things would be likely to result therefrom, specifically including but not limited to, in each case to the extent allocable to the remaining Lease
Term, brokerage commissions and advertising expenses incurred to obtain a new tenant, expenses of remodeling the Premises or any portion thereof for a new tenant, whether for the same or a different use, and any special concessions made to obtain a
new tenant; and 
 (v)    At Landlord’s election, such other amounts in addition to or in lieu of
the foregoing as may be permitted from time to time by applicable law. 
 The term “rent” as used in this
Section 19.2 shall be deemed to be and to mean all sums of every nature required to be paid by Tenant pursuant to the terms of this Lease, whether to Landlord or to others. As used in Sections 19.2.1(i) and
(ii), above, the “worth at the time of award” shall be computed by allowing interest at the rate set forth in Article 25 of this Lease, but in no case greater than the maximum amount of such interest permitted by law. As used
in Section 19.2.1(iii) above, the “worth at the time of award” shall be computed by discounting such amount at the discount rate of the Federal Reserve Bank of San Francisco at the time of award plus one
percent (1%). 
 19.2.2    Landlord shall have the remedy described in California Civil Code Section 1951.4 (lessor
may continue lease in effect after lessee’s breach and abandonment and recover rent as it becomes due, if lessee has the right to sublet or assign, subject only to reasonable limitations). Accordingly, if Landlord does not elect to terminate
this Lease on account of any default by Tenant, Landlord may, from time to time, without terminating this Lease, enforce all of its rights and remedies under this Lease, including the right to recover all rent as it becomes due. 

19.2.3    Landlord shall at all times have the rights and remedies (which shall be cumulative with each other and
cumulative and in addition to those rights and remedies available under Sections 19.2.1 and 19.2.2, above, or any law or other provision of this Lease), without prior demand or notice except as required by applicable law, to seek any
declaratory, injunctive or other equitable relief, and specifically enforce this Lease, or restrain or enjoin a violation or breach of any provision hereof. 

19.3    Subleases of Tenant. If Landlord elects to terminate this Lease on account of any default by Tenant,
as set forth in this Article 19, Landlord shall have the right to terminate any and all subleases, licenses, concessions or other consensual arrangements for possession entered into by Tenant and affecting the Premises or may, in
Landlord’s sole discretion, succeed to Tenant’s interest in such subleases, licenses, concessions or arrangements. In the event of Landlord’s election to succeed to Tenant’s interest in any such subleases, licenses, concessions
or arrangements, Tenant shall, as of the date of notice by Landlord of such election, have no further right to or interest in the rent or other consideration receivable thereunder. 

19.4    Efforts to Relet. No re-entry, repairs, maintenance,
changes, alterations and additions, appointment of a receiver to protect Landlord’s interests hereunder, or any other action or omission by Landlord shall be construed as an election by Landlord to terminate this Lease or Tenant’s right to
possession, or to accept a surrender of the Premises, nor shall same operate to release Tenant in whole or in part from any of Tenant’s obligations hereunder, unless express written notice of such intention is sent by Landlord to Tenant. 

20.    COVENANT OF QUIET ENJOYMENT Landlord covenants that Tenant, on paying the Rent, charges for services and other
payments herein reserved and on keeping, observing and performing all the other terms, covenants, conditions, provisions and agreements herein contained on the part of Tenant to be kept, observed and performed, shall, during the Lease Term,
peaceably and quietly have, hold and enjoy the Premises subject to the terms, covenants, conditions, provisions and agreements hereof without interference by any persons lawfully claiming by or through Landlord. The foregoing covenant is in lieu of
any other covenant express or implied. 

  

					
		  	-34-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

	21.	 LETTER OF CREDIT 

21.1    Delivery of Letter of Credit. In lieu of a cash Security Deposit, Tenant may deliver to Landlord,
concurrently with Tenant’s execution of this Lease, an unconditional, clean, irrevocable letter of credit (the “L-C”) in the amount set forth in Section 8 of the
Lease Summary (the “L-C Amount”), which L-C shall be issued by a money- center, solvent and nationally recognized bank (a bank which accepts deposits,
maintains accounts, has a local San Francisco Bay Area office which will negotiate a letter of credit, and whose deposits are insured by the FDIC) reasonably acceptable to Landlord (such approved, issuing bank being referred to herein as the
“Bank”), which Bank must have a rating from Standard and Poors Corporation of A- or better (or any equivalent rating thereto from any successor or substitute rating service selected by Lessor)
and a letter of credit issuer rating from Moody’s Investor Service of A3 or better (or any equivalent rating thereto from any successor rating agency thereto)) (collectively, the “Bank’s Credit Rating Threshold”), and
which L-C shall be in the form of Exhibit G, attached hereto. Tenant shall pay all expenses, points and/or fees incurred by Tenant in obtaining the L-C.
The L-C shall (i) be “callable” at sight, irrevocable and unconditional, (ii) be maintained in effect, whether through renewal or extension, for the period commencing on the date of this
Lease and continuing until the date (the “L-C Expiration Date”) that is no less than sixty (60) days after the expiration of the Lease Term as the same may be extended, and Tenant shall
deliver a new L-C or certificate of renewal or extension to Landlord at least thirty (30) days prior to the expiration of the L-C then held by Landlord, without any
action whatsoever on the part of Landlord, (iii) be fully assignable by Landlord, its successors and assigns, (iv) permit partial draws and multiple presentations and drawings, and (v) be otherwise subject to the Uniform Customs and
Practices for Documentary Credits (1993-Rev), International Chamber of Commerce Publication #500, or the International Standby Practices-ISP 98, International Chamber of
Commerce Publication #590. Landlord, or its then managing agent, shall have the right to draw down an amount up to the face amount of the L-C if any of the following shall have occurred or be applicable:
(A) such amount is due to Landlord under the terms and conditions of this Lease, and has not been paid within applicable notice and cure periods (or, if Landlord is prevented by law from providing notice, within the period for payment set forth
in the Lease), or (B) Tenant has filed a voluntary petition under the U. S. Bankruptcy Code or any state bankruptcy code (collectively, “Bankruptcy Code”), or (C) an involuntary petition has been filed against Tenant under
the Bankruptcy Code that is not dismissed within thirty (30) days, or (D) the Lease has been rejected, or is deemed rejected, under Section 365 of the U.S. Bankruptcy Code, following the filing of a voluntary petition by Tenant under
the Bankruptcy Code, or the filing of an involuntary petition against Tenant under the Bankruptcy Code, or (E) the Bank has notified Landlord that the L-C will not be renewed or extended through the L-C Expiration Date, and Tenant has not provided a replacement L-C that satisfies the requirements of this Lease at least thirty (30) days prior to such expiration, or
(F) Tenant is placed into receivership or conservatorship, or becomes subject to similar proceedings under Federal or State law, or (G) Tenant executes an assignment for the benefit of creditors, or (H) if (1) any of the Bank’s (other
than Silicon Valley Bank) Fitch Ratings (or other comparable ratings to the extent the Fitch Ratings are no longer available) have been reduced below the Bank’s Credit Rating Threshold, or (2) there is otherwise a material adverse change
in the financial condition of the Bank, and Tenant has failed to provide Landlord with a replacement letter of credit, conforming in all respects to the requirements of this Section 21.1 (including, but not limited to, the
requirements placed on the issuing Bank more particularly set forth in this Section 21.1 above), in the amount of the applicable L-C Amount, within ten (10) days following
Landlord’s written demand therefor (with no other notice or cure or grace period being applicable thereto, notwithstanding anything in this Lease to the contrary) (each of the foregoing being an
“L-C Draw Event”). The L-C shall be honored by the Bank regardless of whether Tenant disputes Landlord’s right to draw upon the L-C. In addition, in the event the Bank is placed into receivership or conservatorship by the Federal Deposit Insurance Corporation or any successor or similar entity, then, effective as of the date such
receivership or conservatorship occurs, said L-C shall be deemed to fail to meet the requirements of this Section 21.1, and, within ten (10) days following Landlord’s notice
to Tenant of such receivership or conservatorship (the “L-C FDIC Replacement Notice”), Tenant shall replace such L-C with a substitute letter of credit
from a different issuer (which issuer shall meet or exceed the Bank’s Credit Rating Threshold and shall otherwise be acceptable to Landlord in its reasonable discretion) and that complies in all respects with the requirements of this
Section 21.1. If Tenant fails to replace such L-C with such conforming, substitute letter of credit pursuant to the terms and conditions of this
Section 21.1, then, notwithstanding anything in this Lease to the contrary, Landlord shall have the right to declare Tenant in default of this Lease for which there shall be no notice or grace or cure periods being applicable
thereto 

  

					
		  	-35-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 
(other than the aforesaid ten (10) day period). Tenant shall be responsible for the payment of any and all Tenant’s and Bank’s costs incurred with the review of any replacement L-C, which replacement is required pursuant to this Section or is otherwise requested by Tenant. In the event of an assignment by Tenant of its interest in the Lease (and irrespective of whether Landlord’s
consent is required for such assignment), the acceptance of any replacement or substitute letter of credit by Landlord from the assignee shall be subject to Landlord’s prior written approval, in Landlord’s reasonable discretion, and the
actual and reasonable attorney’s fees incurred by Landlord in connection with such determination shall be payable by Tenant to Landlord within ten (10) days of billing. 

21.2    Application of L-C. Tenant hereby acknowledges and agrees that Landlord is
entering into this Lease in material reliance upon the ability of Landlord to draw upon the L-C upon the occurrence of any L-C Draw Event. In the event of any L-C Draw Event, Landlord may, but without obligation to do so, and without notice to Tenant (except in connection with an L-C Draw Event under
Section 21.1(H) above), draw upon the L-C, in part or in whole, in the amount necessary to cure any such L-C Draw Event and/or to compensate
Landlord for any and all damages of any kind or nature sustained or which Landlord reasonably estimates that it will sustain resulting from Tenant’s breach or default of the Lease or other L-C Draw Event
and/or to compensate Landlord for any and all damages arising out of, or incurred in connection with, the termination of this Lease, including, without limitation, those specifically identified in Section 1951.2 of the California Civil Code.
The use, application or retention of the L-C, or any portion thereof, by Landlord shall not prevent Landlord from exercising any other right or remedy provided by this Lease or by any applicable law, it being
intended that Landlord shall not first be required to proceed against the L-C, and such L-C shall not operate as a limitation on any recovery to which Landlord may
otherwise be entitled. Tenant agrees and acknowledges that (i) the L-C constitutes a separate and independent contract between Landlord and the Bank, (ii) Tenant is not a third party beneficiary of
such contract, (iii) Tenant has no property interest whatsoever in the L-C or the proceeds thereof, and (iv) in the event Tenant becomes a debtor under any chapter of the Bankruptcy Code, Tenant is
placed into receivership or conservatorship, and/or there is an event of a receivership, conservatorship or a bankruptcy filing by, or on behalf of, Tenant, neither Tenant, any trustee, nor Tenant’s bankruptcy estate shall have any right to
restrict or limit Landlord’s claim and/or rights to the L-C and/or the proceeds thereof by application of Section 502(b)(6) of the U. S. Bankruptcy Code or otherwise. 

21.3    Maintenance of L-C by Tenant. If, as a result of any drawing
by Landlord of all or any portion of the L-C, the amount of the L-C shall be less than the L-C Amount, Tenant shall, within five
(5) days thereafter, provide Landlord with additional letter(s) of credit in an amount equal to the deficiency, and any such additional letter(s) of credit shall comply with all of the provisions of this Article 21. Tenant further
covenants and warrants that it will neither assign nor encumber the L-C or any part thereof and that neither Landlord nor its successors or assigns will be bound by any such assignment, encumbrance, attempted
assignment or attempted encumbrance. Without limiting the generality of the foregoing, if the L-C expires earlier than the L-C Expiration Date, Landlord will accept a
renewal thereof (such renewal letter of credit to be in effect and delivered to Landlord, as applicable, not later than thirty (30) days prior to the expiration of the L-C), which shall be irrevocable and
automatically renewable as above provided through the L-C Expiration Date upon the same terms as the expiring L-C or such other terms as may be acceptable to Landlord in
its sole discretion. If Tenant exercises its option to extend the Lease Term pursuant to Section 2.2 of this Lease then, not later than thirty (30) days prior to the commencement of the Option Term, Tenant shall
deliver to Landlord a new L C or certificate of renewal or extension evidencing the L-C Expiration Date as thirty (30) days after the expiration of the Option Term. However, if the L-C is not timely renewed, or if Tenant fails to maintain the L-C in the amount and in accordance with the terms set forth in this Article 21, Landlord shall have the
right to present the L-C to the Bank in accordance with the terms of this Article 21, and the proceeds of the L-C may be applied by Landlord against any Rent
payable by Tenant under this Lease that is not paid when due and/or to pay for all losses and damages that Landlord has suffered or that Landlord reasonably estimates that it will suffer as a result of any breach or default by Tenant under this
Lease. In the event Landlord elects to exercise its rights as provided above, (I) any unused proceeds shall constitute the property of Landlord (and not Tenant’s property or, in the event of a receivership, conservatorship, or a bankruptcy
filing by, or on behalf of, Tenant, property of such receivership, conservatorship or Tenant’s bankruptcy estate) and need not be segregated from Landlord’s other assets, and (II) Landlord agrees to pay to Tenant within thirty
(30) days after the L-C Expiration Date the amount of any proceeds of the L-C received by Landlord and not applied against any Rent payable by Tenant under this
Lease that was not paid when due or used to pay for any losses and/or damages suffered by Landlord (or reasonably estimated by Landlord that it will suffer) as a result of any breach or default by Tenant under this Lease; provided, however, that if
prior to the L-C Expiration Date a voluntary petition is filed by Tenant, or an involuntary petition is filed against Tenant by 

  

					
		  	-36-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 
any of Tenant’s creditors, under the Bankruptcy Code, then Landlord shall not be obligated to make such payment in the amount of the unused L-C
proceeds until either all preference issues relating to payments under this Lease have been resolved in such bankruptcy or reorganization case or such bankruptcy or reorganization case has been dismissed. Notwithstanding anything to the contrary
herein, if Landlord draws on the L-C due to Tenant’s violation of this Lease beyond applicable notice and cure periods, such draw shall be in the amount required to cure such default. In addition, if
Landlord draws on the L-C due to Tenant’s failure to timely renew or provide a replacement L-C, such failure shall not be considered a default under this Lease and
Landlord shall return such cash proceeds upon Tenant’s presentation of a replacement L-C that satisfies the requirements of this Lease, subject to reasonable satisfaction of any preference risk to
Landlord. 
 21.4    Transfer and Encumbrance. The L-C shall also
provide that Landlord may, at any time and without notice to Tenant and without first obtaining Tenant’s consent thereto, transfer (one or more times) all or any portion of its interest in and to the L-C
to another party, person or entity, regardless of whether or not such transfer is from or as a part of the assignment by Landlord of its rights and interests in and to this Lease. In the event of a transfer of Landlord’s interest in under this
Lease, Landlord shall transfer the L-C, in whole or in part, to the transferee and thereupon Landlord shall, without any further agreement between the parties, be released by Tenant from all liability
therefor, and it is agreed that the provisions hereof shall apply to every transfer or assignment of the whole of said L- C to a new landlord. In connection with any such transfer of the L-C by Landlord, Tenant shall, at Tenant’s sole cost and expense, execute and submit to the Bank such applications, documents and instruments as may be necessary to effectuate such transfer and, Tenant shall be
responsible for paying the Bank’s transfer and processing fees in connection therewith; provided that, Landlord shall have the right (in its sole discretion), but not the obligation, to pay such fees on behalf of Tenant, in which case Tenant
shall reimburse Landlord within ten (10) days after Tenant’s receipt of an invoice from Landlord therefor. 

21.5    L-C Not a Security Deposit. Landlord and Tenant
(1) acknowledge and agree that in no event or circumstance shall the L-C or any renewal thereof or substitute therefor or any proceeds thereof be deemed to be or treated as a “security deposit”
under any law applicable to security deposits in the commercial context, including, but not limited to, Section 1950.7 of the California Civil Code, as such Section now exists or as it may be hereafter amended or succeeded
(the “Security Deposit Laws”), (2) acknowledge and agree that the L-C (including any renewal thereof or substitute therefor or any proceeds thereof) is not intended to serve as a
security deposit, and the Security Deposit Laws shall have no applicability or relevancy thereto, and (3) waive any and all rights, duties and obligations that any such party may now, or in the future will, have relating to or arising from the
Security Deposit Laws. Tenant hereby irrevocably waives and relinquishes the provisions of Section 1950.7 of the California Civil Code and any successor statute, and all other provisions of law, now or hereafter in
effect, which (x) establish the time frame by which a landlord must refund a security deposit under a lease, and/or (y) provide that a landlord may claim from a security deposit only those sums reasonably
necessary to remedy defaults in the payment of rent, to repair damage caused by a tenant or to clean the premises, it being agreed that Landlord may, in addition, claim those sums specified in this Article 21 and/or those sums
reasonably necessary to (a) compensate Landlord for any loss or damage caused by Tenant’s breach of this Lease, including any damages Landlord suffers following termination of this Lease, and/or (b) compensate
Landlord for any and all damages arising out of, or incurred in connection with, the termination of this Lease, including, without limitation, those specifically identified in Section 1951.2 of the California Civil Code. Tenant agrees
not to interfere in any way with any payment to Landlord of the proceeds of the L-C, either prior to or following a “draw” by Landlord of all or any portion of the
L-C, regardless of whether any dispute exists between Tenant and Landlord as to Landlord’s right to draw down all or any portion of the L-C. No condition or term of
this Lease shall be deemed to render the L-C conditional and thereby afford the Bank a justification for failing to honor a drawing upon such L-C in a timely manner.
Tenant shall not request or instruct the Bank of any L-C to refrain from paying sight draft(s) drawn under such L-C. 

21.6    Remedy for Improper Drafts. Tenant’s sole remedy in connection with the improper
presentment or payment of sight drafts drawn under any L-C shall be the right to obtain from Landlord a refund of the amount of any sight draft(s) that were improperly presented or the proceeds of which were
misapplied, and reasonable actual out-of-pocket attorneys’ fees, provided that at the time of such refund, Tenant increases the amount of such L-C to the amount (if any) then required under the applicable provisions of this Lease. Tenant acknowledges that the presentment of sight drafts drawn under any L-C, or the
Bank’s payment of sight drafts drawn under such L-C, could not under any circumstances cause Tenant injury that could not be remedied by an award of money damages, and that the recovery

  

					
		  	-37-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 
of money damages would be an adequate remedy therefor. In the event Tenant shall be entitled to a refund as aforesaid and Landlord shall fail to make such payment within ten (10) business
days after demand, Tenant shall have the right to deduct the amount thereof from the next installment(s) of Base Rent. 

22.    COMMUNICATIONS AND COMPUTER LINE Tenant may install, maintain, replace, remove or use any communications or computer
wires and cables serving the Premises (collectively, the “Lines”), provided that Tenant shall obtain Landlord’s prior written consent, use an experienced and qualified contractor approved in writing by Landlord, and comply with
all of the other provisions of Articles 7 and 8 of this Lease. Tenant shall pay all costs in connection therewith. Landlord reserves the right, upon notice to Tenant prior to the expiration or earlier termination of this Lease, to require that
Tenant, at Tenant’s sole cost and expense, remove any Lines located in or serving the Premises prior to the expiration or earlier termination of this Lease. 
  

	23.	 SIGNS 

23.1    Exterior Signage. Subject to Landlord’s prior written approval, which shall not be unreasonably
withheld, conditioned or delayed, and provided all signs are in keeping with the quality, design and style of the Building and Project, Tenant, at its sole cost and expense, may install (i) identification signage on the existing monument sign
located at the exterior of the Building near the Project entry, and at the entrance to the Building, and 
 (ii) internal directional, suite entry and lobby
identification signage and directory (collectively, “Tenant Signage”); provided, however, in no event shall Tenant’s Signage include an “Objectionable Name,” as that term is defined in
Section 23.3, of this Lease. All such signage shall be subject to Tenant’s obtaining all required governmental approvals. All permitted signs shall be maintained by Tenant at its expense in a first-class and safe
condition and appearance. Upon the expiration or earlier termination of this Lease, Tenant shall remove all of its signs at Tenant’s sole cost and expense. The graphics, materials, color, design, lettering, lighting, size, illumination,
specifications and exact location of Tenant’s Signage (collectively, the “Sign Specifications”) shall be subject to the prior written approval of Landlord, which approval shall not be unreasonably withheld, conditioned or
delayed, and shall be consistent and compatible with the quality and nature of the Project. Tenant hereby acknowledges that, notwithstanding Landlord’s approval of Tenant’s Signage, Landlord has made no representation or warranty to Tenant
with respect to the probability of obtaining all necessary governmental approvals and permits for Tenant’s Signage. In the event Tenant does not receive the necessary governmental approvals and permits for Tenant’s Signage, Tenant’s
and Landlord’s rights and obligations under the remaining terms and conditions of this Lease shall be unaffected. 

23.2    Objectionable Name. Tenant’s Signage shall not include a name or logo which relates to an
entity which is of a character or reputation, or is associated with a political faction or orientation, which is inconsistent with the quality of the Project, or which would otherwise reasonably offend a landlord of the Comparable Buildings (an
“Objectionable Name”). The parties hereby agree that the following name, or any reasonable derivation thereof, shall be deemed not to constitute an Objectionable Name: “Nkarta, Inc.” 

23.3    Prohibited Signage and Other Items. Any signs, notices, logos, pictures, names or advertisements
which are installed and that have not been separately approved by Landlord may be removed without notice by Landlord at the sole expense of Tenant. Any signs, window coverings, or blinds (even if the same are located behind the Landlord-approved
window coverings for the Building), or other items visible from the exterior of the Premises or Building, shall be subject to the prior approval of Landlord, in its sole discretion. 

24.    COMPLIANCE WITH LAW Tenant shall not do anything or suffer anything to be done in or about the Premises or the
Project which will in any way conflict with any law, statute, ordinance or other governmental rule, regulation or requirement now in force or which may hereafter be enacted or promulgated (“Applicable Laws”). At its sole cost and
expense, Tenant shall promptly comply with all such governmental measures. Should any standard or regulation now or hereafter be imposed on Landlord or Tenant by a state, federal or local governmental body charged with the establishment, regulation
and enforcement of occupational, health or safety standards for employers, employees, landlords or tenants, then Tenant agrees, at its sole cost and expense, to comply promptly with such standards or regulations. Tenant shall be responsible, at its
sole cost and expense, to make all alterations to the Building and Premises as are required to comply with the governmental rules, regulations, requirements or standards described in this Article 24. The judgment of any court of competent
jurisdiction or the admission of Tenant in any judicial action, regardless of whether Landlord is a party thereto, that Tenant has violated any of said governmental 

  

					
		  	-38-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 measures, shall be conclusive of that fact as between Landlord and Tenant. For purposes of Section 1938
of the California Civil Code, Landlord hereby discloses to Tenant, and Tenant hereby acknowledges, that the Project, Building and Premises have not undergone inspection by a Certified Access Specialist (CASp). As required by Section 1938(e) of
the California Civil Code, Landlord hereby states as follows: “A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply with all of the applicable construction-related accessibility
standards under state law. Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant from obtaining a CASp inspection of the subject premises for the
occupancy or potential occupancy of the lessee or tenant, if requested by the lessee or tenant. The parties shall mutually agree on the arrangements for the time and manner of the CASp inspection, the payment of the fee for the CASp inspection, and
the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the premises.” In furtherance of the foregoing, Landlord and Tenant hereby agree as follows: (a) any CASp inspection
requested by Tenant shall be conducted, at Tenant’s sole cost and expense, by a CASp approved in advance by Landlord; and (b) pursuant to Article 24 below, but subject to Section 10.2 above, Tenant, at its
cost, is responsible for making any repairs within the Premises to correct violations of construction-related accessibility standards; and, if anything done by or for Tenant in its use or occupancy of the Premises shall require repairs to the
Building (outside the Premises) to correct violations of construction-related accessibility standards, then Tenant shall, at Landlord’s option, either perform such repairs at Tenant’s sole cost and expense or reimburse Landlord upon
demand, as Additional Rent, for the cost to Landlord of performing such repairs. Tenant’s obligations under this Article 24 are subject to the limitation in Section 10.2 above. 

25.    LATE CHARGES If any installment of Rent or any other sum due from Tenant shall not be received by Landlord or
Landlord’s designee within five (5) business days after Tenant’s receipt of written notice from Landlord that said amount is delinquent then Tenant shall pay to Landlord a late charge equal to five percent (5%) of the overdue amount
plus any reasonable attorneys’ fees incurred by Landlord by reason of Tenant’s failure to pay Rent and/or other charges when due hereunder. The late charge shall be deemed Additional Rent and the right to require it shall be in addition to
all of Landlord’s other rights and remedies hereunder or at law and shall not be construed as liquidated damages or as limiting Landlord’s remedies in any manner. In addition to the late charge described above, any Rent or other amounts
owing hereunder which are not paid within ten (10) days after Tenant’s receipt of written notice that said amount is delinquent shall bear interest from the date when due until paid at a rate per annum equal to the lesser of (i) the
annual “Bank Prime Loan” rate cited in the Federal Reserve Statistical Release Publication G.13(415), published on the first Tuesday of each calendar month (or such other comparable index as Landlord and Tenant shall reasonably agree upon
if such rate ceases to be published) plus four (4) percentage points, and (ii) the highest rate permitted by applicable law. 
  

	26.	 LANDLORD’S RIGHT TO CURE DEFAULT; PAYMENTS BY TENANT 

26.1    Landlord’s Cure. All covenants and agreements to be kept or performed by Tenant under this Lease
shall be performed by Tenant at Tenant’s sole cost and expense and without any reduction of Rent, except to the extent, if any, otherwise expressly provided herein. If Tenant shall fail to perform any obligation under this Lease, and such
failure shall continue in excess of the time allowed under Section 19.1.2, above, unless a specific time period is otherwise stated in this Lease, Landlord may, but shall not be obligated to, make any such payment or
perform any such act on Tenant’s part without waiving its rights based upon any default of Tenant and without releasing Tenant from any obligations hereunder. 

26.2    Tenant’s Reimbursement. Except as may be specifically provided to the contrary in this Lease,
Tenant shall pay to Landlord, upon delivery by Landlord to Tenant of statements therefor: (i) sums equal to expenditures reasonably made and obligations incurred by Landlord in connection with the remedying by Landlord of Tenant’s defaults
pursuant to the provisions of Section 26.1; (ii) sums equal to all losses, costs, liabilities, damages and expenses referred to in Article 10 of this Lease; and (iii) subject to
Section 29.21, sums equal to all expenditures made and obligations incurred by Landlord in collecting or attempting to collect the Rent or in enforcing or attempting to enforce any rights of Landlord under this Lease or
pursuant to law, including, without limitation, all reasonable legal fees and other amounts so expended. Tenant’s obligations under this Section 26.2 shall survive the expiration or sooner termination of the Lease
Term. 

  

					
		  	-39-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 27.    ENTRY BY LANDLORD Landlord reserves the right at all reasonable
times and upon reasonable notice to Tenant (except in the case of an emergency) to enter the Premises to (i) inspect them; (ii) show the Premises to prospective purchasers, or to current or prospective mortgagees, ground or underlying
lessors or insurers or, during the last nine (9) months of the Lease Term, to prospective tenants; (iii) post notices of nonresponsibility (to the extent applicable pursuant to then applicable law); or (iv) repair the Premises or the
Building, or for structural repairs to the Building or the Building’s systems and equipment as provided under the Lease. Landlord may make any such entries without the abatement of Rent, except as otherwise provided in this Lease, and may take
such reasonable steps as required to accomplish the stated purposes. In an emergency, Landlord shall have the right to use any means that Landlord may deem proper to open the doors in and to the Premises. Any entry into the Premises by Landlord in
the manner hereinbefore described shall not be deemed to be a forcible or unlawful entry into, or a detainer of, the Premises, or an actual or constructive eviction of Tenant from any portion of the Premises. Landlord shall use commercially
reasonable efforts to minimize any interference with Tenant’s use of or access to the Premises in connection with any such entry, and shall comply with Tenant’s reasonable security measures. Landlord shall hold confidential any information
regarding Tenant’s business that it may learn as a result of such entry. 
 28.    TENANT PARKING Tenant shall
have the right, without the payment of any parking charge or fee (other than as a reimbursement of operating expenses to the extent allowed pursuant to the terms or Article 4 of this Lease, above), commencing on the Lease Commencement Date, to use
the amount of parking set forth in Section 9 of the Summary, in the on-site parking lot and garage which serves the Building. Tenant shall abide by all reasonable rules and regulations which are
prescribed from time to time for the orderly operation and use of the parking facility where the parking passes are located (including any sticker or other identification system established by Landlord and the prohibition of vehicle repair and
maintenance activities in the parking facilities), and shall cooperate in seeing that Tenant’s employees and visitors also comply with such rules and regulations. Tenant’s use of the Project parking facility shall be at Tenant’s sole
risk and Tenant acknowledges and agrees that Landlord shall have no liability whatsoever for damage to the vehicles of Tenant, its employees and/or visitors, or for other personal injury or property damage or theft relating to or connected with the
parking rights granted herein or any of Tenant’s, its employees’ and/or visitors’ use of the parking facilities. Landlord shall not oversubscribe parking. 
  

	29.	 MISCELLANEOUS PROVISIONS 

29.1    Terms; Captions. The words “Landlord” and “Tenant” as used herein
shall include the plural as well as the singular. The necessary grammatical changes required to make the provisions hereof apply either to corporations or partnerships or individuals, men or women, as the case may require, shall in all cases be
assumed as though in each case fully expressed. The captions of Articles and Sections are for convenience only and shall not be deemed to limit, construe, affect or alter the meaning of such Articles and Sections. 

29.2    Binding Effect. Subject to all other provisions of this Lease, each of the covenants, conditions and
provisions of this Lease shall extend to and shall, as the case may require, bind or inure to the benefit not only of Landlord and of Tenant, but also of their respective heirs, personal representatives, successors or assigns, provided this clause
shall not permit any assignment by Tenant contrary to the provisions of Article 14 of this Lease. 

29.3    No Air Rights. No rights to any view or to light or air over any property, whether belonging to
Landlord or any other person, are granted to Tenant by this Lease. If at any time any windows of the Premises are temporarily darkened or the light or view therefrom is obstructed by reason of any repairs, improvements, maintenance or cleaning in or
about the Project, the same shall be without liability to Landlord and without any reduction or diminution of Tenant’s obligations under this Lease. 

29.4    Modification of Lease. Should any current or prospective mortgagee or ground lessor for the Building
or Project require a modification of this Lease, which modification will not cause an increased cost or expense to Tenant or in any other way materially and adversely change the rights and obligations of Tenant hereunder or interfere with
Tenant’s use of the Premises, then and in such event, Tenant agrees that this Lease may be so modified and agrees to execute whatever documents are reasonably required therefor and to deliver the same to Landlord within ten (10) business
days following a request therefor. At the request of Landlord or any mortgagee or ground lessor, Tenant agrees to execute a short form of Lease and deliver the same to Landlord within ten (10) business days following the request therefor. 

  

					
		  	-40-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 29.5    Transfer of Landlord’s Interest. Tenant
acknowledges that Landlord has the right to transfer all or any portion of its interest in the Project or Building and in this Lease, and Tenant agrees that in the event of any such transfer, Landlord shall automatically be released from all
liability under this Lease and Tenant agrees to look solely to such transferee for the performance of Landlord’s obligations hereunder accruing after the date of transfer provided such transferee shall have fully assumed and agreed in writing
to be liable for all obligations of this Lease to be performed by Landlord, including the return of any security deposit or L-C, and Tenant shall attorn to such transferee. 

29.6    Prohibition Against Recording. Except as provided in Section 29.4 of this
Lease, neither this Lease, nor any memorandum, affidavit or other writing with respect thereto, shall be recorded by Tenant or by anyone acting through, under or on behalf of Tenant. 

29.7    Landlord’s Title. Landlord’s title is and always shall be paramount to the title of
Tenant. Nothing herein contained shall empower Tenant to do any act which can, shall or may encumber the title of Landlord. 

29.8    Relationship of Parties. Nothing contained in this Lease shall be deemed or construed by the parties
hereto or by any third party to create the relationship of principal and agent, partnership, joint venturer or any association between Landlord and Tenant. 

29.9    Payment under Protest. If Tenant in good faith disputes any amounts billed by Landlord, other than
(i) Base Rent, (ii) Tenant’s Share of Direct Expenses (as to which Tenant may exercise its rights under Section 4.6, above), Tenant may make payment of such amounts under protest, and reserve all of its
rights with respect to such amounts (the “Disputed Amounts”). Landlord and Tenant shall meet and confer to discuss the Disputed Amounts and attempt, in good faith, to resolve the particular dispute. If, despite such good faith
efforts, Landlord and Tenant are unable to reach agreement regarding the Disputed Amounts, either party may submit the matter to binding arbitration under the JAMS Streamlined Arbitration Rules & Procedures. The non-prevailing party, as determined by JAMS, will be responsible to pay all fees and costs incurred in connection with the JAMS procedure, as well as all other costs and expenses, including reasonable
attorneys’ fees, incurred by the prevailing party. This Section 29.9 shall not apply to claims relating to Landlord’s exercise of any unlawful detainer rights pursuant to California law or rights or remedies used
by Landlord to gain possession of the Premises or terminate Lessee’s right of possession to the Premises. 

29.10    Time of Essence. Time is of the essence with respect to the performance of every provision of this
Lease in which time of performance is a factor. 
 29.11    Partial Invalidity. If any term, provision or
condition contained in this Lease shall, to any extent, be invalid or unenforceable, the remainder of this Lease, or the application of such term, provision or condition to persons or circumstances other than those with respect to which it is
invalid or unenforceable, shall not be affected thereby, and each and every other term, provision and condition of this Lease shall be valid and enforceable to the fullest extent possible permitted by law. 

29.12    No Warranty. In executing and delivering this Lease, Tenant has not relied on any representations,
including, but not limited to, any representation as to the amount of any item comprising Additional Rent or the amount of the Additional Rent in the aggregate or that Landlord is furnishing the same services to other tenants, at all, on the same
level or on the same basis, or any warranty or any statement of Landlord which is not set forth herein or in one or more of the exhibits attached hereto. 

29.13    Landlord Exculpation. The liability of Landlord or the Landlord Parties to Tenant for any default
by Landlord under this Lease or arising in connection herewith or with Landlord’s operation, management, leasing, repair, renovation, alteration or any other matter relating to the Project or the Premises shall be limited solely and exclusively
to an amount which is equal to the lesser of (a) the interest of Landlord in the Project or (b) the equity interest Landlord would have in the Project if the Project were encumbered by third-party debt in an amount equal to eighty percent
(80%) of the value of the Project (as such value is determined by Landlord), including any rental, condemnation, sales and insurance proceeds received by Landlord or the Landlord Parties in connection with the Project, Building or Premises. No
Landlord Parties (other than Landlord) shall have any personal liability therefor, 

  

					
		  	-41-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 and Tenant hereby expressly waives and releases such liability on behalf of itself and all persons claiming
by, through or under Tenant. The limitations of liability contained in this Section 29.13 shall inure to the benefit of Landlord’s and the Landlord Parties’ present and future partners, beneficiaries, officers,
directors, trustees, shareholders, agents and employees, and their respective partners, heirs, successors and assigns. Under no circumstances shall any present or future partner of Landlord (if Landlord is a partnership), or trustee or beneficiary
(if Landlord or any partner of Landlord is a trust), have any liability for the performance of Landlord’s obligations under this Lease. Notwithstanding any contrary provision herein, neither Landlord nor the Landlord Parties shall be liable
under any circumstances for injury or damage to, or interference with, Tenant’s business, including but not limited to, loss of profits, loss of rents or other revenues, loss of business opportunity, loss of goodwill or loss of use, in each
case, however occurring, or loss to inventory, scientific research, scientific experiments, laboratory animals, products, specimens, samples, and/or scientific, business, accounting and other records of every kind and description kept at the
premises and any and all income derived or derivable therefrom. 
 29.14    Entire Agreement. It is
understood and acknowledged that there are no oral agreements between the parties hereto affecting this Lease and this Lease constitutes the parties’ entire agreement with respect to the leasing of the Premises and supersedes and cancels any
and all previous negotiations, arrangements, brochures, agreements and understandings, if any, between the parties hereto or displayed by Landlord to Tenant with respect to the subject matter thereof, and none thereof shall be used to interpret or
construe this Lease. None of the terms, covenants, conditions or provisions of this Lease can be modified, deleted or added to except in writing signed by the parties hereto. 

29.15    Right to Lease. Landlord reserves the absolute right to effect such other tenancies in the Project
as Landlord in the exercise of its sole business judgment shall determine to best promote the interests of the Building or Project. Tenant does not rely on the fact, nor does Landlord represent, that any specific tenant or type or number of tenants
shall, during the Lease Term, occupy any space in the Building or Project. 
 29.16    Force Majeure. Any
prevention, delay or stoppage due to strikes, lockouts, labor disputes, acts of God, acts of war, terrorist acts, inability to obtain services, labor, or materials or reasonable substitutes therefor, governmental actions, civil commotions, fire or
other casualty, and other causes beyond the reasonable control of the party obligated to perform, except with respect to the obligations imposed with regard to Rent and other charges to be paid by Tenant pursuant to this Lease (collectively, a
“Force Majeure”), notwithstanding anything to the contrary contained in this Lease, shall excuse the performance of such party for a period equal to any such prevention, delay or stoppage and, therefore, if this Lease specifies a
time period for performance of an obligation of either party, that time period shall be extended by the period of any delay in such party’s performance caused by a Force Majeure, provided, however, the foregoing delays shall not apply to
Tenant’s termination rights hereunder. 
 29.17    Intentionally Omitted. 

29.18    Notices. All notices, demands, statements, designations, approvals or other communications
(collectively, “Notices”) given or required to be given by either party to the other hereunder or by law shall be in writing, shall be (A) sent by United States certified or registered mail, postage prepaid, return receipt
requested (“Mail”), (B) delivered by a nationally recognized overnight courier, or (C) delivered personally. Any Notice shall be sent, transmitted, or delivered, as the case may be, to Tenant at the appropriate address set
forth in Section 10 of the Summary, or to such other place as Tenant may from time to time designate in a Notice to Landlord, or to Landlord at the addresses set forth below, or to such other places as Landlord may from
time to time designate in a Notice to Tenant. Any Notice will be deemed given (i) three (3) business days after the date it is posted if sent by Mail, (ii) the date the overnight courier delivery is made, or (iii) the date personal
delivery is made. As of the date of this Lease, any Notices to Landlord must be sent, transmitted, or delivered, as the case may be, to the following addresses: 

HCP Life Science Reit, Inc. 

3760 Kilroy Airport Way, Suite 300 

Long Beach, CA 90806-2473 

Attn: Legal Department 

  

					
		  	-42-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 with a copy to: 

HCP Life Science Estates 

950 Tower Lane, Suite 1650 

Foster City, CA 94404 

and 

Allen Matkins Leck Gamble Mallory & Natsis LLP 

1901 Avenue of the Stars, Suite 1800 

Los Angeles, California 90067 

Attention: Anton N. Natsis, Esq. 

29.19    Joint and Several. If there is more than one tenant, the obligations imposed upon Tenant under this
Lease shall be joint and several. 
 29.20    Authority. If Tenant is a corporation, trust or partnership,
Tenant hereby represents and warrants that Tenant is a duly formed and existing entity qualified to do business in the State of California and that Tenant has full right and authority to execute and deliver this Lease and that each person signing on
behalf of Tenant is authorized to do so. 
 29.21    Attorneys’ Fees. In the event that either
Landlord or Tenant should bring suit for the possession of the Premises, for the recovery of any sum due under this Lease, or because of the breach of any provision of this Lease or for any other relief against the other, then all costs and
expenses, including reasonable attorneys’ fees, incurred by the prevailing party therein shall be paid by the other party, which obligation on the part of the other party shall be deemed to have accrued on the date of the commencement of such
action and shall be enforceable whether or not the action is prosecuted to judgment. 
 29.22    Governing Law;
WAIVER OF TRIAL BY JURY. This Lease shall be construed and enforced in accordance with the laws of the State of California. IN ANY ACTION OR PROCEEDING ARISING HEREFROM, LANDLORD AND TENANT HEREBY CONSENT TO (I) THE JURISDICTION OF ANY
COMPETENT COURT WITHIN THE STATE OF CALIFORNIA, (II) SERVICE OF PROCESS BY ANY MEANS AUTHORIZED BY CALIFORNIA LAW, AND (III) IN THE INTEREST OF SAVING TIME AND EXPENSE, TRIAL WITHOUT A JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT
BY EITHER OF THE PARTIES HERETO AGAINST THE OTHER OR THEIR SUCCESSORS IN RESPECT OF ANY MATTER ARISING OUT OF OR IN CONNECTION WITH THIS LEASE, THE RELATIONSHIP OF LANDLORD AND TENANT, TENANT’S USE OR OCCUPANCY OF THE PREMISES, AND/OR ANY CLAIM
FOR INJURY OR DAMAGE, OR ANY EMERGENCY OR STATUTORY REMEDY. IN THE EVENT LANDLORD COMMENCES ANY SUMMARY PROCEEDINGS OR ACTION FOR NONPAYMENT OF BASE RENT OR ADDITIONAL RENT, TENANT SHALL NOT INTERPOSE ANY COUNTERCLAIM OF ANY NATURE OR DESCRIPTION
(UNLESS SUCH COUNTERCLAIM SHALL BE MANDATORY) IN ANY SUCH PROCEEDING OR ACTION, BUT SHALL BE RELEGATED TO AN INDEPENDENT ACTION AT LAW. 

29.23    Submission of Lease. Submission of this instrument for examination or signature by Tenant does not
constitute a reservation of, option for or option to lease, and it is not effective as a lease or otherwise until execution and delivery by both Landlord and Tenant. 

29.24    Brokers. Landlord and Tenant hereby warrant to each other that they have had no dealings with any
real estate broker or agent in connection with the negotiation of this Lease, excepting only the real estate brokers or agents specified in Section 12 of the Summary (the “Brokers”), and that they know of
no other real estate broker or agent who is entitled to a commission in connection with this Lease. Each party agrees to indemnify and defend the other party against and hold the other party harmless from any and all claims, demands, losses,
liabilities, lawsuits, judgments, costs and expenses (including without limitation reasonable attorneys’ fees) with respect to any leasing commission or equivalent compensation alleged to be owing on account of any dealings with any real estate
broker or agent, other than the Brokers, occurring by, through, or under the indemnifying party. The terms of this Section 29.24 shall survive the expiration or earlier termination of the Lease Term. 

  

					
		  	-43-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 29.25    Independent Covenants. This Lease shall be
construed as though the covenants herein between Landlord and Tenant are independent and not dependent and Tenant hereby expressly waives the benefit of any statute to the contrary and agrees that if Landlord fails to perform its obligations set
forth herein, Tenant shall not be entitled to make any repairs or perform any acts hereunder at Landlord’s expense or to any setoff of the Rent or other amounts owing hereunder against Landlord. 

29.26    Project or Building Name, Address and Signage. Landlord shall have the right at any time to change
the name and/or address of the Project or Building (and Landlord shall reimburse Tenant its actual, reasonable costs incurred as a result of such change, if any) and, subject to Section 23.1, to install, affix and maintain
any and all signs on the exterior and on the interior of the Project or Building as Landlord may, in Landlord’s sole discretion, desire. Tenant shall not use the name of the Project or Building or use pictures or illustrations of the Project or
Building in advertising or other publicity or for any purpose other than as the address of the business to be conducted by Tenant in the Premises, without the prior written consent of Landlord. 

29.27    Counterparts. This Lease may be executed in counterparts with the same effect as if both parties
hereto had executed the same document. Both counterparts shall be construed together and shall constitute a single lease. 

29.28    Good Faith. Except (i) for matters for which there is a standard of consent or discretion
specifically set forth in this Lease; (ii) matters which could have an adverse effect on the Building Structure or the Building Systems, or which could affect the exterior appearance of the Building, or (iii) matters covered by Article 4
(Additional Rent), or Article 19 (Defaults; Remedies) of this Lease (collectively, the “Excepted Matters”), any time the consent of Landlord or Tenant is required, such consent shall not be unreasonably withheld or delayed, and,
except with regard to the Excepted Matters, whenever this Lease grants Landlord or Tenant the right to take action, exercise discretion, establish rules and regulations or make an allocation or other determination, Landlord and Tenant shall act
reasonably and in good faith. 
  

	 	29.29	 Development of the Project. 

29.29.1    Subdivision. Landlord reserves the right to subdivide all or a portion of the buildings and
Common Areas, so long as the same does not interfere with Tenant’s use of or access to the Premises or Tenant’s parking rights. Tenant agrees to execute and deliver, upon demand by Landlord and in the form requested by Landlord, any
additional documents needed to conform this Lease to the circumstances resulting from a subdivision and any all maps in connection therewith, so long as the same does not increase Tenant’s obligations or decrease Tenant’s rights under this
Lease. Notwithstanding anything to the contrary set forth in this Lease, the separate ownership of any buildings and/or Common Areas by an entity other than Landlord shall not affect the calculation of Direct Expenses or Tenant’s payment of
Tenant’s Share of Direct Expenses. 
 29.29.2    Construction of Property and Other Improvements.
Tenant acknowledges that portions of the Project may be under construction following Tenant’s occupancy of the Premises, and that such construction may result in levels of noise, dust, obstruction of access, etc. which are in excess of that
present in a fully constructed project. Tenant hereby waives any and all rent offsets or claims of constructive eviction which may arise in connection with such construction, so long as the same does not interfere with Tenant’s use of or access
to the Premises or Tenant’s parking rights. Landlord shall use commercially reasonable efforts to minimize and mitigate noise and vibrations in connection with any such construction. 

29.30    No Violation. Tenant hereby warrants and represents that neither its execution of nor performance
under this Lease shall cause Tenant to be in violation of any agreement, instrument, contract, law, rule or regulation by which Tenant is bound, and Tenant shall protect, defend, indemnify and hold Landlord harmless against any claims, demands,
losses, damages, liabilities, costs and expenses, including, without limitation, reasonable attorneys’ fees and costs, arising from Tenant’s breach of this warranty and representation. 

29.31    Transportation Management. Tenant shall fully comply with all present or future programs required
by applicable laws intended to manage parking, transportation or traffic in and around the Project and/or the Building, and in connection therewith, Tenant shall take responsible action for the transportation planning and

  

					
		  	-44-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

 
management of all employees located at the Premises as required by law by working directly with Landlord, any governmental transportation management organization or any other
transportation-related committees or entities. Such programs may include, without limitation: (i) restrictions on the number of peak-hour vehicle trips generated by Tenant; (ii) increased vehicle occupancy; (iii) implementation of an in-house ridesharing program and an employee transportation coordinator; (iv) working with employees and any Project, Building or area-wide ridesharing program manager; (v) instituting employer-sponsored
incentives (financial or in-kind) to encourage employees to rideshare; and (vi) utilizing flexible work shifts for employees. 

IN WITNESS WHEREOF, Landlord and Tenant have caused this Lease to be executed the day and date first above written. 

 

													
	LANDLORD:	  	                    	 	TENANT:
			
	HCP LIFE SCIENCE REIT, INC.,	  		 	NKARTA, INC.,
	a Maryland corporation	  		 	a Delaware corporation
					
	By:	 	 /s/ Scott Bohn
	  		 	By:	 	 /s/ Paul Hastings

		 	Name:	 	Scott Bohn	  		 		 	Name:	  	Paul Hastings
		 	Its:	 	Vice President	  		 		 	Its:	  	CEO
						
		 		 		  		 	By:	 	  

		 		 		  		 		 	Name:	  	
		 		 		  		 		 	Its:	  	

  

					
		  	-45-	  	 HCP Life Science REIT, Inc.

[600 Shoreline Court]
 [Nkarta,
Inc.]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]